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Dedicated to the memory of m y mother, Judith Arron

and to Sarah

The value the world sets upon motives is often grossly unjust and inaccurate. Consider,
for example, two of them: mere insatiable curiosity and the desire to do good. The

is put high above the former, and yet it is the former that moves one of the most u

men the human race has yet produced: the scientific investigator. What actually urg
him on is not some brummagem idea of Service, but a boundless, almost pathological

thirst to penetrate the unknown, to uncover the secret, to find out what has not be

out before. His prototype is not the liberator releasing slaves, the good Samaritan
up the fallen, but a dog sniffing tremendously at an infinite series of rat-holes.

H. L . Mencken

The right answer to a trivial question is also trivial, but the right question, even when
insoluble in exact form, is a guide to major discovery.

Edward O. Wilson
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1. A B S T R A C T

This thesis describes the investigation of the mechanisms of signal transduction a

by tumor necrosis factor (TNF) superfamily proteins. Ligands of the TNF family enga

TNF receptor (TNFR) family proteins, leading to a wide variety of cellular effects,

these interactions are implicated in inflammation, immune regulation, bone homeosta

and development. TNFR proteins lack intrinsic enzymatic activity, and are coupled t

intracellular signaling cascades by TNFR associated factor (TRAF) proteins, which a
cytoplasmic adaptor molecules. The roles of TRAF1, TRAF2, and TRAF6 are

investigated structurally and functionally in the activation of NF-kB, AP-1, and Sr
family kinases. Cbl proteins are identified as positive and negative regulators of

mediated Src-family kinase signaling. The molecular structure of TRAF6 is determin

and structure-function relationships between TRAF6 and the receptors to which it b

are examined. A physiological role for TRAF1 is identified in the regulation of TRA

This finding elucidates the role of translocation into lipid rafts in TRAF signali

regulation. The implications of these findings are considered primarily in the reci
regulation of immunity and bone homeostasis by TRAF-mediated signaling pathways.

2. General Introduction

2. GENERAL INTRODUCTION

2.1 TNF/TNFR Superfamilies

Lymphotoxin (1) and tumor necrosis factor (TNF) (2) were first identified in the la

1960s and early 1970s as factors produced by immune cells that induced the death of

various types of tumor cells. As molecular cloning became commonplace, it became cl

that the genes that encoded these factors were part of a large family of genes, the

identification of which continues to expand to this day. The TNF superfamily consis

a wide variety of proteins, some cell-bound and others secreted, that regulate a wi

variety of cellular processes. In particular, TNF family proteins regulate the life

of not only tumor cells, but of activated cells of the immune system. They modulate
activation state of immune cells, and as we are increasingly becoming aware, they

mediate the signals that these cells send to each other. TNF family proteins have b

implicated in areas outside of inflammation and immunity, including bone homeostasi
lymph node organogenesis, hair follicle development, and mammary gland development

(3). A holistic view of the TNF family clearly demonstrates that, through TNF famil

proteins, these myriad biological processes are inextricably linked, and the widesp
sequelae of inflammatory processes can be explained through the actions of the TNF
family.

TNF family proteins mediate cellular effects by binding to their cognate cellular

receptors, members of the TNF Receptor (TNFR) superfamily (3-6). TNF family proteins
are expressed as type II transmembrane proteins that form trimers and may interact

their cognate receptors as cell-bound or soluble forms (7). TNFR family proteins ar

I transmembrane proteins with conserved cysteine-rich domains (CRDs) that typically

2. General Introduction

consist of three conserved disulfide bridges (8). These domains form elongated rece

chains that intercalate with protomers of ligand trimers (9). It has been suggested

encounter with a ligand trimer induces the trimerization of a receptor, which leads

intracellular signaling, although recently it has been shown that TNFR proteins sel
assemble in the absence of ligand, undergoing conformational changes upon ligand

engagement that lead to signaling (10). While the extracellular ligand-binding doma

TNFR proteins are similar, there are three divergent subgroups of TNFR proteins tha

be classified by motifs (or lack thereof) in their cytoplasmic tails: death recepto
receptors, and activating receptors. Since TNFR proteins appear to lack intrinsic

enzymatic activity, their intracellular signals are mediated by cytoplasmic adaptor
proteins.

2.1.1 Death Receptors

Apoptosis, or programmed cell death, is a necessary feature of embryonic developmen

lymphocyte homeostasis, CD8+ T cell-mediated killing of virus-infected or tumor cel

and the maintenance of "immune privileged" sites such as the eye (11,12). As opposed
death through necrosis, which is a response to physical injury to cells, apoptosis

highly regulated process in which a cell "commits suicide." Morphological character
of apoptosis include membrane blebbing, cytoplasmic, nuclear, and chromatin

condensation, and DNA fragmentation. The cell is reduced to fragments termed apopto

bodies, which have intact membrane structures that contain surface markers that sig
phagocytic cells to engulf them (13). This orderly process prevents the release of

inflammatory stimuli that characterizes necrosis. During development, as tissues an

structures differentiate, it is essential for certain cells to die in order to gene

morphology. For example, in limb development, if there is a defect in apoptosis, th

tissues in between digits may persist, resulting in webbing. During a cellular immu

-3

2. General Introduction

response, there is massive proliferation of activated lymphocytes. While these acti
lymphocytes are necessary to clear the infectious agent, they can cause collateral
through nonspecific inflammation, and if they persisted, the body would eventually
overrun by lymphocytes. Indeed, mice and humans with mutations in Fas or FasL have

autoimmune syndromes characterized by massive accumulation of activated lymphocytes
and greatly enlarged lymph nodes (14). Thus, activated lymphocytes are extremely

sensitive to apoptotic stimuli and lymphocyte homeostasis is maintained through the

process of apoptosis (4). Death receptors such as TNFR1 and Fas contain a conserved

intracellular "death domain" (DD) that can interact with intracellular DD containin
adaptor proteins such as TRADD and FADD (15-17). FADD couples Fas and the
TNFR1-TRADD complex to caspase-8 activation, which results in the orderly sequence
of proteolytic events of apoptosis.

2.1.2 Decoy Receptors
Decoy receptors of the TNFR superfamily include osteoprotegerin (OPG) (18), DcRl

(19,20), DcR2 (21-24), and DcR3 (25). Their function is to negatively regulate the e

of various TNF family ligands by preventing their interaction with cell-bound recep

that mediate the dominant signals activated by those ligands. OPG is a soluble deco

receptor for TRANCE (discussed in more detail in section 2.3). DcRl is a GPI-linked
decoy receptor for the pro-apoptotic TNF family member TRAIL, DcR2 is a
transmembrane decoy receptor for TRAIL, and DcR3 is a soluble decoy receptor for

FasL. The expression of decoy receptors plays an important role in tempering the po
effects of TNF family members. Another mechanism of generating decoy receptors is

through the proteolytic cleavage of cell-bound TNFR family proteins, rendering them
soluble. This has been shown in the case of TNFR1, TNFR2, CD27, CD30, CD40, and

Fas (26). A third mechanism of generating decoy receptors is through alternative sp

• 4-
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of TNFR family proteins, generating membrane-bound receptors with no cytoplasmic
tails, which has been shown for Fas (27) and CD40 (28).

2.1.3 Activating Receptors

Activating TNF receptors mediate their intracellular signals through a different se
adaptor proteins termed TNF receptor associated factors, or TRAFs. While DD
containing receptors interact with cytoplasmic adaptor molecules that activate the

apoptotic caspase cascade, receptors that interact with TRAF proteins activate a va

of signal transduction pathways that mediate a large number of cellular effects, in
survival, proliferation, differentiation, activation, and migration, to name but a

TRAF proteins will be discussed in greater detail in the next section. Table 2.1 li
known TNFR family proteins (by standardized TNFRSF nomenclature), their ligands,
intracellular adaptor molecules with which they interact, and known physiological
functions (adapted from (3)).
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Table 2.1; T N F R superfamily members

TNFR

Receptor

Other names

Ligand(s)

SF#
IA

Intracellular

Physiological Functions

adaptors
TNFR1

p55,CD120a

TNF-a, LT-a

T R A D D , RIP,

Macrophage activation, G C

TRAF1,2,5

formation

(indirect)
IB

TNFR2

p75, C D 120b

TNF-a, LT-a

TRAF1,2,5

3

LTpR

TNF-R-III

LT-P

TRAF3,5

L N organogenesis

4

OX40

C D 134

OX40L

TRAF1,2,3,5

T cell activation

5

CD40

CD40L

TRAF1,2,3,5,6

B cell proliferation, maturation,

Bacterial response, T cell
homeostasis

(CD 154)

class switching, D C maturation,
activation, survival

6

Fas

CD95, Apol

FasL

FADD

Lymphocyte homeostasis, T cell
cytotoxicity, immune privilege
maintenance

7

CD27

CD27L (CD70)

TRAF2,5

T cell activation

8

CD30

CD30L

TRAFl.2,3,5

T cell regulation, expressed on
Reed-Sternberg cells ( H D )

9

4-IBB

C D 137

4-1BBL

TRAF1,2,3

D C - T cell communication

10A

DR4

Apo2, TRAIL-

TRAIL

FADD

Lymphocyte homeostasis

Rl
10B

DR5

TRAIL-R2

TRAIL

FADD

Lymphocyte homeostasis

IOC

DcRl

TRAEL-R3

TRAIL

None

Decoy for T R A I L

10D

DcR2

TRAIL-R4

TRAIL

None

Decoy for T R A I L

11A

TRANCE

RANK

TRANCE

TRAF1,2,3,5,6

Osteoclastogenesis, D C

(RANKL,

c-Src, c-Cbl

survival/activation, m a m m a r y

-R

OPGL, ODF)

gland development, L N
organogenesis

IIB
12

OPG
DR3

OCIF

TRANCE

None

Apo3,

TWEAK

TRADD

Decoy for T R A N C E

TRAMP
14

HVEM

ATAR

LT-a, LIGHT

TRAF1,2,3,5

H S V receptor, T cell proliferation

16

NGFR

p75

NGF

TRAF6

Neurogenesis

17

BCMA

18

AITR

GITR

19

Troy

Taj

BLyS

B cell responses

AITRL

TRAF1,2,3

Inhibits TCR-induced apoptosis
Regulator of hair follicles?

TACI

BLyS

EDAR

EDA

B cell survival

DR6
LMP1

Self-activating

-6
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2.2 TRAF proteins

There are six known mammalian TRAF proteins, of which TRAF1, 2, 3, 5, and 6 have
been shown to interact directly or indirectly with members of the TNFR superfamily

31). In addition, TRAF6 mediates signaling from several other receptors that are no
TNFR family proteins, including IL-1R, IL-18R, and Toll-like receptors (TLRs). The

physiological role and binding partners of TRAF4 are presently unclear. TRAF protei

are characterized by a highly conserved C-terminal domain called a TRAF domain that

mediates interactions of TRAFs with other proteins. The N-terminal domains of TRAFs

are slightly more divergent, but each TRAF contains one or more zinc-binding domain

that enable the activation of signaling cascades. TRAF proteins have been implicate
the activation of several kinase cascades, including MAP kinases, IkB kinases, and

family kinases, resulting in the ultimate activation of transcription factor comple
including AP-1, NF-kB, Elk-1, ATF2, and others. Thus, TRAF proteins exert their
function by linking TNFR family proteins to these kinase cascades and subsequent
regulation of gene expression.

2.2.1 TRAF identification, genetics, and expression

TRAF1 was first identified through the biochemical purification of intracellular fa
interacting with TNFR2, and TRAF2 was cloned via a yeast two-hybrid system using
TNFR2 as bait (32). TRAF3 (also called CD40bp, LAP-1, and CRAF1) was identified as

an intracellular factor interacting with CD40 and LMP1 (33-35). TRAF4 was identifie
by differential screening of a cDNA library generated from tumor cells (36). The
existence of multiple TRAFs suggested a larger family of proteins with a conserved
domain (the TRAF domain), and degenerate PCR strategies were employed to clone

2. General Introduction

TRAF5 and TRAF6, which were also independently identified by yeast two-hybrid

screening using CD40 as bait and the screening of an EST expression library (37-40)

Since the identification of TRAF6 over 5 years ago, no other proteins strictly defi

belonging to the TRAF family have been identified, although some TRAF-like proteins
that may have divergent functions have been identified recently (41). Evolutionary
conservation of TRAFs is suggested by the identification of a TRAF in the nematode
elegans (42) and two TRAFs in Drosophila (dTRAFl and dTRAF2, (43)). To date, all
six mammalian TRAFs have been deleted in mice by gene targeting, revealing various

physiological roles for each (to be discussed further in section 2.2.5). Of the six

mammalian TRAFs, sequence conservation analysis has shown that TRAFs 1, 2, 3, and 5

are closely related, while TRAFs 4 and 6 are more evolutionarily divergent. Of thes
evolutionary relations, TRAF1 and TRAF2 appear to have arisen after duplication of
common precursor, while TRAF3 and TRAF5 are derived from a different common
precursor (44).

Expression patterns of TRAF proteins are widely variable. TRAF2, 3, and 6 are

expressed in most cell and tissue types (32-35,39,40). The expression patterns of T

4, and 5 are more restricted. The highest levels of endogenous TRAF1 expression hav

been found in tonsils, spleen, lung, and testis (32), while TRAF5 is expressed in s

lung, and thymus (37,38). The expression pattern of TRAF4 underscores its apparent l
of function in the arena of other TRAF proteins (inflammation and immunity), as it

predominantly expressed during embryogenesis and in certain neural tissues (36). Wh

the expression of TRAF2, 3,5, and 6 appears to be largely constitutive in the cells

express those TRAFs, the expression of TRAF 1 is tightly regulated. Most cells with

potential to express TRAF1 express it at very low levels in a resting state. Howeve

inflammatory stimuli including TNF family proteins, IL-1, LPS, and lymphocyte recep

-8
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engagement induces rapid upregulation of TRAF1 expression (45). Promoter analysis o

the trafl locus shows the presence of NF-kB and AP-1 sites (46), thus, intriguingly

transcription factors activated by TRAF-dependent signals upregulate the expression
TRAFL

2.2.2 Structural features of TRAFs
The domain organization of TRAFs comprises a modular structure characteristic of

adaptor proteins whose function is to link structurally dissimilar factors. As show

Figure 1, the C-terminal TRAF domain (32) can be further divided into two sections,
TRAF-N and TRAF-C. The TRAF-N section is helical and adopts the form of a coiled

coil, mediating oligomerization of TRAF proteins. The TRAF-C domain also contribute
to oligomerization as well as to interactions with TNFR family proteins and other
cytoplasmic factors (47). The N-terminal halves of TRAF proteins are somewhat more
divergent, but all TRAFs except for TRAF1 contain a RING finger motif at their Ntermini. The RING finger comprises a set of four closely spaced Zn fingers, which,

turn, consist of two residues that can chelate a single Zn2+ ion (generally cystein

occasionally histidines or acidic residues). C-terminal to the RING finger in TRAF2,

and 6 are five Zn fingers, while in TRAF1, there is a single Zn finger, and in TRAF
there are seven Zn fingers. In addition to the Zn binding motifs in TRAF4 are two

potential nuclear localization signals (NLS), which may direct TRAF4 localization to

nucleus (36), while TRAF1, 2, 3, 5, and 6 are chiefly cytoplasmic in their distribu
While nearly all known interactions between TRAFs and other proteins such as TNFRs
and cytoplasmic factors are mediated through the TRAF domain (31), the RING and Zn

fingers appear to be necessary for the ability of TRAFs to activate kinase cascades
Accordingly, deletion of the N-terminal domains of TRAFs renders them dominant
negative for signal transduction.
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# of a.a. NF-kB/JNK
(mouse)
TRAF1

409

TRAF2

501

activation

+

567
470
TRAF5

-|

TRAF6

•

RING finger

•

Zn finger

•

T R A F - N (coiled coil)

558

+

530

+

TRAF-C
NLS
Figure 2.1. Domain organization of mammalian TRAF proteins.

The structures of the T R A F domains of T R A F 2 and T R A F 3 have been determined by xray crystallography, and have provided important insights into the mode of interaction
between T R A F s and other proteins (48-51). M u c h as T N F family ligands are trimeric,
and their binding to T N F R family receptors dictates receptor trimers, the binding of
T R A F proteins to the cytoplasmic tails of T N F R proteins is also trimeric. The T R A F
domains of T R A F 2 and T R A F 3 adopt a mushroom-shaped structure, with the coiled-coil
T R A F - N domains forming the stalk and the T R A F - C domains forming the cap. The
receptor-binding portion of the T R A F - C domain of T R A F 2 forms a groove in which
receptor sequences bind symmetrically in an extended conformation (51). The interaction
of T R A F 2 with T R A D D , which couples T R A F 2 to T N F R 1 , comprises a more extended
binding interface, and suggests that T R A D D may compete with other receptor sequences
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for TRAF2 (52). The thermodynamic properties of TRAF2-receptor interactions show

significantly lower affinity of TRAF2 monomers for receptor peptides than is the ca

with trimeric TRAF2 (53). This suggests an oligomerization-driven affinity or avidi

enhancement of TRAF-receptor binding interactions, which may illuminate a mechanism
of action for TRAF proteins. It has been shown that induced multimerization of the

terminal halves of both TRAF2 and TRAF6 can activate signaling, which suggests that

in vivo, receptor-induced TRAF trimerization is necessary for the activation of sig
cascades (54).

2.2.3 TRAF-interacting proteins
As adaptor proteins for TNFR family members, TRAFs mediate the assembly of

cytoplasmic signaling complexes at the receptor. They have been shown to interact w
wide variety of cytoplasmic factors, either directly or indirectly, in addition to

family proteins listed in Table 2.1. In addition to forming self-associated homotri
some TRAF proteins can hetero-oligomerize with each other. Specifically, TRAF2 has
been shown to form hetero-oligomers with TRAF1 and TRAF5 (32,55) while TRAF3 can
form hetero-oligomers with TRAF5 (56,57). Interestingly, the hetero-oligomerization

pairs of TRAF 1/2 and TRAF3/5 mirror the evolutionary origin of those pairs of TRAF

(44), which suggests that hetero-oligomerization is a product of closely related st
This may provide a further layer of regulatory roles for TRAFs - the regulation of
TRAFs. TRAF proteins bind to and mediate the function of several general types of

intracellular factors, including kinases, regulators of signaling pathways, structu

proteins, and other adaptor molecules (31). TRAFs are well-characterized activators

MAP kinase signaling pathways, and have been shown to interact with and activate th
cascades at the level of MAP3Ks and MAP4Ks, including ASK1 (58,59), TAK1 (60),
MEKK1 (54), NIK (61), and GCK3 (62). Some other kinases implicated in TRAF

-11
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signaling are Src-family kinases (63,64), IRAK (39), and PKC (65). Most of the

interactions demonstrated for TRAF proteins with kinases are mediated via the TRAF
domain. However, the TRAF domain alone acts as a dominant negative, thus the N-

terminal RING and Zn fingers appear to play a vital role in the activation of thes
cascades (47,66). Known interactions of TRAFs and intracellular factors are listed
Table 2.2 (adapted from (31)).

12-
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Table 2.2. TRAF-interacting cytoplasmic proteins and their functions

Cytoplasmic factor

Interacting

Function

TRAFs
RIP (Receptor interacting protein)

1,2,3

Activation of IKK, assembly of T N F R 1 complex

RIP2

1,2,3,5,6

Simile to RIP

I R A K (IL-1 receptor associated

6

With M y D 8 8 or T I R A P / M A L , mediates signaling

kinase)

from IL-1R and T L R s to T R A F 6

IRAK2, IRAK-M

6

Similar to I R A K

NIK (NF-icB inducing .kinase)

1,2,3,5,6

MAP3K-like kinase upstream of I K K activation

ASK1 (apoptosis signal -regulating

1,2,3,5,6

MjAP3K upstream of J N K activation

T A K 1 (TGF-P associated kinase-1)

6

M . A P 3 K upstream of IKK, J N K

M E K K 1 (MEK/ERK Kinase-1)

2,6
2
2
2

M A P 3 K upstream of J N K

kinase-1

IRE1
G C K (Germinal center kinase)
C D K 9 (cyclin dependent kinase 9)

P K C ^ (protein kinase C, i\ isoform) 6

ER-associated stress kinase
M A P 4 K upstream of J N K
Cell cycle regulation
Mitogenic signaling

TBK1/NAK

2

Upstream of I K K activation

c-Src

1,3,6

Multifunctional tyrosine kinase

1,2

Anti-apoptotic adaptor

1,2
1,2

Inhibitor of T R A F signaling

TANK/I-TRAF

1,2.3

Regulator of T R A F signaling

A20

2
2

Antiapoptotic, anti-inflammatory regulator

cIAP-1

(cellular inhibitor of

apoptosis-1)
cIAP-2
TRIP (TRAF inhibitory protein)

TRADD

(TNFR associated D D

containing protein)
F L A S H (FLICE-associated huge

Similar to cIAP-1

Mediates assembly of T N F R 1 complex, associates
with RIP, F A D D , A 2 0

2

protein)

Assembly of apoptosis-inducing complex with
caspase-8, possible role in I K K activation
Inhibits I K K activation

T6BP (TRAF6 binding protein)

2
6
6

TTRAP

2,3,5,6

Competes

ABIN (A20 binding protein)
ECSIT

Enhances I K K activation
Inhibits T6-IRAK interaction
with T R A F 6

for C D 4 0

inhibitor of T R A F signaling
Filamin

2

Actin-binding protein

MIP-T3

3

Binds to microtubules

Caveolin-1

1,2
3

Required for formation of caveolae

p62 nucleoporin

Mediates nuclear entry

13-
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2.2.4 Signaling pathways activated by TRAFs

TRAFs are defined by their ability to couple TNFR family proteins to signaling path

that result in the cellular effects mediated by TNF family ligands. The most well-s

signaling pathways activated by TRAF proteins are those leading to the activation o

transcription factors NF-kB and AP-1. NF-kB describes a set of five transcription f

subunits: p50, p52, RelA, RelB, and cRel (67,68). An active complex of NF-kB consist

of two of these subunits, either as a homodimer or a heterodimer. NF-kB complexes a
maintained in the cytoplasm in an inactive state by an inhibitory protein, IkB, of

there are several variants (a, (3, y,and e among them). When a cell receives an NF-

activating stimulus, a large, multiprotein complex of IkB kinases (IKK) phosphoryla
IkB on two serine residues (69). Phospho-lKB is then recognized by ubiquitin-

conjugating enzymes, which quickly ubiquitinate it, resulting in its degradation. T

released NF-kB subunits then translocate to the nucleus, where they bind to specifi

promoter sites, activating transcription of a wide variety of genes, including cyto

adhesion molecules, transcription factors, and survival factors. Most TNF family-in

NF-kB activation has been associated with cell proliferation, survival, and differe
signals. Oligomerization of TRAF proteins in a receptor complex results in the
recruitment and activation of various kinases upstream of IKK, including RIP (70),

(61), TAK1 (60), MEKK1 (54), and MEKK3 (71). It is likely that no single one of the
kinases is essential for TRAF-mediated NF-kB activation, but rather they may have

overlapping or cell type-specific roles (72). Recently, in vitro biochemical studie

suggested that the mechanism of TRAF-mediated IKK activation involves the ability o
the RING finger of TRAF6 to act as an E3 ubiquitin ligase, mediating non-classical
linked polyubiquitnation of TRAF6 as well as of the IKK complex (73,74).
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AP-1 describes a dimeric transcription factor complex comprising combinations of Ju

(v-Jun, c-Jun, JunB, or JunD), Fos (v-Fos, c-Fos, FosB, Fral, or Fra2), or activating
transcription factor (ATF2, ATF3, or B-ATF) proteins. c-Jun is activated by JNK, a

stress-related MAP kinase (75). TRAF proteins, in particular TRAF2, activate JNK by
activating upstream MAP3Ks including ASK1 (58,59), MEKK1 (54), TAK1 (60), and
the MAP4K GCK (62). These kinases in turn activate MAPKKs such as MKK4 and

MKK7, which phosphorylate JNK (76). As is the case with IKK kinases, genetic deleti

of several of the MAP3Ks upstream of JNK has not revealed an absolute requirement f

any one of these kinases in TRAF-mediated JNK activation, implying that there may b
some redundancy in TRAF-mediated JNK activation (71,77,78). In lymphocytes, JNK
activation appears to be associated with proliferation and survival signals, while

other cell types, it is associated with apoptotic signals and stress responses (75,7
Notably, JNK is activated in response to physical and osmotic stress as well as in
response to irradiation and DNA damage (79). In addition to JNK, other MAPKs are

activated by TRAF signaling, including ERK and p38. ERK activates the transcription

factor Elk-1, which is involved in cell activation and survival signals. p38 activa
AP-1 component ATF2, which has been implicated in stress and activation responses

(76,79). Recently, we (63) and others (64) have shown that TRAF6-mediated signals c
activate c-Src family tyrosine kinases. c-Src is essential for TRANCE-mediated

osteoclast activation, and Src family kinase-mediated PI3-K activation results in t
activation of Akt, a kinase associated with survival signals.

Some typical examples of TRAF-mediated signaling pathways are illustrated by those
activated by TNF-a, TRANCE, and IL-1. TNF-a has two known transmembrane
receptors, TNFR1 and TNFR2. TNFR1 is a DD-containing receptor, and does not
directly bind to any TRAF proteins, while TNFR2 has no DD and can directly bind to
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TRAF1 and 2 (and possibly TRAF5) (32). While TNFR1 is expressed on most cell types,

the expression of TNFR2 is restricted to hematopoietic cells (80,81). Additionally,

TNFR1 can be stimulated by cell-bound or soluble TNF-a, TNFR2 is only responsive to
cell-bound TNF-a (82). Upon ligand engagement, TNFR1 recruits TRADD and RIP to
the receptor complex via DD interactions (17,70). There are two essential pathways

can be activated at this point - TRADD can recruit FADD, which activates the caspas

cascade, resulting in apoptosis, or it can recruit TRAF2, which activates NF-kB and

signaling, which results in survival or proliferation (17). TNFR2, on the other han

a DD, and can bind to TRAF2, activating survival pathways (32). Interestingly, TNFR

stimulation has been shown to potentiate TNFR 1-mediated apoptosis, and this may be

accomplished through the depletion of available TRAF2 (83). Thus, the available poo
TRAF2 may serve to regulate the balance of life and death in TNF signaling. Figure
diagrams some features of TNF signaling.

TRANCE-R, unlike TNFR1, lacks a DD, and its cytoplasmic tail can recruit TRAF1, 2,

3,5, and 6 (84). The TRAF6 binding sites are distinct from the binding site for the
TRAFs in TRANCE-R. The TRAF1/2/3/5 sites are associated with the activation of NF-

kB and JNK similar to TNFR2, as are the TRAF6 binding sites. In addition, TRAF6 has

been implicated in MAPK activation and c-Src activation (63). IL-1 is not a TNF fa

protein, and its receptor is not a TNFR family protein, although it signals through

TRAF6, but indirectly. IL-1 binding to IL-1R, which is associated with an accessory
protein (IL-lRAcP), induces the formation of a receptor complex that includes the
cytoplasmic factors MyD88 and Tollip. MyD88 and Tollip then associate with the
cytoplasmic factor IRAK. IRAK binds to TRAF6, enabling the activation of similar
downstream signals as from TRANCE-R (39,85-89). IRAK is also a key intermediate in

Toll-like receptor (TLR) signaling (90-92). TLRs recognize repetitive sequences suc
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bacterial and viral products, and are associated with innate immunity. Thus, by mediating
signals from both T N F R family proteins and TLRs, T R A F 6 serves as a molecular bridge
between adaptive and innate immunity. TRAF6-dependent signaling mechanisms from
T R A N C E - R and IL-1R are shown in Figure 2.3.

Figure 2.2. Signaling pathways
activated by TNF. Soluble TNF-

TNF

a acts primarily on TNFR1 while
membrane-bound TNF-a acts on

TNFR1

TNFR2. TNFR1 associates with

TRADD

TRAF2 through T R A D D and RIP,
TRAF2

while T R A F 2 binds directly to

TRAF2

TNFR2. Death domains (DD) are
shown in red.

\ /
NF-kB, AP-1

1
SURVIVAL

TRANCE
Figure 2.3. TRAF6-dependent
IL-1RACP

TRANCE-R

signaling pathways.
family

members

TNFR

such

as

T R A N C E - R and CD40 bind to
TRAF6 as well as other TRAFs,
activating

various

pathways

including Src-family kinases. ILJNK, p38, ERK
TRAF2/5

lTRAF3

1R and Toll-like receptors are
indirectly

NF-kB

linked to T R A F 6

through M y D 8 8 , Tollip, and
s
NF-kB

i
JNK

V

IRAK.

2.2.5 T R A F knockout mice
All six of the T R A F proteins have been deleted in mice by gene targeting, and the
phenotypes of these mice reveal divergent roles for each T R A F . T R A F 1 - / - mice have no
apparent developmental defects but appear to have enhanced inflammatory and T cell
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responses to TNF (93). The biochemical function of TRAF1 in its regulation of TRAF2

revealed in TRAF1-/- cells and will be discussed in detail in section 3.3. TRAF2 ha

targeted by deletion as well as by overexpression of a dominant negative form of TR
in lymphocytes (94,95). TRAF2-/- mice appear relatively normal at birth but become
progressively runted and cachectic and generally die within several weeks. This is
likely due to a "feed-forward" response of macrophages to TNF, as TRAF2-/-

macrophages produce large quantities of TNF in response to TNF stimulation, leading

systemic inflammation. TRAF2-/- cells show a lack of TNF-induced JNK activation but

still have NF-kB activation, although they display an enhanced tendency toward TNF-

induced apoptosis relative to wild-type cells (94). Crossing of TRAF2-/- mice to TN
or TNFR1-/- mice greatly ameliorates the wasting phenotype (96). Overexpression of
dominant negative TRAF2 (lacking the RING and Zn finger domains) in lymphocytes
results in reduced JNK but not NF-kB activation in response to TNF and CD40L (95).
The residual NF-kB activation may be explained by a redundant role of TRAF5, as
TRAF2-/-TRAF5-/- cells have a complete lack of TNF-induced NF-kB activation (97).
TRAF3-/- mice, like TRAF2-/- mice also appear normal at birth but become

progressively runted and die within several weeks. Reconstitution of lethally irrad

mice with TRAF3-/- fetal liver cells produces lymphocyte, granulocyte, and erythroi
lineages in those mice, but T cell responses are somewhat reduced, although CD40

signaling does not appear to be compromised (98). TR..AF4 deletion results in trach

malformation (99). Deletion of TRAF5 produces a relatively mild phenotype, with som
defects in CD40-mediated B cell responses (100). TRAF6-/- mice have severe
osteopetrosis, or thickening of bones, due to a defect in osteoclast function. Two
deletions of TRAF6 have been reported, and one completely lacks osteoclasts (101),

while the other has osteoclasts that are incapable of resorbing bone (102). In addit
both TRAF6-deficient strains have reduced responses to LPS, IL-1, and CD40. Thus,
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despite the similarities in signaling pathways activated by different TRAF proteins, each
appears to have a distinct physiological role.

2.3 Physiological processes regulated by TNF family proteins

TNF family proteins play vital roles in a wide variety of cellular processes, including
development, inflammation, immunity, and bone homeostasis. As TNF/TNFR family
proteins mediate communications between cells, they are important cellular organizers,
mediating the formation of multicellular structures including inflammatory foci,
lymphoid organs, bone, hair follicles, and lactating mammary glands (3). The signals
transduced by TNFR family proteins that activate survival, death, differentiation,
activation, and proliferation determine the dynamic organizing and reorganizing events
that characterize the systems regulated by TNF/TNFR interactions. In particular, we shall
consider the role of these interactions in immunity and bone homeostasis, which are both
typified not by the permanence of any cellular structures but rather by the constant state
of flux that ensures the robustness of each system. Additionally, it is becoming clear that
the apparent divergence of the highly specialized cell types that constitute these
apparently divergent systems is less obvious on a molecular level, and in fact, these
systems are quite interdependent. In particular, the communication between these systems
via TNF/TNFR family proteins is bridged by the processes and systemic metabolic
requirements of inflammation.

2.3.1 Dendritic cells
Dendritic cells (DC) are essential organizers of immune responses. They are highly
specialized cells that capture antigens in peripheral tissues, migrate to lymphoid organs,

and organize T cell responses. The life cycle of the dendritic cell consists of several well-
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defined stages, including differentiation, maturation, activation, and apoptosis (103). All
of these processes are regulated to some extent by the action of TNF family proteins on
DCs, in particular TNF, CD40L, and TRANCE (104), while DCs can stimulate T cells
via expression of OX40L, CD27L, and 4-1BBL (3). Additionally, extracellular signals
not originating from TNF family proteins in DCs are still TRAF-dependent, as DCs are
highly sensitive to bacterial and viral products that signal through TLRs (103), as well as
to IL-1, which utilize TRAF6 in their signaling pathways. DC signals that influence T
cells are shown in Figure 2.4 and T cell signals that influence DCs are shown in Figure
2.5.

4-1 BBL
CD27L
OX40L
Interleukins
Interferons
CD80/CD86
^Integrins,
Tolerance*^

Thymic
Selection

J

Maturation
Survival

Thl/Th2

Figure 2.4. DC-T cell cross-talk I. DCs mediate a wide variety of effects on T cells, in pa
actions of the T N F family proteins 4-1 BBL, CD27L, and OX40L.
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Infection,
Inflammation
LPS
Viral products
IL-1
TNF

Maturation

Survival
TNF
CD40L

Cytokine

TRANCE

\

Interleukins

Migration

Production

Interferons
Integrins
Figure 2.5. DC-T cell cross-talk II. DCs respond to a wide variety of signals from their environment and
from T cells with which they interact. TRAF-dependent factors that influence DCs include LPS, viral
products, IL-1, TNF, CD40L, and T R A N C E .

DCs arise from multipotent precursors of the monocyte lineage. Autocrine TNF
production is thought to contribute to differentiation to immature DCs (105). Immature
DCs reside in peripheral tissues, sampling antigens. They are highly specialized for this
task, efficiently internalizing particles from their environment. At this stage, the
expression of T cell costimulatory molecules such as CD80, CD86, and MHC is low, as
is the expression of TNFR family proteins such as CD40 and TRANCE-R. Many stimuli
can induce the maturation of DCs, including microbial products that bind to TLRs, and
inflammatory cytokines such as IL-1, TNF, and CD40L. As DCs mature, endocytosis
decreases, and the surface expression of costimulatory molecules, CD40, and TRANCER increases (106). Maturing DCs migrate to draining lymph nodes, where they encounter
activated T cells, engaging in a sophisticated cross-talk with them. In the absence of
external survival stimuli, mature DCs rapidly undergo apoptosis (107), which is a likely
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regulatory mechanism preventing autoimmunity. A productive interaction between an

antigen-bearing DC and an antigen-specific T cell involves signals influencing both
DC and the T cell. Stimulation of the TCR and costimulatory receptors such as CD28

upregulate TNF, CD40L, and TRANCE on T cells, which provide survival and activation

signals to the DC, so that it may engage more T cells in an ongoing immune response

(104). Immature DCs are able to stimulate regulatory T cells leading to tolerogenic
responses (108), thus the phenotype of DCs is an important regulator of the quality
intensity of a given immune response.

TNF family members are important regulators of DC function. CD40L induces DC
maturation, survival, and cytokine production (109). CD40L deficiency leads to a
markedly reduced ability of DCs to stimulate T cell-dependent responses (110).
TRANCE- and CD40L- mediated increases in DC survival have potent effects on

antigen-specific T cell responses (107,111,112), suggesting that the persistence of
antigen-bearing mature DCs in the lymph node is an important factor in determining

efficiency of T cell responses. TNF-deficient mice display reduced antiviral respon

which is likely to be due to a defect in maturation (113). The spontaneous apoptosis

mature DCs appears to be at least partially due to autocrine activation of TNFR1, a

TNFR1-/- DCs are highly resistant to spontaneous apoptosis (114). While the importan

of TNF family proteins to DC biology is indisputable, the signaling pathways activa

by TNF family proteins in DCs have not been well documented. A deeper understanding
of the roles of specific signals induced by TNF family proteins in DCs may provide
to manipulate the quality and intensity of immune responses.
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2.3.2 Osteoimmunology: cross-talk between bone and the immune system

It has long been known that the cells of the immune system originate in the bone ma

While the differentiation of lymphocytes and other cells of the hematopoietic syste

bone marrow has been well described, relatively little attention has been paid to t

effects that immune cells have on the bone itself. The possibility that immune cell

affect bone has been suggested in a variety of pathological conditions where normal

growth and remodeling is disrupted, including autoimmune diseases and cancers of th

hematopoietic system. The recent identification of some of the molecular mechanisms

that govern bone physiology and immunity has revealed a striking amount of cross-ta

between the two systems. It is rapidly becoming apparent that the fields of bone bi
and immunology are inextricably intertwined.

2.3.2.1 Bone disease and osteoclasts

Rather than simply serving as a rigid, static frame on which to hang flesh and vita

organs, skeletal bone is the result of a continuous, dynamic process of mineralizat

resorption. These opposing actions are carried out by two cell types, osteoblasts a

osteoclasts, and must be kept in balance to maintain skeletal integrity and systemi

calcium metabolism. A disruption of this balance is most often observed when the ra

resorption by osteoclasts exceeds the rate of mineral deposition by osteoblasts, an

mass is lost, as in osteoporosis (115). Increased bone resorption is observed in man

inflammatory and autoimmune diseases, such as rheumatoid arthritis (116), periodonta
disease (117), and Paget's disease (118). Bone destruction is also common secondary

many cancers, both those that reside in bone like leukemias and multiple myeloma, a

well as breast and prostate cancers (119). A common clinical complication of cancermediated bone resorption is humoral hypercalcemia of malignancy (120).
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Osteoclasts differentiate from multipotent bone marrow-derived cells of the

monocyte/macrophage lineage (121). The life of an osteoclast can be broken down into

four sequential stages: differentiation from multipotent bone marrow progenitors in

mononuclear osteoclasts, fusion into multinucleated cells, activation to resorb bone
apoptosis. These stages are regulated by the interactions of osteoclasts and their

precursors with osteoblasts and other stromal cells in bone tissue, which stimulate

inhibit osteoclastogenesis in response to various stimuli, such as parathyroid horm

(PTH), vitamin D3, and calcitonin. Deficiencies in normal osteoclast function lead t

osteopetrosis, or a thickening of bone due to insufficient resorption, while hypera
of osteoclasts leads to osteoporosis, or loss of bone mass.

Studies in osteopetrotic mice with spontaneous and engineered mutations have reveal

some of the genetic factors responsible for each of the stages in the osteoclast li

Two factors crucial for the differentiation of osteoclasts are M-CSF (macrophage co
stimulating factor) and TRANCE. Mice with a mutated M-CSF gene completely lack
osteoclasts (122), as do mice with targeted deletions of TRANCE and TRANCE-R (123-

125). Not all osteopetrotic mice lack osteoclasts; those with targeted deletions of

(101,102) or the non-receptor tyrosine kinase c-Src (126,127) have osteoclasts, but

are incapable of being activated to resorb bone. Other mutant mice with osteopetros
have demonstrated the importance of the transcription factors NF-kB (128) and AP-1
(129) in osteoclast development.

2.3.2.2 TRANCE/TRANCE-R/OPG regulation of osteoclasts
Studies of TRANCE and its two receptors TRANCE-R and OPG has suggested that cells

of the immune system and the cells that remodel bone may regulate each other's func

TRANCE is normally expressed on osteoblasts and activated T cells, and its activati
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receptor TRANCE-R is expressed on myelomonocytic cells, including osteoclasts and
DCs (104). Although TRANCE and CD40L appear to have largely overlapping functions

in stimulating the activation, survival, and adjuvant properties of DCs (107,130,131

TRANCE has been shown to be essential for certain CD40-independent anti-viral T cel

specific responses (112,132). In addition to its role in the regulation of osteocla
DCs, TRANCE is essential for lymph node organogenesis (133) and it regulates the

function of activated T cells (134,135). OPG is a non-signaling soluble decoy recep
TRANCE that negatively regulates its function by blocking the ability of TRANCE to
bind to TRANCE-R on target cells (18,136).

TRANCE-R signaling through TRAF6 is of particular interest in osteoclasts because
TRAF6 plays a role in TRANCE-mediated NF-kB and JNK activation (84,137). TRAF6

also provides a crucial link to the activation of c-Src, which activates the survi

Akt, prolonging the lifespan of activated osteoclasts (63,64). In addition, c-Src a

leads to the cytoskeletal changes such as membrane ruffling and actin ring formatio
necessary for osteoclasts to resorb bone (127).

Since TRANCE is expressed on activated T cells, and is crucial for T cell-DC
communication, one might expect massive bone resorption under most inflammatory

conditions. Indeed, it has been shown that TRANCE on activated T cells could activa
osteoclasts in an induced arthritis model, and blocking TRANCE with OPG abrogated
bone destruction but not inflammation (138). Furthermore, the bacteria that cause
periodontal disease induce TRANCE expression on T cells, leading to alveolar bone
destruction (139). Under conditions of estrogen withdrawal similar those seen in
postmenopausal osteoporosis, it was found that increased TNF production by T cells
augments TRANCE-mediated osteoclastogenesis (140). In TRANCE-deficient mice, it
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has been shown that some of the osteoclast defects could be rescued by transgenic
overexpression of TRANCE on T lymphocytes (124), which suggests that T cells may
have a role in osteoclast activation under non-pathologic conditions. Figure 2.6

summarizes some key interactions between activated T cells, other inflammatory sign

osteoclasts, and osteoblasts. Our T cells are constantly working to fight off the u

of antigens in which we live, so what prevents them from causing extensive bone los

Infection,
Inflammation
Survival,
^
Cytokine production
\
n \ \
x

/
O C
\ Calciotropi^
/
\
ctimuli
(Precursor)

"^/trancf.
4TRANCE-R

Activation,
Maturation
V
B o n e Resorption
Figure 2.6. The interface between bone and the immune system. TRANCE on activated T cells
stimulates D C as well as osteoclasts. Inflammatory mediators also affect O C function.

2.3.2.3 Regulatory mechanisms for inflammation-induced bone loss
Recently, a crucial counter-regulatory mechanism whereby activated T cells can inhibit
TRANCE-mediated osteoclast development and activation through the action of the
antiviral cytokine IFN-y was demonstrated (141). While the type of T cells involved in
inflammatory responses express TRANCE, they also secrete IFN-y. IFN-y can block
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TRANCE-mediated osteoclastogenesis in vitro, and in mice deficient for the IFN-y

receptor, bone destruction in an autoimmune arthritis model is greatly exacerbated.

As is shown in Figure 2.7, the mechanism for this strong blockade of TRANCE signali

by IFN-y in osteoclast precursors appears to be through activation of the ubiquitin
proteasome pathway for protein degradation (142), specifically targeting TRAF6 for
degradation. Osteoclast formation in the presence of IFN-y could be rescued by
overexpression of TRAF6 in precursor cells, and IFN-y's suppressive effect on
osteoclastogenesis was markedly decreased in mice lacking proteasome components.
Moreover, TRANCE-R is not the only receptor that signals through TRAF6. Signals
downstream of CD40 are also attenuated by IFN-y treatment. TRAF6 is an essential

intermediate in signaling by LPS and IL-1, pathways associated with innate immunity

(101,102). Given that IL-1 (143) and LPS (144) can induce osteoclastogenesis and bo

resorption, it will be interesting to examine the effects of IFN-y on those pathway

well. Figure 2.8 diagrams some key signaling pathways involved in the balance betwe
T cell-mediated osteoclast activation and inhibition.
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Figure 2.7. IFN-y negatively regulates
TRANCE-mediated

osteoclastogenesis.

Activated T cells express both T R A N C E
and IFN-y. While T R A N C E can activate
osteoclastogenesis in a TRAF6-dependent

OPG

manner, IFN-Y upregulates pathways leading
to the degradation of T R A F 6 . This may

IFN-y

explain why inflammatory processes do not
always lead to bone loss.

IFN-yR

TRANCE
OPG

1

IL-1

TRANCE-R

LPS

1
TRAF6
/
I
NF-kB J N K

IFN-y
V
c-Src

Bone

Bone

Mineralization
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Figure 2.8. T h e osteoclast signaling axis. Factors promoting bone resorption by activating osteoclast
function are shown in blue, and factors promoting bone mineralization by inhibiting osteoclast function are
shown in red.
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2.3.2.4 Other inflammatory regulators of osteoclasts

Clearly, we are only beginning to scratch the surface of the relationship between b
biology and the immune system. Other immunomodulatory factors, including TNFa

(145,146), IL-6, IL-11, IL-15, and IL-17 can positively modulate osteoclast function
while IL-4, IL-10, IL-13, IL-18, and TGF-p can inhibit bone resorption (147). The

clinical sequelae of bone destruction in inflammatory diseases are significant, and

treatment initiatives targeting TNF (148) have shown promising preliminary results.
However, systemically targeting TNF, TRANCE, or other immune mediators to prevent
chronic bone loss may result in long-term immunodeficiencies. The future design of

treatments for bone loss must incorporate greater sensitivity to the potential detr

effects of those treatments on normal immune function. Cell type-specific inhibitor

various signaling intermediates in osteoclast activation such as c-Src present a s

right direction (149), and further advances in understanding the differences in sig

pathways activated in osteoclasts and dendritic cells should lead to more therapeut
targets.

The cells that resorb bone come from the same hematopoietic lineage as the cells th

process and present antigens in the immune system. As is highlighted by the regulat
relationships between TRANCE, TRANCE-R, and OPG, immune cells and bone cells

use similar molecular mechanisms in their normal functions. Increasingly, it is bec

evident that there is significant cross-talk between bone and the immune system und

normal physiological conditions as well as in inflammatory pathological conditions.

light of recent advances in the treatment of both inflammatory diseases and osteopo
the challenge now is to carefully navigate the interface between bone (osteo-) and
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immune system. This challenge opens a new field of study, which we propose to call
osteoimmunology (150).

2.4 TNF/TNFR proteins and TRAFs in health and disease

Beyond diseases of bone, there are many other clinical conditions in which dysregul

of TNF family proteins have been implicated, including Crohn's disease, stroke, mul
sclerosis, and Alzheimer's disease (151). Defects in CD40L expression results in X-

linked hyper-IgM syndrome, in which B cell isotype switching is impaired, and patie

are susceptible to a variety of infections (152-155). Similar clinical findings hav
linked to mutations in the CD40 gene (156). LMP1 is a viral protein expressed in

Epstein-Barr virus-infected B cells, mimicking a constitutively active CD40 (35) an
HVEM is a receptor for herpes simplex virus on T cells (157). While the basic
underpinnings of TNFR family signaling are established, the precise mechanisms of

action of TRAFs and their downstream targets are less clear. A greater understandin
TRAF-mediated signaling mechanisms, including: differentiating the mechanisms by

which TRAFs activate different kinase cascades, determining the individual roles of

TRAF, elucidating structure-function relationships of TRAFs and interacting protein
identifying modes of TRAF regulation, and dissecting the roles of combinations of
TRAFs and specific receptors in a cell type-specific manner will be essential to

understanding and manipulating these conditions in the future. The goal of this the
to address some of these issues pertaining to the mechanisms of TRAF signaling.
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3.1 A POSITIVE REGULATORY ROLE FOR CBL FAMILY PROTEINS IN
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3.1.1 S u m m a r y

TRANCE is a TNF family member essential for osteoclast differentiation, and it ind
the activation and survival of osteoclasts and mature dendritic cells. We recently
demonstrated that TRANCE activates Akt via a mechanism involving TRANCER/RANK, TRAF6, and c-Src. Here, we show that TRANCE-R and CD40 recruit TRAF6,

Cbl family scaffolding proteins, and the phospholipid kinase PI3-K in a ligand-depe
manner. The recruitment of Cbl-b and c-Cbl to TRANCE-R is dependent upon the
activity of Src-family kinases. TRANCE and CD40L-mediated Akt activation is

defective in Cbl-b -/- dendritic cells and CD40L-mediated Akt activation is defect

c-Cbl -/- B cells. These findings implicate Cbl family proteins as not only negati
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regulators of signaling, but as positive modulators of TNF receptor superfamily sig
as well.

3.1.2 Introduction

Tumor necrosis factor (TNF) family proteins mediate diverse effects on cells of th

hematopoietic lineage via their cognate receptors, members of the TNF receptor (TNF
family (1). TNFR family proteins lack intrinsic enzymatic activity, but are linked

intracellular signaling cascades through TNFR associated factor (TRAF) proteins, an

numerous TNF family proteins have been shown to activate nuclear factor-kappa B (N

kB) and mitogen-activated protein kinase (MAPK) cascades (2). TNF-related activatio
induced cytokine (TRANCE; also called RANKL, ODF, and OPGL) is a TNF family
member expressed on activated T cells and osteoblasts that regulates the function

dendritic cells and osteoclasts through its cognate receptor, TRANCE-R (also called
RANK) (3). Recently, we demonstrated that in addition to activating NF-kB (4) and
N-terminal kinase (JNK) (5), TRANCE activates Akt, a serine/threonine kinase
implicated in survival signals, through a mechanism involving TRAF6 and the
nonreceptor tyrosine kinase c-Src (6).

c-Cbl is a cytoplasmic adapter molecule that has been implicated in the negative

regulation of signaling from a variety of receptor tyrosine kinases, including grow

factor receptors and antigen receptors in lymphocytes (7,8). A highly related protei

b, has been identified (9). The domain structure of Cbl proteins consists of sever
functional domains, including an SH2-like phosphotyrosine-binding domain, a RING

finger, a proline-rich domain, and a leucine zipper. Originally identified as a vir
oncogene that acquires transforming potential with the 70z deletion (10), Cbl has
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implicated in the negative regulation of tyrosine kinase signaling by shortening t
duration of activating signals (7).

c-Cbl and Cbl-b have been shown to interact with a wide variety of activated signa

molecules including phosphatidylinositol 3-kinase (PI3-K), Src-family tyrosine kina
Syk, and adaptor proteins Grb2 and She (11-14). One mechanism by which they may

negatively regulate signaling is by acting as an E3 ubiquitin ligase, which results

degradation of activated molecules by the proteasome (15-17). This E3 ubiquitin lig

activity has been localized to the RING finger of c-Cbl, and the RING finger has b
associated with the negative regulation of a number of tyrosine kinases, including
epidermal growth factor receptor (EGFR) (18,19), syk (20), and CSF-1R (21), among
others. Cbl-b has been associated with the negative regulation of Vav-mediated JNK
activation (22) and EGFR signaling (23).

Mice with targeted deletions in c-Cbl (24), and recently, Cbl-b (25,26) have been

described; each displays a phenotype of decreased thresholds for lymphocyte activa
and development of autoimmunity. Mice with a targeted deletion in c-Cbl display
enhanced thymic positive selection, likely due to the persistence of activated

costimulatory molecules that are ordinarily targeted for degradation by c-Cbl (24)

/- mice demonstrate T cell hyperactivation and hyperproliferation in response to a

receptor stimulation, uncoupling of T cell receptor (TCR) and CD28 stimulation, and
develop spontaneous autoimmunity (25,26).

In this report, we identify a mechanism by which the TNF family members TRANCE and
CD40L activate Akt through their cognate receptors TRANCE-R and CD40. We
previously demonstrated that, upon ligand engagement, TRANCE-R forms a complex
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with c-Src and TRAF6 (6). We now show that PI3-K and Cbl proteins are also

components of this signaling complex. Examination of the mechanism of the interacti
of c-Cbl and Cbl-b with TRANCE-R shows a requirement for c-Src kinase activity,
which may be regulated by TRAF6. Furthermore, a stable complex of TRANCE-R and

Cbl-b is observable only in presence of a proteasome inhibitor, suggesting that Cbl
negatively regulate TRANCE signaling by downregulating one or more components of

the TRANCE-R signaling complex. Finally, using cells derived from Cbl-b -/- and c-/- mice, we show that Akt activation by TRANCE and CD40L in dendritic cells is

dependent on Cbl-b, while Akt activation in B cells by CD40L is dependent on c-Cbl,
suggesting a novel positive regulatory role for Cbl proteins in signaling.

3.1.3 Experimental Procedures

3.1.3.1 Reagents
MG-132 was from Calbiochem; SAM68 was from Santa Cruz Biotechnology; PPI was
from Alexis Biochemicals, soluble hCD8-TRANCE (TRANCE) was purified from insect

cells as described (27); and soluble mCD8-CD40L (CD40L) was generated in insect ce
and supernatant was used at a 1:100 dilution as described (28).

Antibodies (Abs) specific for phospho-Akt (Ser-473), Akt, and IicB-a were from New
England Biolabs; c-Src (N-16), TRAF6 (H-274), and Cbl-b (N-19) were from Santa Cruz
Biotechnology; phosphotyrosine (4G10-HRP) and the p85 subunit of PI3-K (rabbit
antiserum) were from Upstate Biotechnology Ine; c-Cbl (17) from Transduction
Laboratories; HA (12CA5) from Boehringer Mannheim, and the Flag epitope (M2) were
from Sigma. Anti-TRANCE-R (1E6.66) was previously described (29) and anti-CD40
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(FGK-115) was purified from supernatants of hybridoma cells provided by Dr. Randol
Noelle (Dartmouth University, Hanover, NH).

3.1.3.2 Primary Cells

Mature dendritic cells were generated from bone marrow precursors as described (30
Osteoclasts were generated from bone marrow precursors as described (31).
Lymphocytes were prepared from whole spleens by making single-cell suspensions

followed by erythrocyte lysis and plating for lh on tissue culture plates to deple
adherent cells.

3.1.3.3 Plasmids
Expression constructs encoding FLAG-tagged wild-type mouse TRANCE-R (TR-wt),
chicken c-Src, c-SrcKD (K295M), and HA-tagged human c-Cbl in pcDNA3.1
(Invitrogen) have been described (6). TR-Y345F, Y440F, and Y468F were generated by
the QuickChange method of site directed mutagenesis (Stratagene). HA-tagged human
Cbl-b (WT and AN) constructs in the pCEFL vector were kindly provided by Dr. Stan
Lipkowitz (National Cancer Institute, Bethesda, MD) and have been described (32).

3.1.3.4 Cell Stimulation, Transfection, and Analysis

In vitro differentiated mature dendritic cells and osteoclasts, and freshly isolate

splenocytes were extensively washed to remove exogenous growth factors, cultured in
medium with low serum (0.5% FCS, 2-4 h), then stimulated by adding TRANCE or
CD40L as indicated. After stimulation, cells were washed with ice-cold PBS, lysed,

subjected to immunoprecipitation and western blotting as described (6). In order t

control for equal loading of each timepoint, the protein concentration of each samp
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determined and samples were normalized for total protein content prior to further
processing.

293T cells were transfected by calcium phosphate precipitation as described (4). Th

amount of transfected DNA was held constant to 1 }J.g by addition of empty vector D
where necessary. Cells were processed for analysis 24 h after transfection. Where
indicated, MG-132 or an equivalent amount of vehicle (DMSO) was added to a final

concentration of 10 ,uM 4 h prior to processing. Cells were processed and subject t

immunoprecipitation and western blotting as described (6). All transfection experim
were repeated at least three times and representative results are shown.

3.1.4 Results

3.1.4.1 TRANCE-R and CD40 Interact with PI3-K and c-Cbl Upon Ligand
Stimulation

Since TRANCE activates Akt in dendritic cells (DC) and osteoclasts, and Akt activat

is dependent on the activity of PI3-K, we investigated whether PI3-K was associated
TRANCE-R. In order to determine whether PI3-K is part of the TRANCE-R signaling
complex in primary cells, we immunoprecipitated TRANCE-R from TRANCE-treated
DC. The p85 regulatory subunit of PI3-K was recruited to TRANCE-R in a ligand-

dependent manner (Figure 3.1.1 A, top), which correlates with Akt phosphorylation i

whole cell extract (6). Since PI3-K has been shown to associate with the cytoplasmi
scaffolding protein c-Cbl in a variety of cell types, we probed the TRANCE-R
immunoprecipitates for c-Cbl and found that it associates with TRANCE-R in a
TRANCE-dependent fashion. This correlates with a ligand-dependent increase in

TRANCE-R-associated TRAF6 (Figure 3.1.1 A, top). Immunoprecipitation of c-Cbl from
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dendritic cell lysates confirmed that TRAF6 inducibly associates with c-Cbl upon l
stimulation (Figure 3.1.1 A, bottom).

In order to determine whether other TNFR family members known to signal through
TRAF6 behave similarly to TRANCE-R, we treated DC with CD40L, which, like
TRANCE, promotes the survival and activation of myeloid dendritic cells (33).
Immunoprecipitation of CD40 and western blotting showed that there was a ligand-

dependent increase in the p85 subunit of PI3-K and c-Cbl associated with CD40 (Fig
3.LIB, top). As we have previously found with TRANCE-R (6), Src-family kinase

activity co-precipitates with ligand-stimulated CD40 as assayed by the ability of t
immunoprecipitates to phosphorylate recombinant SAM68, a known Src-family kinase
substrate, in vitro (Figure 3.LIB, bottom).

We previously observed a peak of TRANCE-induced Akt phosphorylation after 20

minutes of stimulation (6). In order to determine if this activation correlates kin
with PI3-K recruitment to TRANCE-R, we stimulated DC with TRANCE for up to 60
minutes. Surprisingly, although PI3-K and c-Cbl continue to accumulate in the
TRANCE-R complex in increasing amounts (Figure 3.1.1C, top), Akt activation
decreases after 20 minutes of stimulation (Figure 3.1.1C, bottom. See also Figure
3.1.4A).

Since TRANCE-mediated Akt activation in DCs is dependent on the activity of Srcfamily kinases and can be inhibited by the Src-family kinase inhibitor PPI (6), we

endeavored to determine whether the association of c-Cbl and PI3-K is dependent on

family kinase activity. We pretreated DCs with PPI or vehicle (DMSO), stimulated the
DCs with TRANCE, and immunoprecipitated c-Cbl. In the absence of PPI, c-Cbl was
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constitutively phosphorylated on tyrosine in unstimulated DCs, and its phosphoryla

state was unaffected by TRANCE treatment. Pretreatment with PPI completely blocked
all c-Cbl phosphorylation (Figure 3.LID, top). However, the phosphorylation state

Cbl did not affect its binding to PI3-K, as PI3-K was constitutively associated wi

regardless of PPI treatment or TRANCE stimulation (Figure 3.LID, bottom). To ensure
that TRANCE stimulation activated signaling by TRANCE-R, we probed whole cell
extracts with antibodies to IkB-oc and observed equivalent TRANCE-dependent
degradation of IkB-cc in both DMSO- and PPI-pretreated cells (not shown).
TRANCE (min.)
0 5 20
e- *m% -«PI3-K
IP: TRANCE-R
- m m i m -4c-Cbl
• " • « — -«TRAF6
-. •—-, -<TRAF6
IP: c-Cbl
m m m t + m -*c-Cbl

Kinase i
Assay

— -«SAM68P

D

c
TRANCE (min.)
0 20 60
M r
— '*PI3-K
IP: TRANCE-R
1 «•"•« m m -«c-Cbl
WCE

CD40L (min.)
0 5 20
'••-4PI3-K
IP: CD40
~qp -«c-Cbl

DMSO
IQuMPPl
TRANCE (min.) 0 5 20 0 5 20
-*c-Cblp
IP: c-Cbl

P>* -- r-^^Akt''

—

—

-«c-Cbl
— -«PI3-K

Figure 3.1.1. PI3-K and c-Cbl are recruited to T R A N C E - R and C D 4 0 upon ligand stimulation in
dendritic cells.
A. Dendritic cells were treated for the indicated number of minutes with T R A N C E (2 |Jg/ml) and lysed.
T R A N C E - R (top) and c-Cbl (bottom) were immunoprecipitated and the immunoprecipitates were probed
with antibodies to PI3-K, c-Cbl, and T R A F 6 as indicated.
B. D C were treated with soluble C D 4 0 L (1:100) for the indicated number of minutes and C D 4 0 was
immunoprecipitated. The immunoprecipitates were probed with antibodies to c-Cbl and PI3-K (top and
middle). A n in vitro Src-family kinase assay was performed on the C D 4 0 immunoprecipitates (bottom)
with recombinant S A M 6 8 as a substrate.
C. D C were treated as in (A), T R A N C E - R was immunoprecipitated, and the immunoprecipitates were
probed with antibodies to PI3-K and c-Cbl as indicated (top). W h o l e cell extracts ( W C E ) were
immunoblotted with antibodies to phospho-Akt (Aktp) and PI3-K as indicated.
D. D C were pretreated with vehicle ( D M S O ) or PPI (10 \xM) for 90 minutes, then stimulated and lysed as
in (A). c-Cbl was immunoprecipitated and the immunoprecipitates were probed with antibodies to
phosphotyrosine, c-Cbl, and PI3-K as indicated.
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3.1.4.2 TRANCE-R and Cbl Proteins Interact only in the Presence of Active Src
To further elucidate the mechanism of c-Cbl's interaction with TRANCE-R, we
transiently transfected HEK 293T cells with constructs driving the expression of c-Cbl, cSrc, or Flag-epitope tagged TRANCE-R from a CMV promoter. In the presence of
overexpressed c-Src, an anti-c-Cbl antibody co-immunoprecipitated TRANCE-R (Figure
3.1.2A, lane a). In the absence of overexpressed c-Cbl, endogenous c-Cbl was sufficient
to demonstrate a c-Src dependent interaction with TRANCE-R (Figure 3.1.2A, lane c).
Conversely, in the absence of overexpressed c-Src, neither overexpressed nor endogenous
c-Cbl could co-precipitate TRANCE-R (Figure 3.1.2A, lanes b and d). To differentiate
between catalytic and structural roles for c-Src in the TRANCE-R/c-Cbl complex, we
cotransfected a kinase-inactive mutant of c-Src (c-SrcKD) with TRANCE-R and c-Cbl.
While the wild-type c-Src construct used has been shown to phosphorylate c-Cbl in
overexpression systems, c-SrcKD does not (34). Immunoprecipitation of TRANCE-R
with the Flag antibody and western blotting revealed that the kinase-active form of c-Src
was able to promote a strong interaction between c-Cbl and TRANCE-R (Figure 3.1.2B,
lane a). The kinase-inactive form of c-Src, however, could not promote a strong
interaction between c-Cbl and TRANCE-R (Figure 3.1.2B, lane b).

To determine if Cbl-b, another Cbl family protein, could also interact with TRANCE-R,
we cotransfected Cbl-b, TRANCE-R, and c-Src or c-SrcKD. Immunoprecipitation of
TRANCE-R with the Flag antibody did not reveal the presence of Cbl-b protein in either
case (Figure 3.1.2C, lanes a and b). However, in the presence of MG-132, a proteasome
inhibitor (35), we were able to coprecipitate Cbl-b with TRANCE-R in a c-Src kinasedependent manner (Figure 3.1.2C, lanes c and d). This suggests that Cbl-b may
downregulate one or more of the essential components of the TRANCE-R complex by
ubiquitination, thus creating a transient interaction between TRANCE-R and Cbl-b.
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Indeed, when we expressed TRANCE-R in the presence of c-Src and full-length Cbl-b,
w e observed a m a r k e d decrease in the a m o u n t of T R A N C E - R protein in the cell extract
(Figure 3.1.2D, lane a). H o w e v e r , w h e n w e either substituted a truncated f o r m of Cbl-b
with a deletion of the N-terminal S H 2 d o m a i n ( C b l - b A N , Figure 3.1.2D, lane b), omitted
c-Src (lane c), or both (lane d), TRANCE-R expression was normal, which suggests that
Cbl-b m a y mediate T R A N C E - R downregulation in a c-Src dependent m a n n e r .

whole cell extracts ( W C E ) were probed with
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3.1.4.3 c-Src Phosphorylates TRANCE-R

Since c-Cbl and Cbl-b interact with TRANCE-R only in the presence of active c-Src,
investigated whether this interaction is dependent on tyrosine phosphorylation of
TRANCE-R. Sequence analysis of the cytoplasmic domain of mouse TRANCE-R

revealed the presence of three tyrosine residues that could potentially serve as ta
c-Src: Y345, Y440, and Y468. Alignment with human TRANCE-R shows that while
Y345 and Y468 are conserved, Y440 is not. There is an additional tyrosine in human
TRANCE-R at position 422, corresponding to position 418 in mouse TRANCE-R (Figure

3.1.3A). In order to determine if any of the tyrosine residues in mouse TRANCE-R ar

phosphorylated by c-Src, we employed site-directed mutagenesis to change each of t
tyrosine residues to phenylalanine. We then cotransfected the tyrosine mutants of
TRANCE-R with c-Src or c-SrcKD and immunoprecipitated TRANCE-R. Western

blotting of the immunoprecipitates with an anti-phosphotyrosine antibody revealed t

wild-type TRANCE-R is phosphorylated by or downstream of c-Src on Y468, as only the
Y468F mutant was not phosphorylated in the presence of c-Src. Neither wild-type
TRANCE-R nor any of its tyrosine mutants was phosphorylated on tyrosine when

cotransfected with c-SrcKD, suggesting that Y468 is a specific target of c-Src act
(Figure 3.1.3B). We then cotransfected TRANCE-R constructs containing tyrosine

mutations with c-Src and Cbl-b or c-Cbl and found that Cbl-b and c-Cbl co-precipit

with all of the Y-F mutants of TRANCE-R, which suggests that the interaction betwee
TRANCE-R and Cbl is not dependent on the tyrosine phosphorylation of TRANCE-R
(Figure 3.1.3C-D). There was no interaction between a mutant of TRANCE-R with the

cytoplasmic tail deleted and c-Cbl or Cbl-b, indicating that the interaction is sp
the cytoplasmic tail of TRANCE-R (data not shown).
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3.1.4.4 C b l Proteins Regulate T R A N C E - and C D 4 0 - M e d i a t e d A k t Activation
Gene-targeted mice with deletions in c-Cbl (24) and Cbl-b (25,26) have been described
recently. In order to determine the role of Cbl proteins in TRANCE and CD40L-mediated
activation of Akt, w e used B lymphocytes, osteoclasts, and D C

derived from mice

deficient in c-Cbl or Cbl-b. In cells derived from Cbl-b-deficient mice, we observed that
neither TRANCE (Figure 3.1.4A) nor CD40L (Figure 3.1.4B) was able to strongly
activate Akt in DC within 20 minutes of stimulation, as opposed to what we observed in
wild-type cells. In all cases, NF-kB activation as measured by IkB-o: degradation was
identical in wild-type and knockout cells. Interestingly, at later time points (>3h),
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TRANCE and CD40L treatment did result in Akt activation in DC, which was similar t
a second wave of Akt activation observed in wild-type cells, suggesting that other
products that activate Akt via a Cbl-b-independent mechanism are upregulated over

time period. Since Akt has been widely characterized as a survival factor, we inves
whether there was a defect in TRANCE- or CD40L-mediated survival in Cbl-b -/- DC.

Perhaps due to the intact secondary wave of Akt activation, there was no difference
observed in TRANCE or CD40L-mediated survival in DC derived from Cbl-b-/- mice
over a 72h period (data not shown). In DC derived from c-Cbl-/- mice, we did not

observe any differences in TRANCE or CD40L-induced Akt activation or survival (dat
not shown).

In contrast to the results obtained in DC, in B lymphocytes from c-Cbl-/- mice, the
a marked deficiency in CD40L-induced Akt activation but Akt activation was intact

Cbl-b-/- B lymphocytes (Figure 3.1.4C). In osteoclasts derived from c-Cbl-/- and Cbl
mice, we did not observe any defects in TRANCE-induced Akt activation (Figure

3.1.4D). Consistent with intact TRANCE-mediated Akt activation in c-Cbl-/- and Cbl-

/- osteoclasts, we did not observe any defects in the differentiation or survival o
osteoclasts derived from these mice as determined by TRAP assay (data not shown).

Taken together, these results suggest that Cbl-b and c-Cbl may have cell type-depe
overlapping roles in Akt activation. It appears that c-Cbl is required for CD40Ldependent Akt activation in B cells while Cbl-b is required for TRANCE and CD40Ldependent Akt activation in DC. In osteoclasts, c-Cbl and Cbl-b appear to be able

substitute for one another in TRANCE-dependent Akt activation. In whole cell extrac

protein expression levels of c-Cbl and Cbl-b in dendritic cells, B lymphocytes, and

osteoclasts do not account for these cell type specific differences in function (d
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shown). It has been reported recently that, in c-Cbl-/- osteoclasts, Cbl-b is compensatorily
overexpressed (36). However, it is possible that the availability of c-Cbl and Cbl-b to the
various receptor signaling complexes differs in a cell type dependent manner due to
other, as yet unidentified components of the signaling complexes.
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3.1.5 Discussion

3.1.5.1 A Positive Signaling Role for Cbl

While Cbl family proteins have been widely held to play a negative role in tyrosine

kinase signaling, our results suggest a positive role as well. c-Cbl and Cbl-b have

demonstrated to associate with the p85 subunit of PI3-K both constitutively and in

response to ligand stimulation in a number of cell types and receptor/ligand pairs
14,37). In dendritic cells, we observed constitutive association between c-Cbl and

which is independent of Src-family kinase activity. Overexpression of Cbl-b has bee

shown to abrogate -Akt activation downstream of EGFR in response to ligand stimula
(23), and the hyperactivation and increased survival of T cells in Cbl-b -/- mice
that Cbl-b negatively regulates TCR and CD28-mediated signaling (25,26). However,

using cells derived from gene-targeted mice, we found that in dendritic cells, Cblrequired for TRANCE and CD40L-induced Akt activation, and in B lymphocytes, c-Cbl

is required for CD40L-induced Akt activation. In osteoclasts, c-Cbl and Cbl-b appe

substitute for one another in TRANCE-induced Akt activation. Cbl proteins, therefor

may positively regulate PI3-K activation via TNFR family proteins in a receptor- an
type-specific manner by recruiting PI3-K to the receptor complex, where it is
phosphorylated by Src family kinases.

3.1.5.2 Potential Negative Roles for Cbl in T R A N C E Signaling

This positive role, however, appears to be short-lived, as Akt activation by TRANCE

CD40L declines in dendritic cells after approximately 20 minutes of stimulation. I
possible that Cbl proteins are responsible for the termination of signaling by
downregulating Src kinases, PI3-K, TRAF6, or TRANCE-R and CD40 via internalization
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and/or ubiquitination. EGFR, a receptor tyrosine kinase, is rapidly autophosphoryla
within several minutes of ligand binding and its major signaling events take place
(38). Cbl-mediated ubiquitination of EGFR becomes evident on the order of 20-30

minutes after ligand binding, and quenches the activation signal over the next 20-3

minutes (15). Since c-Cbl binds exclusively to phosphorylated EGFR, only activated

EGFR is ubiquitinated and targeted for destruction. For productive signaling to occ

there is necessarily a time lag between the activation of the kinase and its destru

is therefore likely that, by acting as a scaffold for the assembly of the PI3-K sig
complex and the TRANCE-R signaling complex, Cbl can make a short-lived positive

contribution to signaling before downregulating activated proteins. Since the TRANC

R-c-Cbl-PI3-K complex is observed in DCs long after Akt activation is quenched (Fi

3.1.1C), it is possible that Akt downregulation is independent of Cbl in the recept
complex.

In support of the notion that Cbl indeed has a role in the negative regulation of T

signaling, we were only able to observe Cbl-b binding to TRANCE-R in the presence o

MG-132, a proteasome inhibitor. Additionally, we found that overexpression of fulllength Cbl-b and c-Src resulted in a marked decrease in TRANCE-R protein in cell

lysates, while eliminating either the N-terminal domain of Cbl-b or c-Src overexpr
did not reduce TRANCE-R protein levels. This suggests that TRANCE-R and/or other
essential activated components of the TRANCE-R signaling complex are targeted for

proteasome-mediated degradation by Cbl-b. Three likely candidates are TRAF6, c-Src,

and PI3-K. Recently, Takayanagi et al. (38) demonstrated that TRAF6 is ubiquitinate
and subsequently degraded by the proteasome in response to TRANCE stimulation in

osteoclast precursor cells. Harris et al. (39) reported that active c-Src is ubiqu

subsequently degraded while the steady-state level of c-Src KD is consistently hig
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that of active c-Src. This may explain the slight increase in c-Src observed in th

cell extract in the presence of MG-132 in Figure 3.1.2C. Fang et al. (41) reported
Cbl-b binds to and induces ubiquitination of the p85 subunit of PI3-K.

3.1.5.3 Roles of TRAF6 and c-Src in Receptor Assembly

We have shown that the C-terminal receptor binding domain of TRAF6 can interact wi
TRANCE-R (4) and c-Src (6). We have also found that the C-terminal half of TRAF6
interacts with c-Cbl and Cbl-b. This interaction promotes the activation of c-Src

tyrosine phosphorylate c-Cbl and Cbl-b, but phosphorylation is dependent on the Nterminal half of TRAF6 (6 and data not shown). Since catalytically active c-Src is
necessary to promote an interaction between TRANCE-R and Cbl proteins, but

phosphorylation of TRANCE-R on a specific tyrosine residue does not affect binding,

is likely that phosphorylation of Cbl proteins ultimately promotes this interaction
Nevertheless, the possibility remains that a component of the complex that has yet

identified is the true target of c-Src that facilitates Cbl-TRANCE-R binding. Ther

addition to activating the PI3-K cascade, c-Src appears to play a vital role in th
of the signaling complex.

3.1.5.4 Physiological Consequences of Cbl in TRANCE and CD40L Signaling

If Cbl-b is essential for Akt activation by TRANCE and CD40L in dendritic cells, wh
there no apparent defect in DC survival in Cbl-b-/- mice? When bone marrow-derived

DC reach maturity after 8 days in GM-CSF culture, they begin to undergo apoptosis i

the absence of survival stimuli (40). However, this process is observable on the or

many hours to days, and is most likely due to high levels of pre-existing bcl-2 pro
(27). In Cbl-b-/- DC, we observed Akt activation after several hours of TRANCE or

CD40L stimulation, consistent with a second wave of activation seen in wild-type DC
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is possible that this Cbl-b independent Akt activation is due to the expression of new
gene products induced by TRANCE or CD40L in DC, since other signaling pathways
activated by these cytokines appear to be intact in Cbl-b deficient cells. NF-kB
activation, as measured by decreasing and subequently increasing IkB levels, follows
identical kinetics in Cbl-b-/- and wild-type DC. Furthermore, the upregulation of IkB

observed in these cells at the 3 h time point suggests that the expression of other proteins
that could potentially activate Akt is upregulated. Attempts to inhibit this second wave of
Akt activation by blocking new gene transcription via the addition of cycloheximide were
unsuccessful, as even extremely low doses of cycloheximide (<50 ng/ml) completely
abrogated even the first wave of Akt activation (data not shown). Therefore, the
contribution of Akt activation to TRANCE and CD40L-mediated DC survival remains to
be determined.

While Akt is principally known as a regulator of cell survival, it is possible that it may
serve other roles as well. Meili et al. have shown that Akt plays an essential role in cell
motility in chemoattractant responses in Dictyostelium (41). In particular, Akt has effects
on actin-mediated cytoskeletal rearrangements. Since dendritic cells, when activated, are
quickly mobilized to migrate from outer tissues to draining lymph nodes, it is possible
that Akt activation by TNF family proteins or other inflammatory mediators such as IL-1
and LPS (6) plays a role in DC migration. Indeed, CD40L-CD40 (42) and LPS-Toll-like
Receptor (43) interactions appear to be required for dendritic cell migration in vivo. We
did not observe significant differences in DC migration in Cbl-b deficient mice (data not
shown), but again, the later wave of Akt activation in Cbl-b -/- DC could be sufficient to
allow DC migration within the experimental time frame. Given the importance of Akt in

a variety of cell functions, further study is warranted to determine its role in DC biology.
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Ubiquitmation/Degradation
of signaling complex components

Survival
Cytoskeletal changes7
Motility?

Figure 3.1.5. M o d e l of the proposed m e c h a n i s m of A k t activation by T R A N C E .
A . Soluble T R A N C E binds to membrane-bound T R A N C E - R , leading to its aggregation. T R A F 6 and c-Src
are recruited to the T R A N C E - R complex.
B. Cbl recruits PI3-K to the T R A N C E - R complex.
C . c-Src, activated b y its association with T R A F 6 , phosphorylates PI3-K, activating it to phosphorylate
m e m b r a n e phosphatidyl inositides. Akt is recruited to these phosphatidyl inositides via its pleckstrin
homology domain and is activated.
D. Cbl acts as an E 3 ubiqutin ligase, leading to the ubiquitination and subsequent degradation of one or
m o r e components of the T R A N C E - R signaling complex, quenching the activating signal.

3.1.5.5 Conclusion
TRANCE and CD40L activate Akt in a variety of cell types. In dendritic cells, the
T R A N C E - R and C D 4 0 signaling complexes recruit T R A F 6 , Src family kinases, PI3-K,
and Cbl in a ligand-dependent manner. The association of TRANCE-R and c-Cbl and
Cbl-b is dependent on Src kinase activity, and TRAF6 can enhance Src-mediated Cbl
phosphorylation. Cbl-b appears to downregulate T R A N C E - R expression in a Srcdependent manner. In c-Cbl and Cbl-b deficient mice, there are cell type-specific

in Akt activation downstream of TRANCE-R and CD40, indicating that Cbl proteins may
be required for T R A N C E and CD40L-dependent PI3-K activation. In Figure 3.1.5, w e

propose a model in which Cbl brings PI3-K to the receptor complex, where it is act
by c-Src with rapid kinetics. Concurrently, but with slightly slower kinetics, Cbl acts as a

ubiquitin ligase, leading to the degradation of one or more of the essential compon
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the signaling complex, quenching the activating signal. Cbl proteins thereby may ac

both positive and negative regulators of TRANCE and CD40L signaling in a kinetical
controlled manner.
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3.2.1 S u m m a r y

We determined crystal structures of TRAF6, alone and in complex with TRAF6-binding
sites from C D 4 0 and T R A N C E - R / R A N K at 2.5, 1.8 and 2.0A resolution. The structures
reveal a distinct receptor-binding groove of T R A F 6 , the key structural determinant of the
interaction. The structural information allows the identification and further confirmation
of TRAF6-binding sequences in the I R A K proteins using quantitative affinity
determinations. This leads to a proposed TRAF6-binding motif, whose structural
requirement was further investigated using site-directed mutagenesis. The mutual
recognition of T R A F 6 with C D 4 0 , T R A N C E - R , and the IL-1 receptor (via I R A K ) was
further demonstrated in vivo by correlating the mutational effects of receptors and of a
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dominant negative form of TRAF6 on downstream NF-kB, JNK, and p38 signaling. The
structures of the TRAF6 complexes also provide a physical model for the connection
Src signaling through cooperative ternary complex formation. These studies jointly

establish the structural basis of TRAF6 as the direct convergence point for the TNF
receptor and the IL-1 receptor superfamilies.

3.2.2 Introduction

Tumor necrosis factor receptor (TNFR) family proteins are important regulators of
immune and inflammatory responses. TNFR family proteins lack intrinsic signaling

activity, but they are coupled to downstream signaling molecules through TRAF (TNFR

Associated Factor) proteins, of which six have been identified (1). Of the known TR
proteins, TRAF6 is of particular interest because, while it functions similarly to

TRAFs in mediating signaling by TNFR family proteins, it is also the only TRAF know
to mediate signaling from receptors other than TNFR family members. Specifically,

TRAF6 has been implicated as a key mediator of signals originating from the interle

(IL)-l receptor (IL-1R) (2) and Toll-like receptors (TLR), which bind to the bacteri
product lipopolysaccharide (LPS) (3). Thus, TRAF6 represents a central point of
convergence for signaling by TNFR and IL-1R/TLR family proteins, and it plays a
critical role in bone homeostasis and both adaptive and innate immunity.

Two TNFR family proteins that bind directly to TRAF6 are CD40 and TRANCE-R.

CD40 is a key regulator of B cell proliferation, survival, and isotype switching, a

a mediator of dendritic cell (DC) maturation, survival, and costimulatory ability (

TRANCE-R is also important for DC survival and costimulation, and it is essential f
osteoclast differentiation, maturation, and survival (5). Additionally, TRANCE has
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shown to be a critical regulator of mammary gland development and lactation (6).

TRAF6 does not directly interact with IL-1R or TLR proteins. IL-1R and TLRs bind to
the cytoplasmic protein MyD88 (7-9), which interacts with the N-terminal portion of

1R associated kinase (IRAK). TRAF6 binds to the C-terminal domain of activated IRAK
in a similar fashion to its interaction with TRANCE-R and CD40 (10).

Studies from knockout mice have shown that TRAF6 is necessary for normal bone
metabolism, as mice deficient in TRAF6 have severe osteopetrosis due to defects in

osteoclast differentiation and maturation (11,12). This phenotype is remarkably sim
that found in mice deficient for TRANCE (13,14), TRANCE-R (15), and c-Src (16),
which has suggested that TRAF6 may serve to link TNF signaling pathways to Src-

family tyrosine kinase pathways (17). Additionally, TRAF6-deficient mice have defec

in signaling by IL-1, CD40L, and LPS, which results in deficiencies in nitric oxide
production by macrophages as well as in B lymphocyte proliferation and isotype
switching (11). Furthermore, TRAF6-/- mice display defects in lymph node
organogenesis (12), which has also been observed in TRANCE-deficient mice (13,14).

TRAF6 has the characteristic domain structure of TRAF proteins, with an N-terminal
containing a RING finger and several zinc finger domains, which have been shown to

essential for the activation of downstream signaling pathways, including NF-kB, MAP

and Src-family kinases (2,17,18). The C-terminal half of TRAF6 consists of the high
conserved TRAF domain (19), with a coiled-coil domain required for TRAF

oligomerization and a receptor-binding domain. The C-terminal half of TRAF6 acts as
dominant negative inhibitor of signaling by binding to the receptor but preventing
activation of downstream kinases (2).
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Of the six TRAF proteins, TRAFs 2, 5, and 6 can activate the NF-kB and MAPK
signaling pathways including ERK, p38, and JNK (1). Although TRANCE-R and CD40
have been shown to activate NF-kB and MAPK via TRAF2 and TRAF5 in

overexpression experiments (20,21), there is evidence that in primary cells, TRAF6 m

be the key physiological mediator of signaling by these receptors. In TRAF6-/- oste

precursor cells, TRANCE stimulation fails to activate NF-kB, p38, or JNK (22). In t

cytoplasmic tails of both TRANCE-R and CD40, the binding site for TRAF6 is proximal

to the membrane and is distinct from the binding site for TRAFs 1, 2, 3, and and 5,
bind to more C-terminal sites on each receptor. Furthermore, the sequence of the
receptor-binding TRAF domain of TRAF6 is the least conserved of all the TRAFs (2),
suggesting that TRAF6 may have a distinct mode of receptor binding from the other
TRAF proteins.

Although the RING and zinc fingers in the N-terminal half of TRAF6 are necessary fo
the activation of downstream kinases, the receptor-binding domain is important

structurally because oligomerization of TRAF6 at the receptor in response to ligand

stimulation is a physiological prerequisite for signaling (23). A detailed structur
understanding of the receptor binding mode of TRAF6 will help to elucidate the

mechanism of TRAF6 signaling and will provide a framework for the rational design o
immunomodulatory and anti-osteoporotic therapeutics.

3.2.3 Results and Discussion

3.2.3.1 Identification of the core receptor binding site for TRAF6

As a first step toward understanding the molecular basis of the signaling specifici

TRAF6, we used CD40 as a prototype since it contains a rather short cytoplasmic dom
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(residues 216-277). The C-terminal region of this domain (residues 246-277) contain
known TRAF2-binding site, while the N-terminal region (residues 216-245) has been
implicated in TRAF6 binding (24,25). To pinpoint the TRAF6-binding site of CD40, we

generated a series of deletions within this region and measured the binding affinit
these peptides to the TRAF domain of TRAF6 (residue 333-508), using isothermal

titration calorimetry (ITC) (Figure 3.2.1 A) (26). The interaction of TRAF6 with th

N-terminal region of the CD40 intracellular domain exhibited a dissociation constan
"60 U.M. A short peptide of CD40 (residues 230-238) conferred close to 90% of the

binding energy to TRAF6, while further deletion abolished the interaction. This sho
region of CD40 formed the biochemical basis for the structural studies on TRAF6
interactions.

3.2.3.2 Crystal structures of TRAF6

We determined three crystal structures of the TRAF-C domain of TRAF6 (residues 346-

504), in its free form and in complex with the minimal TRAF6-binding site from huma
CD40 (230-KQEPQEIDF-238) and the homologous sequence of human TRANCE-R
(342-QMPTEDEY-349), at 2.5A, 1.8A and 2.0A respectively. To facilitate
crystallization, the CD40 sequence in the complex contains a mutation (N237D) that

been shown previously to enhance affinity to TRAF6 (Figure 3.2.1 A) (21). The overa
architectures of the three TRAF6 structures are rather similar, with rms distances
among the peptide-bound and 0.6A between the free and bound forms. Previous
structural and biochemical studies have established that TRAF proteins are able to

trimers (23,27-29), as a way to sense receptor trimerization and oligomerization by
trimeric extracellular ligands (30). Even though the current TRAF6 structures are

monomeric due to the deletion of their coiled-coil regions, the putative 3-fold ax

structures can be located. When this is aligned in the vertical orientation, the re
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peptides lie along a surface ridge from the top (near the cellular membrane) to the bottom
(towards the cytoplasm) ends of the molecule (Figure 3.2.IB). This directionality of the
peptides makes possible the direct docking of the receptors onto TRAF6 after exiting
from their transmembrane regions. The peptides extend the total length of 25A along this
side of TRAF6 and bury ~580A2 surface area.

220
230
240
KKVAKKPTNKAPHPKQEPQE1NFPDDI.PGS
KQEPQEINFPDDLPGS
KQEPQEINF
below detection
fiEINF
KOEPOEIDF
I 1.0
I I 2.0
I
3.0 4.0
AQ (kcal/mol)

•V59MM
Kdj=98|pM
K„-237mH
Kd=84|pM
5.0 6.0

B

loop

Figure 3.2.1. O v e r v i e w of the
structures.
A . M a p p i n g of T R A F 6 - b i n d i n g
site on CD40, showing a
representative
isothermal
titration curve (left) and the A G
and KD of the interaction of
T R A F 6 with C D 4 0 deletion
series (right).
B. Ribbon drawings of the
structure of TRAF6 in complex
with CD40, viewing down the
putative three-fold axis of the
TRAF6 molecule (left) and with
the three-fold axis in a vertical
orientation (right).
C. Structural superposition of
the TRAF6/CD40 complex with
a T R A F 2 / C D 4 0 complex,
showing the distinct peptide
directions
in
the
two
complexes. Same orientations
as in (B).

v

Substantial structural differences between T R A F 6 and T R A F 2 (27-29) result in dramatic
differences in the bound peptides, yielding a 40° cross in the peptide directions in their
respective complexes (Figure 3.2.IC). The most prominent conformational difference
resides at the (33-(34 loop of TRAF6, which exhibits up to 11.5A in Ca distances relative
to TRAF2. This loop is displaced away from the receptor-binding site so that it no longer
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interacts with the peptides in the TRAF6 complexes. The conformational change of th
^3- (341oop is most likely brought about by the replacement of a 398-GxGxGxG-404
sequence in TRAF2 and other TRAFs with non-glycine residues in TRAF6. In TRAF2,

the (33- (34 loop is highly twisted. The glycine residues are crucial for maintaini

successive tight (3-turns of type II' (residues 399-DGTG-402) and type II (residues

GAGT-405) respectively, which require glycines at specific positions. These two tur

are further proceeded by a type I turn (395-YLNG-398) within the same loop. In TRAF

the analogous residues continue further along the p3 strand, followed by a sharp ty

turn at P398 (i+1 residue) to create a 90° bend in the loop. Most other connections

between (3 strands show modest but significant differences in C„ positions (2-5A). A

superposition of the TRAF6 structure in complex with CD40 with a TRAF2 structure in

complex with CD40 shows an rms distance of 1.2A for 127 aligned Ca positions within
3.0A.

Both main chain and side chain hydrogen bonding interactions appear to play key
anchoring roles in receptor recognition by TRAF6. A large portion of the receptor
peptides (Q234-F238 for CD40 and T345-Y349 for TRANCE-R) assumes a typical anti-

parallel (3 conformation and makes main chain hydrogen bonds with residues P468-G47

in the (37 strand of TRAF6 (Figure 3.2.2A and 3.2.2B). The side chains of E235 of C

and E346 of TRANCE-R fit snugly into a surface groove and form hydrogen bonds to th

main chain amide nitrogens of L457 and A458. In CD40, the carboxylate of D237 m.ake

a hydrogen bond and a salt bridge to K469 of TRAF6. This salt bridge may explain th
higher affinity of the N237D mutant of CD40 to TRAF6. In TRANCE-R, the carboxylate

of D347 forms hydrogen bonds and a salt bridge to the guanidinium group of R392. Th
TRAF6 surface is in general rather basic, formed, among others, by the side chains
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R392 and K469, and is complementary to these acidic residues in the CD40 and
TRANCE-R sequences (Figure 3.2.2C).
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Figure 3.2.2. Structural details of the
interaction of T R A F 6 with C D 4 0 and
TRANCE-R.
A. Details of the TRAF6/CD40 interaction.
B. Details of the TRAF6/TRANCE-R
interaction.
C. Electrostatic characteristics of TRAF6
interactions, shown here for the TRAF6/CD40
interaction.
D. Stereo view of the superposition of CD40
with TRANCE-R peptides.
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A m o n g the eight residues that directly contact T R A F 6 (Q231-F238 of C D 4 0 and Q 3 4 2 Y349 of TRANCE-R), there are other important hydrophobic and hydrophilic
interactions. Residue K230 of CD40 does not make any van der Waals contacts to
TRAF6, in contrast with the previous notion that K230 is important for TRAF6
interaction (21). Residues Q231-P233 of CD40 and Q342-P344 of TRANCE-R interact
with hydrophobic TRAF6 residues F471 and Y473 to close the partially exposed
hydrophobic core. In particular, the proline residue in both structures is completely
buried. The side chains of Q231 of CD40 and Q342 of TRANCE-R are relatively less
well defined and highly exposed to solvent, even though they appear to form several
potential hydrogen bonds (Table 3.2.2). A dramatic difference exists between the
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conformation of residue F238 of CD40 and the corresponding residue Y349 of

TRANCE-R. While F238 inserts in between a series of aromatic and positively charge

side chains including F410, R392, H394 and H412 of TRAF6, Y349 binds at the surface

of this highly basic and aromatic region of TRAF6. A model building excise shows th
the extra hydroxyl in Y349 appears to expel its insertion into the same pocket.

Comparison of the CD40 and the TRANCE-R conformations by aligning the
corresponding TRAF6 structures reveals the structural conservation and variation
between the two sequences (Figure 3.2.2D). As residues E235 of CD40 and E346 of

TRANCE-R superimpose extremely well and form crucial hydrogen bonding interactions

with TRAF6, we denote this residue as the P0 position of the TRAF6-binding sequence

Residues P233 of CD40 and P344 of TRANCE-R are therefore at the P.2 position, while
residues F238 of CD40 and Y349 of TRANCE-R reside at the P3 position. Main chain

conformations are identical between the P^ to the P0 positions and slight deviatio

at the P,-P3 positions. Asp residues at both P, and P2 are able to form hydrogen bo

(Figure 3.2.2A and 3.2.2B), while a Glu at P2 is no longer able to preserve the sam

interaction. There are significant conformational adjustments in the side chains of
hydrogen bonding partners in TRAF6 (R392 and K469) in the presence and absence of

these specific interactions. The difference in the side chain positions of the P3 r

not a consequence of the main chain difference, but rather a change in the side cha
torsion.
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Table 3.2.1. Crystallographic statistics.
NATIVE

CD40 COMPLEX

TRANCE-R

COMPLEX
CRYSTAL
PEPTIDE
PROTEIN CONSTRUCT
SPACE GROUP
CELL DIMENSIONS (A)

DIFFRACTION DATA
RESOLUTION (A)
RSYM (LAST SHELL) (%)
COMPLETENESS (LAST
SHELL) (%)
REFINEMENT
RESOLUTION (A)
SIGMA CUTOFF
N U M B E R OF PROTEIN
RESIDUES
N U M B E R OF PROTEIN
ATOMS
N U M B E R OF SOLVENT
ATOMS
N U M B E R OF
REFLECTIONS USED
R M S D B O N D LENGTH (A)
R M S D BOND ANGLE (°)
R ( I W ) (%)

NONE

HCD40
346-504

HTRANCE-R
346-504

A=32.2, B=55.6,
C=47.7,_=101.0°

P2,2,2,
A=39.9, B=43.8,
C=101.4

P2,2121
A=38.0,B=45.0,
C=106.5

40-2.5
9.2(24.1)
92.8 (90.4%)

40-1.8
5.6(22.1)
99.1 (93.0)

40-2.0
5.5 (13.9)
96.0 (86.9)

20-2.5

20-1.8

20-2.0

2.0
155

2.0
164

2.0
161

1269

1340

1331

45

122

80

5538

14644

12396

20.4 (27.4)

20.3 (25.8)

21.3(24.2)

346-504

P2,

3.2.3.3 Affinities of various T R A F 6 - b i n d i n g sequences for T R A F 6 a n d identification
of a consensus binding site
To determine whether the observed interaction of TRAF6 with CD40 and TRANCE-R
can be applied to the signal transduction of the IL-1R/TLR superfamily, we utilized the
structural information to identify and align putative TRAF6-binding sequences from

IRAK and its homologues IRAK2 and IRAKm (Figure 3.2.3). We used isothermal

titration calorimetry to measure the affinities of these sequences for TRAF6. These

experiments showed that all the identified sequences in IRAK proteins produced bin

affinities similar to that of the CD40 peptide (Figure 3.2.3), clearly demonstratin
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generality of the TRAF6 interaction and the mechanism of convergence of TRAF6

signaling by the two superfamilies of receptors. In contrast, two sequences from NG

and TACI, which were previously implicated in TRAF6 binding (31,32) but do not bear

any recognizable structure-based sequence homology, failed to interact with our TRA

construct. It is possible that these sequences bind to a different region of TRAF6.

hCD40
hCD40 (N237D)
mCD40
hTRANCE-R
mTRANCE-R
hIRAK
mIRAK
hIRAK-2
hIRAK-M
Motif xxPxEdd(FXIXE)
Position
Other sequences
hTACI
hNGF receptor

230-KQEPQEINF-238
230-KQEPQEIDF-238
234-RQDPQEMED-242
341-RQMPTEDEY-349
337-RKIPTEDEY-345
701-RQGPEESDE-709
666-SQGPEESDE-674
523-SNTPEETDD-531
475-PSIPVEDDE-483

KD(MM)
237
84

KA(103M-1)
4.2±0.9
11.912.2

78

12.814.1

56

17.912.3

64
143

15.713.0
7.011.3

Pj^PQ^P3
SPEPVETCSFCFPEC
EGEKLHSDSGISVDS

below
below

detection
detection

Figure 3.2.3. Structure-based identification and alignment of TRAF6-binding sequences, showi
proposed TRAF6-binding motif and the measured KD of the interactions.

T h e structural and sequence information led to a putative TRAF6-binding motif of
xxPxEdd(F/Y/D/E) (positions P_4 to P3) (Figure 3.2.3), which is distinct from what was
proposed earlier (21,24). The inclusion of the P.4and P3 residues in the motif is based on
the role of their main chain atoms in closing the hydrophobic core of TRAF6. The Asp
residues at positions P, and P2 are shown in lower case, as these may be the most
favorable residues due to the specific hydrogen bonds, but other residues, especially
acidic residues are tolerated at these positions due to the general charge complementarity
with TRAF6. Based on the current structural information, we suspect that the Asp and
Glu residues at the P3 position may adopt the Y349 conformation in TRANCE-R, rather
than the inserted F238 conformation, due to a potential unfavorable charge burial.
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T o establish the importance of the peptide sequence in the context of full-length C D 4 0

intracellular domain, we used native gel shift and size exclusion chromatography to

determine the mutational effects of CD40 and TRAF6 on this mutual recognition in vi
(Table 3.2.2). We performed mutagenesis for five out of the eight CD40 residues in
contact with TRAF6. These residues exhibit either substantial surface area burials

potential hydrogen bonding interactions. Mutations E235A (P0) and F238A (P3) result

in complete abrogation of binding, demonstrating the importance of these residues i
TRAF6 recognition. While P233A (P.2) did not show qualitative difference in TRAF6

binding, a P233Q mutation abolished the interaction, confirming that the buried bin
pocket for P233 could not accommodate large side chains. On the TRAF6 side, we

individually mutated all contacting residues involved in CD40 interaction to alanin
determine the energetic contributions of their side chains. Two residues, F471 and

were singled out as the most crucial, as they produced drastic effects in the quali

gel-shift and size exclusion assays. Other individual mutations did not produce qua

differences in CD40 binding, suggesting that these residues contribute collectively

than singly, to the interaction. In addition, it is possible that the relative impo
TRAF6 residues may be somewhat different for different interacting sequences.

Our structural observation raises the question whether the conserved Glu at the P0

position of the TRAF6-binding motif is analogous to the P0 position (a Glu or a Gin
the TRAF2-binding motif (29). Interestingly, even though the binding peptides for
TRAF6 and TRAF2 take their own courses on the surface of the TRAF proteins, they

intercept near the P0 residues (Figure 3.2.IC). In TRAF2 complexes, three Ser resid
(S453-S455) appear to form a tight grip at the side chain of the P0 Glu or Gin. In
these three residues are replaced by L456-L457-A458. Reciprocal movements in both
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TRAF6 and the peptides are apparent to accommodate the P0 Glu at this position. The
side chains of L456 and L457 move away from E235 to create an optimal cavity for E235
to approach in the main chain amides of L457 and A458 for hydrogen bonding
interactions. In addition, an E235Q mutation of CD40 did not produce qualitative
difference in TRAF6 binding (Table 3.2.2). These observations led us to propose a model
of co-evolution between TRAF proteins and their binding sequences, in which the P0
residue serves as a primary conserved feature or anchoring point in this process.

Table 3.2.2. Structural characteristics a n d mutational effects of the T R A F 6 / C D 4 0
interaction as assessed by native gel shift a n d size exclusion chromatography.
Mutations

Effects

Surface area burial

+
+

109 A

Side chain exposure in the complex

Human CD40 mutations
0.28 Q231A(PJl)
P233A (P.2)

105 A

0.10

P233Q
0.20 E235A (P0)
E235Q
0.55 N237A (P2)

123 A

+
+

F238A (P3)

56A
129A

0.31

3lA
36A
36A
26A
46A
62A
46A
56A
37A
25A

0.10

Human TRAF6 mutations
R392A (R400)*
F410A(F418)*
E448A
L456A
P468A
K469A (K477)*

+
+
+
+
+
+

F471A(F479)*
Y473A(Y481)*
V474A
T475A

+
+

0.01
0.20
0.24
0.43
0.27
0.01
0.01
0.26
033

+: binding preserved, no or minor effects; -: binding disrupted, major effects
* s h o w n in parentheses are corresponding residues in m o u s e T R , A F 6 used in the
dominant negative experiments (see below)
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3.2.3.4 Mapping of potential TRAF6-binding sites in CD40, TRANCE-R, and IRAK
Previous studies have localized a single TRAF6 binding site in CD40 to a membrane
proximal region (21). In TRANCE-R, we (20) and others (24) have identified at least two
regions of potential TRAF6 interaction: one in what we have defined as the membrane
proximal "N domain" of the cytoplasmic tail of TRANCE-R, and another in the "M
domain," which is C-terminal to the N domain. The binding site(s) for TRAFs 1, 2, 3, and
5 is in the extreme C-terminal portion of TRANCE-R, the "C domain," and this domain
does not appear to interact with TRAF6 (20). In IRAK, similar to TRANCE-R, two
potential TRAF6-interacting regions have been identified in the C-terminal portion of the
molecule, defined as " C l " and " C 2 " (10).

With our structural information about the

consensus binding sequence for TRAF6 (xxPxEdd[F/Y/E/D], Figure 3.2.3), we identified
one T R A F 6 binding site in C D 4 0 and three potential T R A F 6 binding sites each in
T R A N C E - R and I R A K (Figure 3.2.4A). T w o of the predicted binding sites in T R A N C E R are located in the "M" region and two of the predicted binding sites in IRAK are
located in the "Cl" region defined by previous mapping studies (Figure 3.2.4B).

Consensus
mCD40
mTR-sitel
mTR-site2
mTR-site3
hIRAK-aitel
hIRAK-aite2
hIRAK-site3
Tfi-FL «Mrefla5miftyTrin^

237
340
373
447
542
585
704

12 3
P x d d(F/l/D/E)
-PQ HED
-PT D EY
-PL VGE
-PG D HE
-PQ NSY
- P VSilclS SiteZ
D E S«e3
- P E 342 S 375
D E 449
N + I Ml
235-358 1 354-536

F i g u r e 3.2.4. Identification o f c o n s e n s u s
TRAF6-binding sequences in m C D 4 0 ,
m T R A N C E - R , and hIRAK.
A. Alignment of consensus TRAF6-binding
sequences. P0 position is boxed in gray.
rHAFl/2/3/S
binding
C
| 53a-625~~|

B. Schematic domain structure of T R A N C E R and IRAK. FL denotes full-length; N, M ,
and C in TRANCE-R follow convention in
(20).

DD

denotes death domain, U D

unknown domain, and K D kinase domain
(IRAK). TRAF6-binding sites are marked
with arrows and the P0 residue number is
noted.
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3.2.3.5 Functional mapping of predicted TRAF6-binding residues on CD40,
TRANCE-R, and IRAK

In order to determine the relative in vivo contributions of each residue in the pre
TRAF6-binding consensus sequences of mCD40, mTRANCE-R (site 1), and hIRAK (site

3), we changed potential TRAF6-interacting residues by site-directed mutagenesis an

analyzed the ability of these mutants to activate NF-kB in a luciferase reporter as

Mutation of positions P.4, P.2, P0, P2, and P3 revealed that each of the residues f
P3 contributed to TRAF6-mediated NF-kB activation, while the side chain of postion

was unimportant for TRAF6-mediated NF-kB activation, in agreement with the structur
observation that the contribution of the P.4 position to TRAF6 binding is from the

chain Ca. In CD40, there was a variable degree of inhibition in each of the mutants

E239A mutation, predicted by our structural observations to be at the center of the
TRAF6 binding groove (postion P0), producing the most significant block in NF-kB
activation (Figure 3.2.5A). The residual NF-kB activity in the CD40 mutants is due
incomplete block of TRAF6 binding and/or normal binding to other TRAFs including
TRAF2 and TRAF5 through CD40's C-terminal TRAF-binding site, shown to interact
with TRAFs 1, 2, 3, and 5 but not TRAF6 (21). In order to map similar sites on
TRANCE-R and IRAK and rule out the possibility of other TRAFs contributing to NFkB activation, we examined deletion constructs of TRANCE-R and IRAK predicted to
have only a single TRAF6 binding site (TR-N and IRAK-AC 1, Figure 3.2.4B). Without

the potential for residual activity mediated by other TRAFs, it is clear that singl

mutations of P 2, P0, P2, and P3 are all capable of substantial inhbition of TRAF6NF-kB activation by TR-N and IRAK-AC1 (Figure 3.2.5, B and C). To examine whether
other TRAF6-mediated signaling pathways are blocked by these mutations, we
performed an in vitro JNK assay on overexpressed TR-N and its mutants, obtaining

similar results (Figure 3.2.5D). Taken together, these data suggest that mutation o
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the predicted TRAF6-interacting residues of the consensus binding site is sufficient to
block TRAF6-mediated signaling by CD40, TRANCE-R, or IRAK.
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Figure 3.2.5. Functional importance of predicted T R A F 6 - b i n d i n g residues in C D 4 0 , T R A N C E - R ,
and IRAK.
A. Site-directed mutagenesis was employed to generate point mutations in residues predicted to bind to
TRAF6 in mCD40. CD40 (wild-type and mutants, 100 ng) were transfected in 293T cells with an NF-kBresponsive luciferase reporter plasmid (75 ng) and 3-galactosidase (25 ng). Relative luciferase activity was
normalized for 3-galactosidases activity. Representative results of at lest 3 separate transfections are
shown.
B. Mouse TRANCE-R consisting of the extracellular domain and residues 235-368 of the cytoplasmic tail
(TR-N, wild-type and mutants, 50 ng) was transfected as in A.
C. Human IRAK (full-length, FL; and with a deletion of residues 522-618, AC1; wild-type and mutants,
100 ng) was transfected as in A.
D. As in B, but TR-N constructs were transfected with JNK1 and the lysates were subjected to an in vitro cJun N-terminal kinase assay. M E K K 1 was included as a positive control.

3.2.3.6 Functional m a p p i n g of predicted receptor-binding residues o n T R A F 6
We next determined the importance of the observed TRAF6 interface for signaling by
C D 4 0 , T R A N C E - R , and I R A K using a dominant negative assay. T h e receptor-binding
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TRAF domain of TRAF6 has been shown to exert a strong dominant negative phenotype
on endogenous signaling by these receptors, presumably due its ability to bind to

receptors and its lack of the N-terminal domains necessary for downstream signaling

(2,33,34). Mutant TRAF domain constructs of TRAF6 that are defective in receptor or

IRAK binding, on the other hand, should then be incapable of or exhibit reduced abi
for dominant negative interference.

We created the following point mutants of dominant negative mouse TRAF6 (T6.DN,
residues 289-530) by site-directed mutagenesis: R400A, F418A, K477A, F479A, and
Y481A (see Table 3.2.2 for the corresponding human TRAF6 residues). When co-

expressed with CD40, R400A, F479A and Y481A exhibited significantly reduced ability

to inhibit NF-kB activation, while the F418A and K477A mutants retained the ability
reduce NF-kB activation nearly as well as wild-type TRAF6.DN (Figure 3.2.6A). When
co-expressed with TR-N, all of the TRAF6.DN mutants could inhibit NF-kB activation

to varying degrees, but none of the mutants could block activation as strongly as w

type TRAF6.DN (Figure 3.2.6B). Taken together, these functional data are consistent
with the TRAF6 interface defined by structural studies.

To test the effect of the TRAF6.DN mutants on IL-1 mediated NF-kB activation, we
transfected 293T cells with the various TRAF6.DN constructs and NF-kB responsive
reporter elements, and treated them for 6 hours with IL-1. The F418A and K477A

mutants could block NF-kB induction as effectively as wild-type TRAF6.DN, while the

others demonstrated virtually no blockade (Figure 3.2.6C), confirming the functiona

significance of the observed structural information on IL-1 signaling as well. As t

several known IRAK isoforms, the complete inability of some of the TRAF6 mutants to
exert dominant negative interference on NF-kB activation confirmed our structural
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observation on the conserved recognition of TRAF6 for all three IRAKs including IR
IRAK2 and IRAKm.

Figure 3.2.6. Functional importance of
predicted receptor and IRAK-binding sites on
TRAF6.
A. Residues 289-530 of mouse T R A F 6 (T6DN,
wild-type and mutants as indicated, 800 ng) was
cotransfected with wild-type mouse C D 4 0 (100
ng). NF-kB activity was determined as in A.
B. A s in A, but with wild-type T R - N (50 ng)
instead of CD40.
C. T6.DN (wild-type and mutants as indicated,
800 ng) was transfected as in A and B. Cells
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3.2.3.7 Relative contributions of each TRAF6-binding site in TRANCE-R and IRAK
Since there are multiple predicted TRAF6-binding sites in both TRANCE-R and IRAK,

we assayed the relative contribution of each of these binding sites to signaling by

length TRANCE-R and IRAK. As mutation of the P0 glutamate residue was sufficient to

substantially reduce TRAF6-mediated signaling by all of the consensus sites examine

Figure 3.2.5, we employed only P0 E-A mutations to examine each predicted site in f
length TRANCE-R and IRAK individually and in combination. Single mutations of

E342A, E375A, and E449A resulted in minimal effects on the ability of overexpressed

TRANCE-R to activate NF-kB. Double mutations, particularly 342/375 and 342/449, and
to a lesser extent 375/449, slightly reduced NF-kB activation by TRANCE-R, but not
substantially. Triple mutation of E342A, E375A, and E449A (E3A) markedly reduced
TRANCE-R-mediated NF-kB activation (Figure 3.2.7A). It is somewhat surprising that
any single TRAF6-binding site was sufficient to mediate TRANCE-R-induced NF-kB

activation almost to the level of the wild-type sequence. The functional NF-kB acti

potential by these mutants was confirmed structurally by their ability to bind to a
immunoprecipitate TRAF6. The relative amount of TRAF6 immunoprecipitated by
TRANCE-R mutants correlated with the relative ability of these mutants to activate

kB. In particular, double mutants with the site 1 E342A mutation (342/375 and 342/4
co-precipitated less TRAF6 than did the 375/449 mutant, and the E3A mutant coprecipitated a negligible amount of TRAF6 (Figure 3.2.7B).
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Figure 3.2.7. Relative contributions of each TRAF6-binding site to T R A N C E - R and I R A K signaling.
A. Full-length TRANCE-R (wild-type and mutants as indicated, 50 ng) was transfected and NF-kB
activity was determined as in Figure 3.2.5.
B.

TRANCE-R (wild-type and mutants as indicated, 500 ng) was co-transfected with wild-type TRAF6
(500 ng). Cell lysates were immunoprecipitated with an antibody to T R A N C E - R (1E6.66) and
immunoprecipitates (IP) and whole cell lysates (WCE) were probed with anti-Flag M 2 antibody.

C. TRANCE-R constructs consisting of the ectodomain/transmembrane region and residues 354-536 of
the cytoplasmic tail (TR-M, see Figure 3.2.4B for diagram, wild-type and mutants as indicated, 50 ng)
were transfected as in A.
D. Full-length IRAK (wild-type and mutants as indicated, 100 ng) was transfected as in A.

In the double mutants, mutation of the two " M " region glutamates (375/449) consistently
produced less inhibition of NF-kB activation than did either double mutant involving the
"N" region glutamate (342/375 and 342/449), so we examined the relative contribution of
sites 2 and 3 in the context of the "M" region alone. Unexpectedly, the E375A mutation
almost completely abolished TR-M-mediated NF-kB activation, while the E449A
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mutation had minimal effect (Figure 3.2.7C). Similar results were obtained with 342
and 342/449 mutants of the "N+M" regions, omitting the "C" region (data not shown).
This discrepancy between the "M" region or "N+M" region alone and the full

cytoplasmic tail of TRANCE-R suggests a potential cooperativity between the C-term

portion of TRANCE-R and the third TRAF6 binding site. Whether this is due to bindin

of other TRAFs to the "C" region or differential protein folding leading to masking
site 3 in the absence of the "C" region is unclear at this point.

Mutation of the three predicted TRAF6-binding sites in IRAK revealed, unexpectedly,

slight gain of NF-kB-activating potential by mutation of site 1 (E544A), as full-le

IRAK with a single E544A mutation activated NF-kB slightly more strongly than wildtype full-length IRAK. Single mutation of E587A and E706A both reduced NF-kB
activation by IRAK, while double mutation of E544A with either E587A or E706A
slightly increased NF-kB activation over single mutants of either E587A or E706A.
Triple mutation of E544A, E587A, and E706A almost completely reduced NF-kB
activation by IRAK to background levels (Figure 3.2.7D). The increased activity

observed in single and double mutants containing E544A suggests that site 1 in IRAK
may somehow negatively regulate IRAK signaling by sequestering TRAF6 away from

the other two sites while not allowing it to activate downstream signals or through
other, unknown mechanism. Given that the mode of TRAF6 interaction with TNFR
family receptors is trimeric, it is likely that the mode of TRAF6 interaction with

similarly trimeric. There may be structural constraints of trimeric IRAK that preve
trimeric TRAF6 from interacting properly with site 1, thus sequestering monomeric

TRAF6 at that site, preventing it from trimerizing and activating downstream signal
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3.2.3.8 The role of TRAF6 in ligand-dependent signaling by TR-N
In order to confirm the functional role of TRAF6 in TRANCE-mediated signaling, we
generated stable HEK 293 cell lines expressing TR-N and TR-N-E342A. Stable clones
were selected that expressed similar levels of surface TR-N as determined by FACS
analysis (data not shown). In response to TRANCE stimulation, 293/TR-N cells

demonstrated strong activation of JNK as measured by an in vitro kinase assay, whil
293/TR-N-E342A cells did not activate JNK in response to TRANCE (Figure 3.2.8A,

top). Similarly, TRANCE stimulation of 293/TR-N cells resulted in p38 activation as

measured with phospho-p38 specific antibodies, while TRANCE did not activate p38 in
293/TR-N-E342A cells (Figure 3.2.8A, bottom). In order to measure TRANCEdependent NF-kB activation, we transfected 293/TR-N and 293/TR-N-E342A cells with
an NF-kB reporter plasmid, stimulated the cells for 24h with soluble TRANCE, and

measured reporter activity. While 293/TR-N cells showed a robust activation of NF-k
in response to TRANCE, 293/TR-N-E342A cells had no measurable NF-kB induction in

response to TRANCE (Figure 3.2.8B). Thus, the observed effects achieved by transien

overexpression of TR-N constructs elsewhere in this report are similar to those fou
ligand-dependent situation with stable expression of TR-N. Furthermore, TR-N is
functional for surface expression and ligand-dependent signaling through TRAF6 and
will be a useful tool to isolate TRAF6-specific signals emanating from TRANCE-R.
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3.2.3.9 Relative contributions o f T R A F 6 - b i n d i n g sites a n d T R A F 1 / 2 / 3 / 5

binding

sites to C D 4 0 and T R A N C E - R signaling
To account for residual, non-TRAF6-mediated NF-kB activation by TRANCE-R and
CD40, we overexpressed an excess of TRAF2 or TRAF6 constructs lacking the Nterminal zinc-binding domains as dominant negatives (T2.DN and T6.DN). With wild-

type full-length CD40, T6.DN inhibited NF-kB activation slightly more than did T2.D
CD40-E239A activated NF-kB as strongly as CD40-WT + T6.DN, while CD40-E239A +

T2.DN showed no NF-kB activation, suggesting that the defined TRAF6-binding site i

CD40 is the only TRAF6-binding site in CD40 capable of signaling (Figure 3.2.9A). A

similar set of transfections with TR-N and TR-N-E342A shows that TR-N activates NF
kB exclusively through TRAF6, as T2.DN had no effect on the ability of TR-N to
activate NF-kB (Figure 3.2.9B). To determine if the C-terminal TRAF1/2/3/5 binding

site(s) contribute to the residual non-TRAF6-dependent NF-kB activation in full-le
TRANCE-R, we transfected the TR-FL-E3A construct with T6.DN and T2.DN. T6.DN
had minimal effect on the residual activity of TR-FL-E3A to activate NF-kB, while
T2.DN abolished the residual NF-kB activity (Figure 3.2.9C). Since TRANCE-R has
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three TRAF6-binding sites, in order to more directly compare it to C D 4 0 , w e deleted the
"M" region, which contains two TRAF6-binding sites, leaving only site 1 (TR-AM,
Figure 3.2.4B). The relative inhibition of TR-AM and TR-AM-E342A signaling by
T 6 . D N and T 2 . D N (Figure 3.2.9D) w a s comparable to that observed in C D 4 0 - W T and
C D 4 0 - E 2 3 9 A (Figure 3.2.9A). Thus, the presence of three TRAF6-binding sites in
T R A N C E - R as opposed to a single TRAF6-binding site in C D 4 0 suggests that T R A F 6
m a y play a more dominant role in T R A N C E - R signaling. This m a y explain the observed
absence of N F - k B , J N K , and p38 activation in T R A F 6 - / - cells upon T R A N C E treatment
despite the presence of other TRAFs in those cells (22).
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Figure 3.2.9. Relative contributions of T R A F 6 - and TRAFl/2/3/5-binding sites to C D 4 0 and
T R A N C E - R signaling.
A. CD40 constructs (wild-type and E239A as indicated, 100 ng) were cotransfected with empty vector,
TRAF6 residues 289-530 (T6.DN, 800 ng) or TRAF2 residues 241-501 (T2.DN, 800 ng) and subjected
to an NF-kB reporter assay as in Figure 3.2.5.
B. As in A, but with TR-N (50 ng) instead of CD40.
C. As in A, but with full-length TRANCE-R (TR-FL, W T and triple E-A mutant, E3A, as indicated, 50
ng).
D. As in A, but with full-length TRANCE-R or TRANCE-R with a deletion of residues 254-536 (TR-AM,
W T and E342A as indicated).
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3.2.10 Formation of a ternary complex consisting of T R A F 6 , C D 4 0 , and c-Src
A specific role of T R A F 6 in anti-apoptotic signaling (17,35) has recently been
demonstrated by its activation of the Ser/Thr kinase Akt, which specifically
phosphorylates and inactivates pro-apoptotic molecules such as B A D and pro-caspase-9
(36-38). For T R A N C E - R , this Akt activation appears to be mediated by c-Src, a member
of the Src tyrosine kinase family, with T R A F 6 acting upstream of c-Src activation. Mice
deficient in either T R A F 6 (11,12) or c-Src (18) share similar phenotypes in T R A N C E - R mediated osteoclast function. A universal role of T R A F 6 as an upstream event for Akt
activation through the Src kinases has also been implicated for C D 4 0 (39-41) and IL1/Toll-like receptor signaling (17).
Figure 3.2.10. Ternary complex formation
of T R A F 6 , C D 4 0 , and c-Src.
A. Mapping of the potential Src-binding site

*

on

the surface of the T R A F 6 / C D 4 0

complex. C D 4 0 peptide: ball and stick
model; T R A F 6 : green; proline-rich sequence
of T R A F 6 : orange.
B. Native gel electrophoresis, showing the
proline-rich
sequence of
TRAF6
proposed Src-binding
site on a receptor

B

CD40

TRAF6

c-Src

complex
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The structures of TRAF6 in complex with CD40 and TRANCE-R suggest a model for a

ternary complex formation among TRAF6, a receptor and a Src kinase (Figure 3.2.10A)
TRAF6 is the only TRAF family member that contains a putative SH3 domain binding
sequence (462-PxxPxxP-468) as an insertion between the strands (36 and [57.

Interestingly, residues 465-468 within this proline-rich sequence are disordered in
free TRAF6 structure and become ordered in the CD40 and TRANCE-R-bound
structures. Previous binding studies using in vitro translated proteins suggested

interacts with TRAF6 via these proline-rich sequences and with TRANCE-R via a regio

immediately after its TR.^VF6-binding site. In the TRAF6 complexes, these proline-r
residues are situated adjacent to the bound CD40 and TRANCE-R receptor peptides,

suggesting that a Src kinase may interact with an integrated surface formed by both
TRAF6 and the receptors.

To determine whether such a ternary complex can be assembled in vitro, we assessed

pattern of native gel shift using purified TRAF6, GST-CD40 intracellular domain and

Src (Figure 3.2.10B). The native gel clearly shows that a ternary complex is formed
addition of the three proteins, as shown by the disappearance of protein bands

corresponding to the individual components. Therefore, the biochemical evidence fur

suggests a cooperative (rather than a competitive) assembly of the ternary complex,

providing an explanation for the interdependence of TRAF6 and Src kinases in the si
transduction of these receptors. The experiment also demonstrates a direct linkage
TRAF protein to a downstream molecule among the many that have been implicated but
not proven in TRAF signaling.
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3.2.4 Conclusion
Our studies of the TRAF domain of TRAF6 reveal the structural underpinnings of its

interaction with TNFR family proteins and components of the IL-lR/Toll-like recepto

family signaling complex. Previous studies have demonstrated that TRAF6 is divergen

from other TRAF proteins in that it binds to unique receptor sites and participates
signal transduction downstream of non-TNFR family proteins through its association

with IRAK. While the overall structure of TRAF6 is similar to that of TRAF2, its mo

of binding to receptor sequences is quite divergent, although it centers around a c

binding residue on the receptor (Glu) similar to TRAF2's binding to a central recep
residue (Gin). This suggests an evolutionary point of divergence between TRAF6 and

TRAFs 1, 2, 3, and 5. Identification of a consensus binding sequence for TRAF6 reve
that there are numerous TRAF6 binding sites in TRANCE-R and IRAK, which we have
confirmed functionally. Finally, we propose a potential mechanism by which TRAF6
links TNFR family proteins and the c-Src tyrosine kinase, in a cooperative ternary
complex assembly. Given the importance of TRAF6 in bone remodeling and adaptive

and innate immunity, structural information about its mode of signaling is an impor
starting point for the rational design of anti-osteoporotic and anti-inflammatory
molecules.

3.2.5 Experimental Procedures

3.2.5.1 Isothermal titration calorimetry
Peptides containing putative TRAF6-binding sequences were chemically synthesized
with amino-terminal acetylation and carboxy-terminal amidation. The molecular mass
each peptide was verified by MALDI-TOF mass spectrometry. A different TRAF6

construct (residues 333-508), which was expressed and purified similarly as describ
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the TRAF6 construct used for crystallization, was used for ITC experiments due to i

higher expression yield. Both protein and peptides were dialyzed extensively agains
50mM sodium phosphate at pH 7.5 for at least two days at 4°C to ensure buffer

equilibration. Accurate concentrations of the protein and peptide samples after dia

were determined by quantitative amino acid analysis. ITC experiments were performed

20°C for determination of binding enthalpy and affinity using a microcalorimetry sy

(MicroCal Inc.). Approximately 20 to 45 injections were titrated for each measuremen

The data were analyzed by the ORIGIN data analysis software (MicroCal Inc.) (26). T

heat of dilution obtained from injecting a ligand into the buffer was subtracted be
fitting process.

3.2.5.2 Protein expression, purification and crystallization

The TRAF proteins contain an N-terminal effector domain of RING and zinc-fingers a

a C-terminal TRAF domain that can be further divided into a coiled-coil region and
homologous TRAF-C domain for receptor interaction (1,19). A combination of genetic,

biochemical and crystallographic methods was used in identifying a crystallizable T

domain construct of TRAF6 and a detailed description will be presented elsewhere. I

summary, the TRAF6 construct (residues 346-504) containing a carboxy-terminal His-t

was expressed in E. coli with overnight IPTG induction at 20°C. The protein was pur

by Ni-affinity chromatography and gel filtration. The protein was concentrated to a
3 mg/ml and crystallized under 5-25% PEG8K and lOOmM Tris at pH 7.5. For complex
formation with TRAF6-binding peptides, a 10-fold molar excess of a mutant human
CD40 peptide (230-KQEPQEIDF-238) or a human TRANCE-R peptide (342-

QMPTEDEY-349) was included in the crystallization drops. Crystals grew as thin plat
and chunky prisms respectively in the absence and presence of the peptides.
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3.2.5.3 Data collection and structure determination
Preliminary crystal characterization and screening were conducted on an Raxis-IV

imaging plate detector mounted on a Rigaku RU300 X-ray generator. Diffraction data
were collected at the X4A beamline of NSLS and the Al beamline of CHESS. The

structures were determined by molecular replacement using the program Replace . The
atomic model of the TRAF domain of TRAF2 was modified by removing the side chains

of residues that are not conserved in TRAF6. Structural refinement was performed by

simulated annealing protocol in CNS (42). Ribbon and stick models were created usin

Setor (43) and the molecular surface representation was calculated and presented by
Grasp (44).

3.2.5.4 Native gel shift and size exclusion chromatography

Native gel shift experiments were performed using the PhastGel system (Pharmacia) a
8-25% gradient polyacrylamide gel. Size exclusion chromatography was carried out
using a Superdex 200 (10/30) column (Pharmacia).

3.2.5.5 Transfection and Reporter Assays
Mouse CD40 was cloned by RT-PCR from whole spleen mRNA and inserted into the
pFLAG-CMVl cloning vector (Sigma). Flag-tagged mouse TRANCE-R consisting of the
extracellular domain and residues 235-368 or 354-536 of the cytoplasmic tail (TR-N
TR-M), mouse TRAF6 consisting of residues 289-530 (T6.DN), and TRAF2 consisting
of residues 241-501 (T2.DN) have been described (20). Site-directed mutagenesis of
CD40, TRANCE-R, IRAK, and TRAF6.DN was performed on the indicated residues by
the Quick-change method (Stratagene). All constructs were confirmed by sequencing.
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293T HEK cells were transfected in 6-well plates with the indicated amounts of CD40
TR-N, and TRAF6.DN and mutants along with 75 ng of an NF-KB-luciferase reporter

plasmid and 25 ng of a (3-galactosidase plasmid to control for transfection efficie
Transfection amounts were kept constant at 1 (ig by addition of empty pFLAG-CMV 1

vector. Cells were harvested 24-30 h after transfection and reporter activity was a

as described (20). Where indicated, cells were treated with 1 ng/ml recombinant hum
IL-1 (R & D) 6 hour prior to harvesting.

For the in vitro JNK kinase assay, full length TRANCE-R, TR-N, TR-N mutants, and
MEKK1 were transfected along with JNK1 (100 ng) as indicated. JNK1 was
immunoprecipitated with an a-JNKl antibody (E-17, Santa Cruz Biotechnology), and

the immunoprecipitates were subjected to an in vitro kinase assay using recombinant

GST-c-jun (1-79, Calbiochem) as a substrate as described previously (45). Transfect
efficiency was confirmed by western blotting the immunoprecipitates with a-JNKl.

Stable cell lines expressing TR-N and TR-N-E342A were generated by co-transfection

HEK 293 cells with the indicated expression vectors with a vector carrying a neomyc

resistance plasmid (pcDNA3.1). Cells were selected for resistance to G418 and clone
limiting dilution. Clones with similar levels of surface expression of TR-N were
identified by FACS analysis.
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3.3.1 S u m m a r y

TRAF2 is a critical adaptor molecule for TNF receptors in inflammatory and immune
signaling. In response to ligand engagement, TRAF2 is recruited to CD40 and

translocates to lipid rafts in a RING finger-dependent process, which is required f

ability to activate downstream kinases. TRAF1 can displace TRAF2 and CD40 from raf

fractions, and it promotes the ability of TRAF2 to sustain activation of signal cas

Replacement of the RING finger of TRAF2 with a raft-targeting dual acylation signa

restores JNK activation and association with the cytoskeletal protein Filamin, but
kB activation. TRAF1-/- dendritic cells show attenuated responses to secondary
stimulation by TRAF2-dependent factors. These findings offer insights into the

mechanism of TRAF2 signaling and identify a physiological role for TRAF1 as a posi
regulator of TRAF2 signaling.
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3.3.2 Introduction

Tumor necrosis factor (TNF) family proteins are essential regulators of the life an
of hematopoietic cells, bone and mammary gland homeostasis, and embryonic

development (1). Signaling through TNF receptor (TNFR) proteins is mediated in part

TNFR associated factor (TRAF) adaptor proteins, which have been shown to activate t
transcription factor NF-kB, MAP kinases, and Src-family kinases (2). Of the six

mammalian TRAFs, sequence conservation analysis has shown that TRAFs 1, 2, 3, and 5

are closely related, while TRAFs 4 and 6 are more evolutionarily divergent. Of thes
evolutionary relations, TRAF1 and TRAF2 appear to have arisen after duplication of
common precursor, while TRAF3 and TRAF5 have arisen from a different common
precursor (3).

The general domain organization of TRAF proteins, of which TRAF2 is the archetype,

comprises an N-terminal zinc-binding domain, specifically a RING finger followed by

several Zn fingers, and a C-terminal TRAF domain, consisting of a coiled-coil which
permits TRAF oligomerization (TRAF-N) and a receptor binding domain (TRAF-C)
(4,5). There are some exceptions to this scheme, most notably in TRAF1, which has a

terminal TRAF domain that is highly homologous to TRAF2, but lacks the RING and all
but one of the Zn fingers. The specificity conferred by a particular TRAF-binding

receptor is conferred by its relative affinity for the different TRAF proteins, the
specific expression of TRAFs, and the stoichiometry of TRAFs in a given receptor
complex. Trimeric TNF family ligands bind to trimerized TNFR family proteins,
dictating a trimeric mode of binding of TRAFs in which the affinity and avidity of
proteins for receptor complexes is greatly enhanced (6-9)
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Although TRAFs are essential adaptors for signaling through TNFR family proteins, t
do not appear to possess intrinsic enzymatic activity and the precise mechanism of

action is as yet unknown. It is clear that the TRAF domain of TRAF2 is necessary fo
direct interactions with TNFR proteins such as TNFR2, CD40, TRANCE-R, CD30 and

others, as well as interactions with cytoplasmic factors including TRADD, RIP, NIK,
ASK1, GCK, c-IAPs, I-TRAF, TRIP, A20 and others (2,10,11). However, expression of

the TRAF domain alone inhibits signaling by TNF family ligands, and indeed, mutants
TRAF2 lacking the RING finger act as dominant negative factors for NF-icB and MAPK

activation (12,13). The N-terminal RING and Zn fingers are therefore required for th
activation of these cascades. The RING finger has been proposed to interact with
MEKK1, a MAP3K that is potentially involved in TNF-a induced JNK activation

(14,15), and the actin-binding protein Filamin (16), but physical association of the
finger of TRAF2 and these proteins has not been rigorously demonstrated. TRAF2A, a
splice variant of TRAF2 identified only in the murine traf2 locus which carries a

acid insert in the RING finger, cannot activate NF-kB, but is capable of JNK activa

(3,17). It has been recently shown in vitro that the RING fingers of TRAF2 and TRAF

can serve as E3 ubiquitin ligases, mediating non-degradative K63 polyubiquitination
some interacting partners of TRAFs as well as TRAFs themselves. This

polyubiquitination is linked to the ability to activate the IKK complex upstream of

kB (18,19). Ubiquitination of TRAFs may also lead to signal-dependent degradation, t
serving as a means of downregulating TRAF-dependent signals (20).

While most TRAFs are constitutively present in the cell types in which they are

expressed, TRAF1 is absent in most resting cells (21). Expression of TRAF1 is rapid
upregulated in response to NF-kB and AP-1 activation by a variety of inflammatory

mediators, including TNF-a, CD40L, LPS, and lymphocyte receptors (22-24). By itself,
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TRAF1 does not appear to activate signaling cascades activated by TRAF2, although i

can hetero-oligomerize with TRAF2 (4) and interact with many of the same receptors

cytoplasmic proteins as TRAF2 (11). While the exact physiological role of TRAF1 is
unknown, it appears to positively regulate survival signals mediated by TRAF2

(22,25,26). Recently, TRAF1 was found to be a target of caspases, and the resulting

cleavage product negatively regulated the anti-apoptotic signals of TRAF2 during T
induced cell death (27,28).

An emerging theme in cell surface receptor signaling is detergent-resistant liquid

lipid membrane microdomains, or lipid rafts (29-32). Contrary to the long-held flui

mosaic model of membranes as proteins floating freely in a sea of phospholipids, it

appears that the membrane lipids may have regions of higher-order organization enr

in cholesterol and sphingolipids that coalesce around activated transmembrane rece

protein complexes. These complexes are resistant to solubilization at low temperatu

non-ionic detergents such as Triton X-100 and thus may serve to assemble or exclud
various signaling complex components, which may enhance signaling specificity.

Recently, several reports have demonstrated that CD40 engagement or Epstein-Barr vi
LMP1 expression results in recruitment of CD40 or LMP1, TRAF2, TRAF3, and several

other proteins to lipid rafts, which are thought to be intrinsic to some of the sig
functions of CD40 and LMP1 (33-37).

In this report, we examine the role of the translocation of TRAF2 into detergent-in
complexes in the TRAF2-dependent activation of NF-kB and JNK. In response to CD40

stimulation, TRAF2 translocates into lipid rafts in a RING finger-dependent process

which is required for kinase activation. TRAF1, which is upregulated in response to
TRAF2-mediated signals, regulates the removal of CD40 and TRAF2 from insoluble
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complexes, but increases the ability of TRAF2 to mediate sustained activation of NF
and JNK. Substitution of the RING finger of TRAF2 with a lipid raft-targeting dual

acylation signal rescues JNK activation, but not NF-kB activation by TRAF2, suggest

that raft translocation is necessary and sufficient for JNK activation, but insuffi
NF-kB activation. Finally, in TRAF1-/- dendritic cells, we show that maturation by
CD40L leads to a loss of soluble TRAF2 and a concomitant reduction in TNF, TRANCE,

and CD40L-mediated survival, revealing a positive physiological role for TRAF1 in t
regulation of TRAF2-dependent signaling.

3.3.3 Results

3.3.3.1 TRAF1 increases the detergent solubility of TRAF2
Recently, it has been shown by several groups that CD40 engagement results in
translocation of TRAF2 to detergent resistant lipid-ordered membrane microdomains,

lipid rafts (33-37). Since TRAF1 can hetero-oligomerize with TRAF2 and interact wit

the TRAF2 binding site of CD40, we investigated the effect of TRAF1 on the solubili
of TRAF2 in non-ionic detergent (0.75% Triton X-100). Transient overexpression of
TNFR or TRAF proteins leads to self-aggregation and signaling, mimicking ligand
engagement, so we co-transfected HEK 293T cells with constant amounts of plasmids
driving the expression CD40 and TRAF2, while titrating the amount of TRAFl. In the

absence of TRAFl, a majority of TRAF2 was found in the insoluble fraction, while th

addition of TRAFl resulted in a dose-dependent redistribution of TRAF2 to the solub

fraction (Fig. 3.3.1 A). The N-terminal zinc-binding RING finger of TRAF2 has been

shown to be essential for NF-kB (12) and JNK (13) activation. It has also been sugg

that the zinc binding capacity of TRAF2 is required for its translocation into lipi

(33). To determine if the RING finger of TRAF2 mediates translocation into the inso
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fraction, we cotransfected CD40 and wild-type TRAF2 or TRAF2 with a deletion of the

first 87 amino acids (T2A87), which comprise the RING finger, with or without TRAFl
T2A87 was found completely in the soluble fraction, regardless of TRAFl expression
(Fig. 3.3.IB). Like TRAFl, TRAF5 has been shown to hetero-oligomerize with TRAF2
(38). In order to determine if TRAF5 can mediate solubilization of TRAF2, we
cotransfected CD40, TRAF2, and TRAFl or TRAF5. While TRAFl can mediate
solubilization of TRAF2, TRAF5 cannot (Fig. 3.3.IC), suggesting a unique role for
TRAFl.

To determine if TRAFl could indeed mediate translocation of TRAF2 out of lipid raft
under sustained signaling conditions, we performed sucrose density gradient
centrifugation on extracts of cells transfected with CD40, TRAF2 or T2A87, with or

without TRAFl, treated for the last 6 h prior to lysis with soluble CD40L. In cells
transfected with CD40 and TRAF2, both CD40 and TRAF2 could be found in the low-

density raft fractions, co-migrating with the known raft-associated tyrosine kinase

(Fig. 3.3.ID, upper left). However, addition of TRAFl resulted in redistribution of
CD40 and TRAF2 out of the raft fractions (Fig. 3.3.ID, upper right). T2A87 was not
found in significant amounts in the raft fractions with or without TRAFl, and even
absence of overexpressed TRAFl, T2A87 coexpression resulted in a steady-state
reduction of CD40 in the raft fractions as compared to coexpression with wild-type
TRAF2 (Fig. 3.3.1D, bottom). Although TRAFl resulted in a complete loss of TRAF2

from the raft fractions, there was still a considerable amount of insoluble TRAF2 i

crude cell extract, which may represent cytoskeleton-associated TRAF2 ((35) and fur

discussion below). To visually examine the distribution of TRAF2 in the cell, we cotransfected TRAF2 fused at its C terminus to EGFP (TRAF2-GFP) with or without CD40

and TRAFl. Fluorescence microscopy 24 hours after transfection revealed that TRAF2-
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GFP by itself was distributed throughout the cytoplasm with several aggregates in the
cell, w h i c h is consistent with the ability of overexpressed T R A F 2 to self-associate.
Coexpression of C D 4 0 resulted in the complete redistribution of T R A F 2 - G F P to punctate
structures distributed throughout the cell. Addition of T R A F l to T R A F 2 - G F P alone or
with C D 4 0 resulted in the continuous distribution of T R A F 2 throughout the cytoplasm

(f7ig.3.3.1E).
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Figure 3.3.1. T R A F l

regulates the

detergent solubility of T R A F 2 .
A. 293T H E K cells were transfected in 6well plates with the indicated amounts of
C D 4 0 , T R A F l , and T R A F 2 . Total D N A
content was maintained constant at 1 )J.g by
the addition of empty vector. Cells were

w m
— •1 • « • -«T2&87
... - ,-0mmVUk\ k mm- TRAFl *•
•«CD40 *•
-TRAFl

mmmmm
. 8 8 M B

lysed in 0.75% Triton X-100, and soluble
(S) and insoluble (I) fractions

were

immunoblotted as indicated. After probing
with T R A F 2 antibodies (C-20), blots were

+TRAF1

stripped and reprobed with anti-Flag M 2 to
detect T R A F l and CD40.
B. As in (A), but with 0.1 jig of T R A F 2 or an N-terminal truncation mutant removing thefirst87 residues
(comprising the R I N G finger) of T R A F 2 (T2A87). 0.5 ,ug of T R A F l was transfected where indicated (+).
C. As in (A), with T R A F 5 where indicated.
D. 293T cells were transfected with 1.5 jig of T R A F 2 or T2A87, 2.5 ng of T R A F l , and 1.0 ng of C D 4 0
where indicated. Cells were treated with C D 4 0 L 6 h prior to harvesting then subjected to sucrose gradient
density centrifugation as described in Experimental Procedures and immunoblotted as indicated.
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E. 293T cells were transfected as in (A) with TRAF2-GFP or GFP alone (0.2 ng), CD40
TRAFl (0.3 ng) as indicated. Cells were visualized by fluorescent microscopy 24 h after transfection.

3.3.3.2 Differential effects of T R A F 2 and T R A F 6 on C D 4 0 localization

While oligomerization at the receptor appears to be necessary for the translocatio

TRAF2 and CD40 into lipid rafts (33), it is unclear whether receptor engagement pe
sufficient for stable translocation of the receptor. The cytoplasmic tail of CD40
defined TRAF binding sites, one that is proximal to the membrane to which TRAF6
binds, and a more distal site which binds to TRAFs 1, 2, 3, and 5 (7). While TRAF2
TRAF3 have been shown to be recruited to membrane rafts by CD40 engagement in

primary cells (34), TRAF6 does not appear to play a prominent role in CD40-associa
lipid rafts (33). In order to compare the contributions of TRAF2 and TRAF6 to CD40
translocation, we generated point mutants of CD40 that are deficient in binding to

TRAF2, TRAF6, or both. Based on structural studies, we (section 3.2) and others (7)
have identified E239 of mouse CD40 (corresponding to E235 of human CD40) as a
critical binding residue for TRAF6 and Q253 (corresponding to Q252 of human CD40)

as a critical binding residue for TRAF2. Cotransfection of CD40 and alanine mutatio
E239, Q253, or both with TRAF2 followed by immunoprecipitation of CD40
demonstrated that TRAF2 binding to CD40-Q253A is greatly attenuated (Fig. 3.3.2A,

top). A similar cotransfection of CD40 constructs with TRAF6 and immunoprecipitati

of TRAF6 demonstrated that TRAF6 binding to CD40-E239A is greatly attenuated (Fig.

3.3.2A, bottom). Sucrose density gradient fractionation revealed that wild-type CD4
CD40-E239A translocated to raft fractions, but to a greater extent in the presence
overexpressed TRAF2 than in the presence of overexpressed TRAF6. However, CD40Q253A and the double E239A/Q253A mutant remained in the soluble fraction in the
presence of overexpressed TRAF2 or TRAF6 (Fig. 3.3.2B). Since CD40-WT is found in
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the raft fraction in the presence of overexpressed TRAF6 at similar levels to those of
CD40-E239A, raft translocation of CD40 appears to be dependent on its ability to bind to
TRAF2, but not to TRAF6. Furthermore, a higher level of raft-associated CD40-E239A
than CD40-WT was observed in the presence of overexpressed TRAF2, which suggests
that TRAF6 binding may actually decrease the steady-state affinity of CD40 for the raft
fraction.
A
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C N N. (O
m ^ ^ m m + CD40- WT
+T6
j>^ WHJfUl ImN ^ CD40/mutants
+T2
WCE tm •»^-**«TRAF2
* 1 ^^^^BAd40-E239A
+T6</' . *
mmmmm'*
ro
+T2
" j Z 2 8 ^ CD40-Q2 5 3 A
+T6
< S ~
+T2
CT, rn ^
+T6 "" ,n-r-'7^mmmmmmmlCD40-Z39/Z53
. fY> cn Oi
C c\j cy, m
WCE «s» «uj
» —a mm
w -«CD40/mutants
1 (*•> "" m
-«CD40/mutants
m *the„TRAF6
Figure 3.3.2. TIP:aTRAF6!(«,»,.
R A F 2 regulates
steady-state detergent solubility of CD40.
A. 293T cells were transfected with Flag-tagged CD40 constructs (0.5 ng of W T or mutants as indicated)
and TRAF2 (0.5 ng. top) or Flag-tagged TRAF6 (0.5 ng» bottom). CD40 was immunoprecipitated with
anti-Flag M 2 antibodies and immunoprecipitates were probed for TRAF2 and CD40 as indicated. TRAF6
was immunoprecipitated with anti-TRAF6 antibodies and immunoprecipitates were probed for CD40 and
TRAF6 as indicated.
B. As in Fig. ID, but cells were transfected with CD40-WT or the indicated mutants (1.0 ng) and TRAF2
or TRAF6 (1.5 ng) and subjected to sucrose density gradient centrifugation and immunoblotting.

3.3.3.3 T R A F l promotes sustained T R A F 2 - m e d i a t e d signaling
It has previously been shown that stable expression of T R A F l promotes sustained J N K
activation by TNF-a (22). We found that, with the transfection of limiting amounts of
TRAF2 (100 ng) and treatment with TNF-a (5 ng/ml) over the final 6 hours prior to cell
lysis, TRAFl co-expression increased the steady-state level of JNK activation, which
correlates with the redistribution of TRAF2 from the insoluble fraction to the soluble
fraction (Fig. 3.3.3A). Short-term treatment by TNF-a (<30 minutes) induced high levels
of JNK activation in untransfected cells or cells transfected with TRAF2 and varying
amounts of TRAFl ((22) and data not shown). In an NF-tcB-luciferase reporter assay,
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levels of luciferase activity should reflect the integrated total of NF-kB activat

the time between transfection and cell lysis. We found that, although increasing le
TRAFl expression had little effect on the ability of limiting amounts of CD40 (50

alone to activate NF-kB, in the presence of limiting amounts of TRAF2 (100 ng), TRA

overexpression could increase sustained NF-kB reporter activity (Fig. 3.3.3B). Thus

ability of TRAF2 to mediate the sustained activation of downstream signal cascades
appears to correlate with its solubility.

Figure 3.3.3. T R A F l

TRAFl (ng) 0
0 0.1 0.5
TRAF2(ng) 0 0.1 0.1 0.1
Kinase assay
**». 4 M M M > •* GST-c-jun""
IP: JNK 1
Probe:JNK1 • * >
Probe:
aTRAF2

promotes sustained

TRAF2-mediated J N K and N F - k B activation.
A. 293T cells were transfected with T R A F l and
T R A F 2 as indicated. 6 h prior to harvesting, 10

r»jNKip
• * *l-«JNK1
-«TRAF2
-«TRAF2

ng/ml T N F - a was added to the culture medium.
Cells were lysed in 0.75% Triton X-100 and
subjected to an in vitro J N K kinase assay or
fractionation as in Fig. 1.
B. 293T cells were transfected with varying
amounts of T R A F l

(0, 0.1, or 0.5 ng. indicated

by broadening line), C D 4 0 (50 ng), and T R A F 2
(0.1 ng) as indicated and subjected to an NF-kB
reporter assay. Values are indicated as fold
increase over background, and are normalized
against an internal standard (P-galactosidase).

3.3.3.4 Raft translocation of T R A F 2 is necessary and sufficient for J N K , but not N F k B activation

Since the RING finger of TRAF2 is necessary for NF-kB (12) and JNK (13) activation,

as well as for raft translocation (Fig. 3.3.2), we investigated whether raft transl

sufficient for the ability of TRAF2 to activate these signals. Many Src-family kin

acylated, leading to their accumulation in membrane rafts (29). Previously, fusion
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N-terminal myristoylation/palmitoylation signal sequence of Lck to Akt has been us
force membrane localization of Akt, leading to constitutive Akt activity (39). We

therefore generated cDNA encoding the myristoylation-palmitoylation signal from Lc

linked to the N-terminus of T2A87 (M/P-T2A87), thus directing redistribution of T2A
to the membrane raft fraction in a RING finger-independent manner. When

overexpressed with or without CD40 and/or TRAFl, M/P-T2A87 was localized primarily

in the insoluble fraction, although co-expression of TRAFl could redistribute a sm
amount of M/P-T2A87 to the soluble fraction (Fig. 3.3.4A). M/P-T2A87 could not
substantially activate NF-kB (Fig. 3.3.4B). However, in a JNK assay, overexpressed

M/P-T2A87 was able to rescue the deficiency in JNK activation by T2A87, although on

about half as efficiently as wild-type TRAF2 (Fig. 3.3.4C). This bifurcation of the

to activate JNK and NF-kB indicates that the RING finger's ability to mediate raft

translocation is necessary and sufficient for JNK activation. However, raft transl

is not sufficient to activate NF-kB, suggesting that the RING finger has an essent
function in addition to raft translocation that is required for NF-kB activation.

Since it has been suggested that the RING finger of TRAF2 is necessary to interact
the MAP3K MEKK1 (14), which may be, in turn, necessary for JNK activation (15), we

tested the ability of M/P-T2A87 to induce the translocation of MEKK1 to detergentresistant membranes. Co-expression of wild-type TRAF2, T2A87, and M/P-T2A87 with
MEKK1 and lysis in 0.75% Triton X-100 showed that the ability of TRAF2 to mediate
translocation of MEKK1 into the insoluble fraction correlated with its ability to
JNK. Wild-type TRAF2 and M/P-T2A87 induced the translocation of MEKK1, but

T2A87 did not (Fig. 3.3.4D, top). ASK1, another MAP3K known to interact with TRAF2
and activate JNK, interacts with the TRAF domain of TRAF2. Unlike MEKK1, the

association of ASK 1 and TRAF2 is not dependent on the RING finger of TRAF2 (40,41)
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Accordingly, A S K 1 did not translocate to detergent-resistant m e m b r a n e s upon coexpression with TRAF2 (Fig. 3.3.4D, bottom). The apparent necessity of the RING finger

for interaction with MEKK1 actually reflects a requirement for lipid raft translocation but
not the physical presence of the RING finger. Thus, since MEKK1 was previously shown
to interact with a TRAF2 fusion construct with the C-terminal TRAF domain replaced by
FKBP (14), it appears that MEKK1 interacts with the Zn fingers of TRAF2, and this
interaction is dependent upon the ability of TRAF2 to translocate to lipid rafts.
A
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Figure 3.3.4. Forced raft localization of T R A F 2 is sufficient to activate J N K , but not N F - k B .
A. 0.1 ng °f wild-type T R A F 2 (wt), T 2 A 8 7 , or T 2 A 8 7 with an N-terminal myristoylation-palmitoylation
signal peptide (M/P-T2A87) was cotransfected with or without T R A F l (+, 0.5 ng). with or without C D 4 0
(+, 0.2 ng) as indicated. Soluble and insoluble fractions w e r e prepared as in Fig. 3.3.1. T h e relative
proportion of soluble T R A F 2 or its mutants w a s determined b y densitometry and is indicated b e l o w the
immunoblots (Note: this is a reflection of values relative to o n e another, but does not provide an absolute
measure of solubility).
B . Cells were transfected with the indicated T R A F 2 constructs (0.4 n g ) and subjected to an N F - k B reporter
assay as in Fig. 3.3.3B.
C . Cells were transfected as in (B) and subjected to an in vitro J N K assay as in Fig. 3.3.3A.
D . Cells w e r e transfected with the indicated T R A F 2 constructs (0.3 n g ) and M E K K 1 or A S K 1 (0.3 n g ) as
indicated and soluble and insoluble fractions were prepared and immunoblotted.
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3.3.3.5 Raft translocation is necessary for the interaction of TRAF2 with the acti
binding protein Filamin
Some TRAF proteins have been shown, upon activation, to localize to the actin

cytoskeleton (35), potentially mediated through binding to Filamin (16). Furthermor
although nearly all of the known interactions TRAF2 has with other proteins appear
mediated through the TRAF-C domain, it was proposed that TRAF2 interacts with
Filamin through its RING finger domain (16). The presence of non-raft-associated,

insoluble TRAF2 but not T2A87 in crude extracts (Fig. 3.3.2A) led us to investigat

whether raft translocation was necessary for binding to cytoskeletal components. We

cotransfected Filamin with TRAF2, T2A87, or M/P-T2A87 in the presence or absence of

TRAFl. We then lysed the cells in 0.5% NP-40 to more efficiently dissociate M/P-T2A
from membrane rafts, and separately lysed a small aliquot of cells in 0.75% Triton

to show raft association. Immunoprecipitation of Filamin and western blotting revea

that, surprisingly, M/P-T2A87 could interact with Filamin as efficiently as wild-ty
TRAF2, while non-acylated T2A87 could not (Fig. 3.3.5, left side). Thus, it appears

as in the case of MEKK1 (Fig. 3.3.4D), the RING finger is not essential for physica

interaction of TRAF2 and Filamin, but raft translocation, ordinarily mediated by th

RING finger, is necessary for Filamin binding. Furthermore, TRAFl was able to compe
for binding to Filamin with TRAF2, thus in the presence of overexpressed TRAFl,

TRAF2 did not bind to Filamin (Fig. 3.3.5, right side). This suggests that sequestr

into the cytoskeleton by Filamin may serve to inactivate TRAF2 after it has translo
into membrane rafts, thus downregulating sustained or repeated TRAF2 signaling by

internalization and possible degradation (36). By preventing TRAF2 from interacting
with Filamin, TRAFl may therefore prolong and enhance TRAF2 mediated signaling.
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Figure 3.3.5. Interactions with T R A F 2
a n d the actin-binding protein Filamin
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are d e p e n d e n t o n raft translocation of
TRAF2.
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Cells were transfected as indicated with
HA-tagged Filamin (a.a. 1644-2118; 0.3
ng), T R A F 2 constructs (0.3 ng). and
TRAFl

(0.3 ng) as indicated. Upon

harvesting, 8 0 % of the cells were lysed in
0.5%

NP-40,

subjected

to

immunoprecipitation of Filamin with
antibodies against HA, and immunoblotted
as indicated. The remaining cells were
lysed in 0.75% Triton X-100 and soluble
and

insoluble

fractions

were

immunoblotted as indicated.

3.3.3.6 T R A F l recycles T R A F 2 for signaling via serial receptor e n g a g e m e n t in
dendritic cells
TRAFl is not ordinarily expressed at high levels in non-activated cells, but it is rapidly
upregulated by NF-kB activation downstream of TNF family ligand stimulation (22).
Therefore, we hypothesized that TRAFl may play a physiological role in situations
where multiple T N F family ligands that signal through T R A F 2 engage cells over time.
Dendritic cells (DCs) are known to respond to numerous TNF family members
throughout their life cycle, including TNF-a, CD40L, and TRANCE. Furthermore,
histological studies have shown that TRAFl expression is consistently elevated in DCs,
perhaps more so than in any other cell type examined (21). Using bone marrow-derived
DCs from wild-type mice and mice with a targeted deletion of the TRAF domain of
TRAFl (TRAFl-/-; Y. Pewzner-Jung et al, manuscript in preparation), we found that
CD40L or LPS maturation induces comparable levels of CD86 expression on CDllc+
cells (Fig. 3.3.6A), suggesting that TRAFl is not required for DC differentiation or
maturation.
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In wild-type D C s , T R A F l expression is relatively low in the immature stage, but is
greatly upregulated by maturation in CD40L or LPS (Fig. 3.3.6B). Treatment of
immature or LPS-matured DCs from wild-type or TRAFl-/- mice with CD40L induced

similar levels of NF-kB activation as measured by IkB degradation (Fig. 3.3.6B, la
2, 5-6, 7-8, and 11-12). In DCs matured in CD40L, there was a marked deficiency in
kB activation by CD40L restimulation in TRAFl-/- DCs as compared to wild-type DCs

(Fig. 3.3.6B, lanes 3-4 and 9-10). Consistent with this deficiency in NF-kB activat
there was substantially less pre-existing soluble TRAF2 in CD40L-matured TRAF1-/-

DCs than in CD40L-matured wild-type DCs (Fig. 3.3.6B, lanes 1 and 3 vs. lanes 7 and

9). Similar levels of pre-existing soluble TRAF2 were observed in immature and LPSmatured TRAFl-/- DCs and wild-type DCs prior to CD40L restimulation (Fig. 3.3.6B,

lanes 5 and 11). CD40L restimulation in all cases resulted in similar short-term (2

minutes) reductions of soluble TRAF2, consistent with previous observations (34,36).

Once mature, DCs quickly undergo apoptosis in the absence of survival stimuli provi
by activated T cells including TNF family ligands such as TNF-a, CD40L, and TRANCE

(42). We found that TRAFl-/- DCs matured in CD40L display severely impaired surviva

in response to TNF-a stimulation and partially impaired survival in response to CD4
with a negligible defect in TRANCE-mediated survival. TRAFl-/- DCs matured in LPS,

which does not signal through TRAF2, had comparable survival responses to wild-type
DCs under stimulation by TNF-a, CD40L, and TRANCE (Fig. 3.3.6C). Thus, TRAFl
appears to be dispensable for the first TRAF2-dependent signal (CD40L-induced

maturation), but its upregulation by the maturation signal maintains high levels of
TRAF2, enabling subsequent TRAF2-dependent signals (TNF-a or CD40L-induced
survival) to occur. While TRANCE can activate NF-icB through TRAF2 in vitro, (43),
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predominantly signals through T R A F 6 (43,44), which m a y explain the negligible
difference in survival observed in CD40L-matured wild-type and TRAFl-/- DCs.
Figure 3.3.6. T R A F l - / - dendritic cells
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(immature, lanes 1-2 and 7-8; CD40L
matured, lanes 3-4 and 9-10; LPS
matured, lanes 5-6 and 11-12), starved in
medium containing 0.5% serum for 2 h,
and restimulated with CD40L (1:200) as
indicated for 20 minutes (even numbered
lanes; odd numbered lanes were not
restimulated). Cells were lysed and the
soluble fractions were immunoblotted as
indicated. Normalized ratios of soluble

BMDC survival, 48h

T R A F 2 relative to the level of soluble
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were determined by densitometry and
are indicated below the P-actin blots.
C. D C s

prepared as in (A) were
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3.3.4 Discussion

The data presented in this report reconcile widely varying observations about TRAF2
signaling to provide a potential mechanism of TRAF2's action. First, the mechanism

TRAF2 signaling centers on its ability to translocate to lipid rafts. The N-termina
finger domain of TRAF2 is necessary both for TRAF2's ability to activate signaling

cascades and to translocate to lipid rafts. Enforced raft translocation of TRAF2 la

RING finger (T2A87) rescues T2A87's ability to activate JNK, but not NF-kB. Second,
under conditions of sustained stimulation through TRAF2-dependent receptors, TRAF2
becomes mostly insoluble and total cellular TRAF2 decreases. Third, TRAFl is known

be upregulated by activation of NF-kB and AP-1, often in TRAF2-dependent signaling.
TRAFl can displace TRAF2 from rafts and promote sustained TRAF2-mediated

signaling in response to a single stimulus or multiple stimuli over time. Thus, a d
model emerges of translocation of the receptor complex mediated by TRAF2, which is

likely to be the trigger for signal activation in response to a stimulus. The physi

role for TRAFl is to "reset" the system by dissociating TRAF2 from insoluble comple
and enabling subsequent stimuli to transduce signals through TRAF2.

Prior reports have suggested that a receptor, such as CD40, translocates to rafts u
ligand engagement and this leads to binding of TRAF proteins (33,34). In agreement

the potential requirement for zinc binding ability for TRAF2 to translocate to raft
we have found that TRAF2 requires its N-terminal RING finger domain to translocate

the insoluble fraction (Fig. 3.3.1). Nevertheless, a mutant of TRAF2 lacking the RIN

finger, T2A87, is fully capable of binding to CD40 and acting as a dominant-negativ

TRAF signaling (12.13). Furthermore, we have found that T2A87 overexpression actual
reduces the amount of raft-associated CD40 (Fig. 3.3.ID), so the TRAF domain of
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TRAF2 can clearly interact with CD40 in the soluble fraction. Although short-term
stimulation of a CD40 mutant that cannot bind to TRAF2 resulted in its apparent

translocation to lipid rafts (33), our data show that steady-state residence in lip
CD40 is dependent on its ability to bind to TRAF2 (Fig. 3.3.2). This suggests that

ability to activate downstream signals upon binding to a receptor is tied to the ab

TRAF2 to translocate the receptor complex to lipid rafts. It is thought that the Ndomain of TRAF2 somehow activates kinases that lead to NF-kB and MAPK signaling.

However, with the exception of MEKK1 (14), all of the kinases known to interact wit
TRAF2 interact with the C-terminal receptor-binding domain (11). Our data suggest
MEKK1 does not physically associate with the RING finger of TRAF2 since enforced
raft translocation of M/P-T2A87 induces JNK activation and translocation of MEKK1

(Fig. 3.3.4). This apparent discrepancy may be explained by the observation that wil
type TRAF2 did not interact with MEKK1 until TNF-a stimulation (14). TNF-a
stimulation likely induced the translocation of TRAF2 to lipid rafts, where it may
had better access to MEKK1 or to intermediary proteins linking TRAF2 to MEKK1.

Taken together with observations by the same authors that a construct with replacem

of the TRAF-C domain of TRAF2 with an inducible multimerization signal could intera

with and activate MEKK1, our data suggest that TRAF2 interacts with MEKK1 via its Z
fingers, but can only do so upon raft translocation. Regardless, the importance of

MEKK1 in TNF-a mediated JNK activation is disputable, as genetic deletion targeting

different regions of MEKK1 has shown opposite results with regard to its role in TN

mediated JNK activation (15,45). Thus, all of the known protein-protein interactions
mediated by TRAF2 appear to be via the C-terminal receptor-binding TRAF domain or

Zn fingers, but not the RING finger. This favors a model wherein receptor engagemen
by a ligand recruits TRAF2 and cytoplasmic factors including MAP3Ks, first in the

soluble fraction. Subsequently, the RING finger mediates translocation of the recep
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complex to lipid rafts, which may simultaneously activate and release the kinases i
concerted mechanism, the details of which are still unclear.

While the ability of TRAF2 to translocate to rafts appears to be tied to its abilit

activate signal cascades, we have found that in primary cells under circumstances o

sustained receptor engagement (~16h) in the absence of TRAFl, the steady-state lev
TRAF2 in the soluble fraction decreases and TRAF2-dependent receptors become

refractory to further stimulation (Fig. 3.3.6). Others have demonstrated that, under
term periods of signaling (<1 h), TRAF2 becomes insoluble and degrades in response

CD40 (36) and CD30 engagement (46). Stimulation of TNFR2 has resulted in a depletio
of soluble TRAF2, potentiating TNFR 1-mediated cell death (47). Thus, while

translocation into lipid rafts is essential for TRAF2 to activate signaling process

translocated, it appears that a given complex of TRAF2 is inactivated, thus support

idea that translocation and kinase activation are concerted, instantaneous processe

TRAFl, however, is able to displace TRAF2 away from the insoluble fraction back int

the cytosolic fraction. The mechanism of how this happens is unclear, but it is pos

that TRAFl hetero-oligomerizes with TRAF2, displacing it from rafts, and/or it comp

with TRAF2 for binding sites on the receptor. In support of this, in transient tran
assays with prolonged TNF-a stimulation or overexpression of CD40 and TRAF2, which
simulates prolonged stimulation, TRAFl not only increases the solubility of TRAF2,
it also increases JNK and NF-kB activation (Fig. 3.3.3).

The presence of considerable amounts of TRAF2 in insoluble complexes that are not r
associated (Fig. 3.3.ID) indicates that there may be another subcellular location
insoluble TRAF2 complexes. TRAF2 has been shown to interact with Caveolin-1 (48)
and the actin-binding protein Filamin (Fig. 3.3.5 and (16)) and has been suggested
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accumulate in perinuclear (49) or cytoskeletal compartments after signaling (35).

may ultimately lead to degradation of TRAF2 (36,46). Given TRAF2's association with

lipid rafts and caveolae, a reasonable model suggests that, upon receptor enagement
TRAF2 first translocates to membrane rafts, where it can activate kinase cascades.

may be internalized via caveolae, whereupon it is trafficked to cytoskeletal compa

and/or degraded. Since we found that only TRAF2 that is capable of raft translocat

can bind to Filamin and that TRAFl can disrupt the interaction of TRAF2 and Filami

(Fig. 3.3.5), it appears that cytoskeletal trafficking of TRAF2 is a consequence of

translocation. Furthermore, it is likely that TRAFl influences the intracellular t

of activated TRAF2 by solubilizing it not only from lipid rafts, but also from cyto

structures. This may, in turn, prevent or reduce the degradation of activated TRAF2

complexes, thereby increasing the available levels of soluble TRAF2 for subsequent

signaling by engagement of multiple TNF receptor family proteins over time (Fig. 3.

The implications of TRAFl's ability to regulate the solubility of TRAF2 leading to

positive signaling outcomes are supported by several studies. Previously, we have f
that transgenic overexpression of TRAFl in T cells leads to prolonged survival of

activated CD8+ T cells that may otherwise be subject to TNF-a induced apoptosis (2

Others have shown that TRAFl, in concert with TRAF2, c-IAPl, and C-IAP2, contribute

to the suppression of TNF-a induced caspase-8 activation and subsequent cytoprotec

(25). In stable transfectants overexpressing full-length TRAFl, but not in transfec

expressing an N-terminal truncation of TRAFl, NF-kB and JNK activation was sustaine

(22). It has recently been observed that TRAFl is a target of caspases during apop

which results in a decrease in its cytoprotective properties and a concomitant dec
sustained antiapoptotic signaling by TRAF2 (27,28). During the preparation of this

manuscript, it was reported that TRAFl deficiency results in "positive"' modulation
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TNF-a signaling in T lymphocytes (50). The increased TNF-induced skin necrosis

observed in those TRAFl-/- mice is reminiscent of the "feed-forward" TNF-induced TN

overproduction in TRAF2-/- cells (51), and thus may point to a "negative" role of T

in one aspect of TNF signaling but that "negative" role is in terms of a "positive"
TRAF2 regulation.

In this study, in TRAFl-/- DCs, CD40 signaling in the short term (up to 20 minutes)
immature cells is intact and comparable to that of wild-type cells, enabling NF-kB

activation and functional maturation, as well as depletion of TRAF2 from the solubl

fraction (Fig. 3.3.6). Since the signaling and functional outcomes in immature wild

and TRAFl-/- DCs are indistinguishable, and since immature wild-type DCs express lo

levels of TRAFl, it is likely that the initial stimulation is TRAFl-independent. Ho
after 24 hours of stimulation by CD40L and a brief starvation period followed by
restimulation, there is a marked difference between wild-type and TRAFl-/- cells.
Despite similar CD40L-dependent induction of CD40 expression in wild-type and
TRAFl-/- DCs (data not shown), CD40L can re-activate NF-kB in wild-type cells, but
NF-kB activation in TRAFl-/- cells is greatly attenuated. This correlates directly

level of pre-existing TRAF2 in the soluble fraction. These signaling events correla
strongly with substantially reduced DC survival mediated by the TRAF2-dependent
factors TNF-a and CD40L in TRAFl-/- DCs matured in CD40L as compared to those
matured in LPS, a TRAF2-independent factor. In TRAFl-/- DCs matured in CD40L,

TNF-a provided virtually no survival effect, while CD40L was able to promote surviv

albeit to a lesser extent than in wild-type DCs, and TRANCE promoted similar survi

levels in wild-type and TRAFl-/- DCs. This is consistent with the fact that TRAF2 i
predominant TRAF protein that mediates survival signaling downstream of TNFR1,
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while CD40 and TRANCE-R can signal through TRAF6 as well as through TRAF2
(7,43).

The role of TNF family ligand signaling in dendritic cell homeostasis is well

documented. Dendritic cells residing in peripheral tissues become activated by the

presence of inflammatory mediators, including IL-1, LPS, and TNF-a, or the presence

activated T cells, which may express TNF-a, CD40L, or TRANCE (52). Recently, it has

been shown that transgenic overexpression of CD40L in epidermis leads to chronic s

inflammation and autoimmunity, mediated in large part by the excessive activation a
maturation of Langerhans cells, which are epidermal DCs (53). TNF-a deficient mice
have attenuated antiviral responses, in part due to deficiencies in maturation and

upregulation of costimulatory factors due to a lack of auctocrine TNF-a production
There are two receptors for TNF-a: TNFR1 and TNFR2. TNFR1 can activate both the

apoptotic caspase cascade and, via the interaction of TRADD with TRAF2, it can acti

pro-survival signaling, while TNFR2 lacks a death domain and cannot activate caspas
(1). The spontaneous apoptosis of mature DCs appears to be at least partially due
autocrine activation of TNFR1, as TNFR1-/- DCs in culture are highly resistant to

spontaneous apoptosis (55). Given that TRAFl is highly expressed in DCs (21) and i

regulates the availability of TRAF2 for anti-apoptotic signaling, it is likely that

balance between caspase activation and pro-survival signals is regulated to some e
DCs by TRAFl. This hypothesis is consistent with our finding in TRAFl-/- DCs that
maturation of DCs by CD40L tilts the balance of TNF-a signaling from survival to
apoptosis due to a depletion of soluble TRAF2.

What remains unclear is the mechanism of action of the RING finger that enables

translocation of TRAF2 and the associated receptor complex. One potential mechanism
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has emerged recently in studies examining a non-classical polyubiquitination mecha
mediated by the RING finger of TRAF6 (18,19). In these elegant in vitro studies, a

protein complex that can activate IKK, leading to NF-kB activation, was biochemica

purified. It was found that TRAF6 associates with the ubiquitin-conjugating enzyme

Ubcl3 and UevlA, which results in polyubiquitination on K63 of ubiqutin (as oppose

proteasome-targeting K48 polyubiquitination), which is attached to TRAF6 itself, in
process dependent on the RING finger and oligomerization of TRAF6. This
ubiquitination step, in turn, activates a complex consisting of the TAK1 (a MAP3K),
TAB1, and TAB2, which can subsequently activate the IKK complex upstream of NF-kB
as well as MKK6, which is upstream of JNK. Interestingly, TAB2 has been shown to

translocate from membrane-associated fractions to the cytoplasm upon activation of
TAK1/TAB1/TAB2 complex (56). While it is unclear whether TRAF2 undergoes the

same process as TRAF6, it is tempting to speculate that the formation of K63-linked

polyubiquitinated complexes is tied to the translocation of TRAF2 to lipid rafts. T

particularly intriguing hypothesis in light of the fact that various forms of ubiq

have been tied to trafficking between cellular compartments (57). It is possible, t

ubiquitinated TRAF2 can then interact with raft-associated proteins, possibly incl
the TAK1/TAB1/TAB2 complex or an analog of this complex with similar function,

displacing them into the cytoplasm where they can phosphorylate substrates leading

NF-kB and JNK activation. Clearly, the role of ubiquitination in RING-dependent ra
translocation and kinase activation merits further investigation.
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4. Recycling of TRAF2 leading to
sustained signaling/availability to
other TNFR family members

Figure 3.3.7. Proposed model of the mechanism of TRAF2 signaling and its regulation by TRAF
Upon ligand engagment, a T N F R family protein recruits TRjAF2 and various kinases via the C-terminal
T R A F domain of TRAF2. The receptor complex assembles in the soluble fraction. Upon complex
assembly, the N-terminal RING finger of TRAF2 mediates translocation of the receptor complex into
detergent-resistant lipid rafts. This translocation event simultaneously activates and releases the kinases,
while isolating TRj\F2 in an insoluble complex that may be internalized and/or degraded. The activated
kinases ultimately activate transcription factors such as NF-kB and AP-1,

which upregulate the expression

of TRAFl. TRAFl then releases TRAF2 from insoluble complexes by hetero-oligomerization with TRAF2
or competing for receptor binding sites. This results in an increase of soluble TRAF2 that is available for
subsequent signaling events mediated by other TRAF2-dependent TNFR family proteins.

Conclusion
While previous reports have concluded that T R A F signaling takes place within the rafts,
our results suggest a slightly altered model (Fig. 3.3.7). Since the receptor, T R A F 2 , and
downstream signaling components can interact in soluble lysates, and especially since
T 2 A 8 7 cannot translocate to rafts but can still interact with both the receptor and
downstream components, it appears that the act of translocation is coupled to the
activating event. Thus, upon receptor engagement, the receptor, T R A F 2 , and downstream
signaling molecules assemble in the soluble fraction. Subsequently, T R A F 2 translocates
with the receptor to lipid rafts, simultaneously releasing and activating the downstream
kinase. It is unclear what the exact mechanism of activation of the downstream kinase is,
but it is possible that K63-linked polyubiquitination and/or raft-associated kinases such as
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c-Src either directly or indirectly activate these kinases. TRAF2 is now sequester

rafts, unable to stimulate additional molecules of downstream kinases. As TRAF2 has
been shown to interact with caveolin-1 (48) and the actin-binding protein Filamin

which is a raft translocation-dependent process (Fig. 3.3.6), it is possible that T

and/or other components of the receptor complexes are internalized and degraded. A

result of this initial signaling, NF-kB and AP-1 are activated and TRAFl gene expr
is turned on. TRAFl protein levels rise, and now TRAFl can relocate TRAF2 to the

soluble cytoplasmic fraction and potentially protect it from degradation, where it

assemble receptor signaling complexes and continue the cycle. This allows for what

appears to be "sustained" signaling or restimulation through the same receptor, or
stimulation through multiple TNFR family proteins that bind to TRAF2 over time.

3.3.5 Ex.perimental Procedures
3.3.5.1 Reagents
Recombinant mouse TNF-a, ILA, and GM-CSF were from R&D Systems, LPS (E.
Coli 055:B5) was from Sigma, soluble hCD8-TRANCE (TRANCE) was purified from
insect cells as described (58), and soluble mCD8-CD40L (CD40L) was generated in
insect cells and supernatant was used at a 1:200 dilution as described (59).

Antibodies (Abs) specific for lKB-a were from New England Biolabs; TRAF2 (N-19 and
C-20), TRAFl (N-19), Lyn (44), JNK1 (N-19), MEKK1 (C-22), and ASK1 (H-300) were
from Santa Cruz Biotechnology; P-actin (Ab-1) was from Calbiochem; HA (12CA5)
from Boehringer Mannheim; the Flag epitope (M2) was from Sigma; and TRAF6 was
generously provided by Dr. Sankar Ghosh (Yale University).
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3.3.5.2 Constructs
Mouse CD40 was cloned by RT-PCR from whole spleen mRNA and inserted into the
pFLAG-CMVl cloning vector (Sigma). Mouse TRAF2 and T2A87 in pcDNA3.1 have
been previously described (60). To make M/P-T2A87, complementary oligonucleotides
encoding the N-terminal 12 residues of Lck (MGCVCSSNPEDD) with appropriate

flanking restriction sites were annealed, digested, and ligated into the expressio
encoding T2A87 at the 5' end of T2A87. To make TRAF2-GFP, cDNA encoding EGFP
from the EGFP-N3 vector (Clontech) was ligated into pcDNA3.1. TRAF2 was amplified
by PCR using a C-terminal primer that fused sequence encoding a flexible linker

(GGGS)2 to the C-terminus and eliminated the stop codon, and this product was liga
frame upstream of EGFP. ASK1 in pcDNA3 was generously provided by Dr. James

Woodgett (Ontario Cancer Institute, University of Toronto) and HA-tagged Filamin (a
1644-2118) was generously provided by Dr. Ulrich Siebenlist (NIAID, NIH). MEKK1 in
pCFL and Flag-tagged mouse TRAFl, TRAF5, and HA- and Flag-tagged TRAF6 have

been previously described (43). Site-directed mutagenesis of CD40 was performed on

indicated residues by the Ex-Site method (Stratagene). All constructs were confirme
sequencing.

3.3.5.3 Dendritic cells
Dendritic cells were generated from bone marrow precursors via a modification of

existing protocols (61,62). Bone marrow precursors were plated in 24-well tissue cu
plates at a density of 106/ml, 1 ml/well, in RPMI-1640 medium containing 5% heat-

inactivated FBS, 10 mM HEPES (pH 7.0), (3-mercaptoethanol, penicillin, streptomycin

and rmGM-CSF (25 ng/ml) and rmIL-4 (5 ng/ml) for 7 days in a 37°, 5% C02 incubator,

with replacement of 800 fil of medium on days 2 and 4 and the addition of 500 jil o
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medium on day 6. On day 7, cells were left alone or stimulated overnight with CD40

(1:200) or LPS (100 ng/ml). On day 8, cells were removed for FACS analysis, transfer

to a new 24 well plate for restimulation (see below), or transferred into 96-well p

(105 cells/well in 200 ul of medium without GM-CSF or IL-4, containing 5% serum an
the indicated stimuli [TNF-a, 10 ng/ml; CD40L, 1:200; or TRANCE, 1 ug/ml] in
triplicate) for survival assays. Maturation was assayed by FACS analysis of CD86,
CD80, and I-Ab expression, gated on CDllc+ cells on a FACSCalibur (Becton-

Dickinson). Survival was assayed by FACS analysis of propidium iodide exclusion aft
48 h as described previously (58).

3.3.5.4 Cell Stimulation, Transfection, and Analysis

In vitro differentiated dendritic cells were extensively washed to remove exogenou

growth factors, cultured in medium with low serum (0.5% FBS, 2-4 h), then stimulate
by adding TNF-a, TRANCE, or CD40L as indicated. After stimulation, cells were
washed with ice-cold PBS, lysed, and subject to SDS-PAGE and western blotting. In

order to control for equal loading of each timepoint, the protein concentration of
sample was determined and samples were normalized for total protein content prior
further processing.

293T cells were transfected in 6-well plates by calcium phosphate precipitation as

described (43). The amount of transfected DNA was held constant to 1 fig by additi
empty vector DNA where necessary. Cells were processed for analysis 24-30 h after
transfection. For NF-kB reporter assays, cells were transfected with the indicated

amounts of expression constructs and mutants along with 75 ng of an NF-KB-lucifera

reporter plasmid and 25 ng of a [3-galactosidase plasmid to control for transfecti
efficiency. Transfection amounts were kept constant at 1 ag by addition of empty
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pFLAG-CMVl vector. Luciferase and [3-galactosidase activity was measured as

described (43). In vitro JNK assays were performed on cell lysates as described (59

transfection experiments were repeated at least three times and representative resu
shown.

Where indicated, cells were harvested in 1 ml ice-cold PBS, then lysed in a solutio
150 mM NaCl, 20 mM HEPES (pH 7.0), 10% glycerol, and 0.75% Triton X-100 with

protease and phosphatase inhibitors (1 mM PMSF, 1 u.g/ml leupeptin, 0.1 U/ml aproti
10 mM NaF, and 5 mM Na3V04). For lysis in NP-40, cells were lysed in HNE buffer (20
mM HEPES, pH 7.0; 150 mM NaCl, 5 mM EDTA) with 0.5% NP-40 and protease

inhibitors. Cell lysates were incubated on ice for 20-30 minutes, vortexed extensiv

and centrifuged in a microfuge at maximum speed at 4° for 10 minutes. Soluble fract
were removed and subjected to SDS-PAGE or immunoprecipitation. Insoluble fractions

were washed extensively in lysis buffer and solubilized via the addition of SDS gel

loading buffer, vortexing, and boiling for 10 minutes. Immunoprecipitation was carr

out by the addition of an antibody as indicated to the soluble fraction, rotation a

3 h, followed by the addition of 15 ul protein G-sepharose equilibrated in lysis b

rotation at 4° for 1 h. The beads were washed 3 x in lysis buffer containing deterg

once in lysis buffer without detergent. SDS gel-loading buffer was added and sample
were boiled and subjected to SDS-PAGE and western blotting.

3.3.5.5 Sucrose density gradient centrifugation

293T cells were transfected as indicated in 10 cm tissue culture plates with 4 ug t
DNA. Six hours prior to harvesting, CD40L (1:200) was added to the culture medium.

Cells were harvested in ice-cold PBS and lysed in 1 ml of HNE containing 0.25% Trit
X-100, incubated on ice for 30 minutes, and vortexed extensively. One ml of an 80%
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sucrose solution in HNE was mixed with the lysate, and this was overlaid with 2 ml
30% sucrose solution in HNE, followed by 1 ml of a 5% sucrose solution in HNE. The

samples were centrifuged in a Beckman SW55Ti rotor at 200,000 x g overnight at 4° a

described (35). 0.5 ml fractions were taken from the top of the gradient to which 2

of 2x SDS gel-loading buffer was added. 30 ul of each fraction was subjected to SDS
PAGE and western blotting.
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3.4 SUPPLEMENTARY RESULTS

The results presented in this section do not clearly fit anywhere into the three ma

results sections, but comprise some important observations about TRAF signaling tha

contribute to the continuity of this thesis. Although the results presented here ar

comprehensive, they are presented in support of ideas that will be addressed in the
general discussion in section 4. These results pertain to TRAF-mediated activation
Src-family kinases, which represents a new TRAF-activated signaling pathway
previously identified by our laboratory (1).

3.4.1 Phosphorylation of TRANCE-R by c-Src downregulates the surface expression
of TRANCE-R

Joseph R. Arron, Masha Vologodskaia, and Yongwon Choi

TRANCE and c-Src are essential components of the signaling processes that underlie
osteoclast biology. Gene targeting experiments have demonstrated that TRANCE is
required for the differentiation of osteoclasts from hematopoietic precursors (2).

Although mice deficient in c-Src have osteoclasts, osteoclast function in c-Src-/-

severely impaired, leading to osteopetrosis (3). Osteoclasts from these mice fail t

undergo cytoskeletal rearrangements such as the formation of ruffled borders and ac
rings necessary for bone resorption (4). Since TRANCE is necessary to induce these
morphological and functional changes in mature osteoclasts (5), we reasoned that
TRANCE and c-Src acted in a shared biochemical pathway. We recently demonstrated

that TRANCE treatment results in activation of Akt in osteoclasts and dendritic cel

that this process is dependent upon c-Src activity. Exposure to TRANCE leads to th
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association of c-Src with TRANCE-R and an increase in the kinase activity of Src-f

kinases (1). Furthermore, as we have shown in Section 3.1, c-Src mediates tyrosine
phosphorylation of TRANCE-R on a specific residue (Y468 in mouse TRANCE-R) (6).
We therefore investigated the role of tyrosine phosphorylation of TRANCE-R in its
expression and signaling.

Although a Y468F mutation in mouse TRANCE-R abolished phosphorylation of

TRANCE-R by c-Src, it did not affect the ability of TRANCE-R to interact with c-Cb

Cbl-b (6). In order to further investigate the role of TRANCE-R tyrosine phosphory

in TRANCE-mediated signaling, we attempted to generate cell lines that stably expr
wild-type TRANCE-R or TRANCE-R with a Y468F mutation (TR-wt or TR-Y468F).
Using the pMI retroviral vector, we generated retroviruses containing a construct
the expression of TR-wt or TR-Y468F followed by an internal ribosomal entry site
(IRES) and cDNA encoding human CD2. Using these retroviruses, we infected
KMls8.3.5.1 (K8) T cell hybridomas, which do not ordinarily express TRANCE-R on

their surface as determined by FACS analysis (data not shown). Two days after infec

FACS analysis of the bulk cell population revealed the presence of hCD2+, TRANCE-R+

cells infected with wild-type TR-wt and TR-Y468F viruses (Figure 3.4.1, left panels

Ten days after infection and selection in 500 Ug/ml G418, the bulk population of c
contained hCD2+, TRANCE-R+ cells only in the sample infected with TR-Y468F. In
samples infected with TR-wt, there were no TRANCE-R+ cells despite the presence of

hCD2+ cells (Figure 3.4.1, middle panels), suggesting that, despite the presence of

mRNA, cell surface expression of TR-wt was impaired. Infected cells were cloned by

limiting dilution, and representative clones are shown in the right panels of Figur
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Figure 3.4.1. Phosphorylation of T R A N C E - R on Y468 prevents stable cell surface expression of
TRANCE-R.
KMls8.3.5.1 T cell hybridoma cells (K8) were infected with retroviruses driving expression of wild-type
TRANCE-R (TR-wt) or TR-Y468F upstream of an IRES-hCD2 insert. F A C S analysis of infected K8 cells
is shown 2 d after infection (left panels). 10 d after infection and G418 selection (middle panels), and
representative clones obtained by limiting dilution (right panels).

W e next determined whether T R A N C E - m e d i a t e d signaling leading to the activation of
Src-family kinase dependent pathways is affected by the Y468F mutation in TRANCE-R.
We have previously found that the activation of Akt by TRANCE is dependent on
TRAF6 and Src-family kinases (1), so we investigated TRANCE-mediated Akt activation
in K8/TR-Y468F stable cells. While K8 cells alone did not show activation of Akt or
JNK in response to TRANCE stimulation, K8/TR-Y468 cells showed Akt and JNK
activation in response to TRANCE (Figure 3.4.2). K8/TR-wt cells did not show
activation of any signaling pathways in response to the addition of soluble TRANCE,
consistent with the observation that they do not express TRANCE-R on their surface
(data not shown).
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Previously, w e have attempted to generate stable cell lines expressing wild-type fulllength TRANCE-R on the cell surface, and these attempts have failed in a wide variety of
c o m m o n cell lines, including H E K 293, Cos, C H O , H e L a , and others (data not shown).
While TRANCE-R mRNA expression has been detected in numerous cell types and

tissues, including skeletal muscle, thymus, liver, colon, small intestine, and adrenal gland
(7), high levels of cell surface expression of T R A N C E - R have only been observed on
mature DCs. Notably, high surface expression of TRANCE-R has not been observed on
immature DCs, macrophages, or naive lymphocytes (8). Osteoclasts and activated
lymphocytes respond to T R A N C E stimulation, but cell surface expression of T R A N C E R on these cell types is very low relative to the expression of TRANCE-R on mature
DCs. Taken together with the finding that TR-Y468 can be stably expressed on the cell
surface, these observations suggest that tyrosine phosphorylation of T R A N C E - R

on

Y468 in most cell types may activate a strong internalization or degradation signal.

Why, then, is TRANCE-R expressed at such high levels on mature DCs? As DCs mature,
they downregulate endocytosis so as to express the highest possible levels of peptide M H C complexes and costimulatory molecules on their surface for efficient T cell priming
(9). The downregulation of endocytosis by mature DCs appears to be tied to the
regulation of Rho-family GTPases, particularly Cdc42 (10). Thus, the high levels of
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surface TRANCE-R expression in mature DCs may be a by-product of low endocytic

activity in mature DCs. The normal or elevated endocytic activity in the cell lines
mentioned above or immature DCs may be sufficient to prevent high stable levels of
surface TRANCE-R expression in those cells. Further investigation of the role of
phosphorylation of Y468 in TRANCE-R and cytoplasmic factors that bind to phospho-

Y468 may reveal important regulatory processes that underlie the efficient endocyto
displayed by immature DCs.

3.4.2 The N-terminus of TRAF6 has a unique role in c-Src activation

Joseph R. Arron, Takashi Kobayashi, and Yongwon Choi

TRAF6 and c-Src have overlapping roles in TRANCE signaling in osteoclasts, as

determined by genetic and biochemical experiments (1,3,4,11-13). We have found that

TRAF6 can interact with c-Src (1) and c-Cbl (6). Furthermore, while the interactio
c-Src and c-Cbl appears to be dependent only on the TRAF domain of TRAF6,

expression of full-length TRAF6 leads to the activation of c-Src, resulting in the

phosphorylation of c-Cbl. Thus, similar to the activation of IKK and JNK signal cas
(14,15), there is a requirement for the N-terminal RING and Zn fingers of TRAF6 to

activate c-Src. We have shown in that the RING finger of TRAF2 is necessary for it

translocation to lipid rafts and the activation of IKK and JNK cascades (Section 3.
has been well established that acylated Src-family kinases localize to lipid rafts
order to determine if the N-terminal RING and Zn fingers of TRAF2 and TRAF6 have

unique roles, we generated chimeric TRAF proteins, comprising the N-terminus of one
TRAF and the TRAF domain of another TRAF. This approach has been previously used
to dissect the differential signals transduced by TRAF3 and TRAF5 (17).

142

3. Results

W e generated two chimeric T R A F 2 - T R A F 6 constructs: 1) Residues 1-240 of m T R A F 2
fused to residues 289-530 of mTRAF6 (N2-C6), and 2) residues 1-288 of TRAF6 fused
to residues 241-501 of TRAF2 (N6-C2). Overexpression of TRAF2, TRAF6, N2-C6, and
N6-C2 induced NF-kB and JNK activation (Figure 3.4.3A and B), although the N2-C6

construct activated NF-kB at 3-4-fold levels lower than did similar amounts of TRA
TRAF6, or N6-C2. When we transfected the various TRAF constructs with c-Cbl and

limiting amounts of c-Src and examined tyrosine phosphorylation of c-Cbl, we found

TRAF6 and the N6-C2 construct could promote efficient phosphorylation of c-Cbl, bu
TRAF2 and N2-C6 could not, although there was a slight increase over background

levels in phospho-c-Cbl in the presence of overexpressed TRAF2 (Figure 3.4.3C). Thu

while the TRAF domain is sufficient for TRAF6 to interact with c-Src and c-Cbl, th

termin.al RING and Zn fingers have a unique role in the activation of c-Src, and t

function cannot be substituted by the N-terminal domain of TRAF2. Conversely, the N

terminal RING and Zn fingers of TR.*AF6 are able to confer c-Src activating abilit
TRAF domain of TRAF2.
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Figure 3.4.3. Differential abilities of the Nterminal R I N G and Zn fingers of T R A F 2 and
T R A F 6 to activate c-Src.
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Despite numerous observations that T R A F 2 and T R A F 6 activate similar signaling
pathways through the action of their RING and Zn fingers (18), our findings suggest that
the functions of these domains may be divergent, and this may point to divergent
mechanisms of action between TRAF2 and TRAF6. Thus, there are two potential
mechanisms whereby TRAF2 and TRAF6 can achieve signaling specificity: 1) binding to
different receptor sites (Section 3.2) and 2) differential ability to activate signaling
cascades through the action of the N-terminal RING and Zn fingers.
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4. GENERAL DISCUSSION

This thesis investigates the proximal components of TNFR family protein signal
transduction, specifically pertaining to the assembly and regulation of signaling

complexes mediated by TRAF proteins. Evolutionary, structural, and functional studi
have all established a distinction between the TRAF proteins that activate signal
downstream of TNFR family proteins. This distinction is exemplified in examination
TRAF2 and TRAF6. While TRAF2 and TRAF6 appear to interact with an overlapping

subset of intracellular molecules and TNFR family proteins, there are key distincti

be made. Not only do TRAF2 and TRAF6 interact with different receptor sequences via

their TRAF domains, but the functions of their N-terminal domains are also divergen
While it has long been understood that TRAFs were crucial for assembling signaling
complexes upon TNF family ligand engagement of TNFRs, the mechanism of action of

TRAFs has not been well characterized. The work presented in this thesis, along wit
other recent reports, makes significant progress toward delineating a mechanism of
for TRAF proteins. Two emerging themes in the mechanisms of TRAF signaling are

ubiquitination and lipid raft translocation. Another important consideration in TR

signaling lies in the other, often-ignored side of signal transduction - the negati

regulation of signaling. Mechanisms of negative regulation of TRAF signaling appea

be tied to the very things that are required for signal activation, and it will be
to examine these phenomena in the context of signaling in general.

4.1 Distinctions between TRAF6 and other TRAFs
Examples of the two major types of signal-activating TRAFs are TRAF6 and TRAF2.
TRAFl, 3, and 5 have more in common with TRAF2 than with TRAF6, although there
are some key differences between them. Of TRAFl, 3, and 5, only TRAF5 has been
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shown to activate NF-kB and AP-1 similar to TRAF2 (1,2). However, while TRAF2

interacts directly with many receptors, TRAF5 may interact only indirectly with so

receptors via hetero-oligomerization with TRAF3 (3). TRAF3 does not activate NF-kB
AP-1, but it is apparently essential for normal development and immune regulation

This essential role of TRAF3 may lie in its ability to recruit TRAF5 to receptors,

may be additional regulatory roles for it that have not yet been identified. TRAFl

highly homologous to TRAF2 in its TRAF domain, but it lacks the N-terminal structu

(RING and multiple Zn fingers) that enable TRAF2 to activate signals (5). Nonethel

as we have seen in section 3.3, TRAFl is a key regulator of TRAF2-mediated signali
most likely due to its ability to hetero-oligomerize with TRAF2 and regulate its

subcellular distribution. TRAFl, 2, 3, and 5 all interact with similar receptor sit
with slightly different affinity/avidity profiles (6).

TRAF6 has the most evolutionarily divergent TRAF domain, although its
oligomerization appears to activate NF-kB and AP-1 very similarly to TRAF2. TRAF6

binds to a distinct receptor sequence from TRAF2, as we have defined in section 3.2

Thus, one obvious level of specificity that may be conferred by TRAF6 is that it ca

potentially interact with a completely different array of receptors. Furthermore, T

can interact with IRAK proteins, which, unlike TNFR proteins, are intracellular ada

for non-TNFR family receptors (7,8). The IL-l/TLR family of receptors is very impor

in general inflammation and innate immunity, thus TRAF6 is a bridge between innate
adaptive immunity. Not only does TRAF6 have key roles in immunity, but the same

inflammatory factors and repetitive sequences that mediate innate immunity can als

affect bone homeostasis (section 2.3.2). TRAF6 has been shown to be vital for osteo

physiology, and we have recently found that dendritic cells, which arise from the s
hematopoietic precursors as osteoclasts, are also dependent on TRAF6 for their
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maturation (T. Kobayashi et al., unpublished data). Thus, by virtue of the fact that D C s
and O C s come from the same precursors, and the same factors are responsible for the
final stage of their maturation and activation, and these factors are all dependent on
TRAF6 for signal transduction, it is apparent that TRAF6 plays a central role in
osteoimmunology. Figure 4.1 details the roles of T R A F 6 in the parallel development of
D C s and OCs.
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Figure 4.1. Parallel lifecycles of dendritic cells a n d osteoclasts a n d the role of T R A F 6 in
osteoimmunology.
D C s and O C s differentiate from c o m m o n myeloid hematopoietic precursors. Factors mediating D C
differentiation include G M - C S F , IL-4, and T N F . D C differentiation is dependent on the combination of the
N F - k B subunits p50 and RelA (F. Ouaaz, J. Arron, Y. Zhang, Y. Choi, and A. Beg, manuscript submitted).
O C differentiation is dependent on M - C S F , T R A N C E , and the transcription factors c-Fos and the
combination of N F - k B subunits p50 and p52 (9). The maturation of D C s and O C s are both mediated by
TRAF6-dependent factors, including L P S , C p G , and IL-1. C D 4 0 L also induces D C maturation, while
T R A N C E induces O C maturation. Mature, activated D C s and O C s rapidly undergo apoptosis in the
absence of survival signals provided by T R A N C E and C D 4 0 L . T R A N C E - m e d i a t e d D C survival is
dependent on the combination of the N F - k B subunits p50 and cRel, while T R A N C E - m e d i a t e d O C survival
is dependent on Akt.

Since it appears likely that the T R A F domain of T R A F 2 and T R A F 6 is responsible for
most protein-protein interactions (Sections 2.2 and 3.3), it might be reasonable to
conclude that the specificity of signaling mediated by T R A F 2 and T R A F 6 is encoded in
the T R A F domain, because it determines which upstream molecules are coupled to which
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downstream molecules. For example, IRAK has three TRAF6 binding sites and no
TRAF2 binding sites while TNFR2 has one TRAF2 binding site and no TRAF6 binding
sites. Since TRAF2 and TRAF6 interact with overlapping but distinct subsets of

intracellular signaling molecules, one would expect there to be a qualitative diffe

between the effects of IL-1 and TNF on a given cell. Nonetheless, the specificity o

TRAF signaling does not appear to be localized exclusively to the TRAF domain. As w

have shown in section 3.3, the RING finger of TRAF2 mediates its translocation to l

rafts, and without TRAFl, TRAF2 remains in insoluble complexes after translocation.

TRAF6, on the other hand, does not appear to accumulate in insoluble complexes ((10

and data not shown). While translocation appears to be necessary for the ability of

TRAF2 to activate signaling cascades, it is unclear whether the same can be said fo
TRAF6.

4.2 c-Src activation by TRAF6
While the N-terminal RING and Zn fingers of both TRAF2 and TRAF6 mediate the

activation of NF-kB and AP-1, the N-terminal half of TRAF6 can also strongly activa

c-Src, while the N-terminal half of TRAF2 can only weakly activate c-Src, if at all

(section 3.4). This result is particularly interesting in light of the fact that we previous
observed that c-Src and c-Cbl interacted with TRAFl, TRAF3, and TRAF6, but not with
TRAF2 or TRAF5 ((11) and data not shown). In fact, the pattern of coimmunoprecipitation of c-Src and c-Cbl with various TRAFs correlates with the tendency
of the TRAFs to localize in the soluble fraction of cells lysed in Triton X-100 (data not
shown). Thus, it is possible that the reason we did not observe co-immunoprecipitation of
c-Src and c-Cbl with TRAF2 is because that interaction may have taken place in the
insoluble fraction, which, at the time, we ignored. In support of the notion that the TRAF
domain of TRAF2 can in fact interact with c-Src and c-Cbl, the N6-C2 chimeric TRAF
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construct could activate c-Src-mediated c-Cbl phosphorylation (section 3.4).

Alternatively, while there is no doubt that the TRAF domain of TRAF6 can interact w

c-Src, it may be possible that elements in the N-terminal half of TRAF6 can also i

with c-Src when oligomerized (as is the case in the N6-C2 construct, where the TRAF

domain of TRAF2 mediates oligomerization). Previously, we did not observe interacti

between c-Src with the N-terminal half of TRAF6 alone (11), but it is apparent tha

N-terminal half of TRAF6 can activate signaling by itself if it is oligomerized ar
by some means other than the TRAF domain (12,13). However, our biochemical and
strucutural studies (section 3.2) suggest that c-Src can interact with a specific

TRAF domain distal to the N-terminal half of TRAF6. Thus, if c-Src can interact wit
only the TRAF domain, then there is a unique ability of the RING and Zn fingers of

TRAF6 to mediate c-Src activation. If c-Src can also interact with the oligomerize
RING and Zn fingers of TRAF6 but not TRAF2, then the specific ability of the Nterminal half of TRAF6 to interact with c-Src may mediate c-Src activation. While

currently available data do not completely rule out either possibility, the fact t
can interact with the TRAF domain alone of TRAF6 favors the first possibility.

4.3 Ubiquitination as a mechanism of TRAF signaling

If the RING finger of TRAF proteins is not required for the interaction of TRAFs an

other proteins known to interact with TRAFs (section 3.3), how does it activate sig

cascades? One established function of RING finger domains is the ability to mediate

ubiquitination of other proteins by acting as E3 ubiquitin ligases (14). For exampl
(section 3.1) and others (15-17) have shown that Cbl family proteins mediate the

degradation of activated signaling molecules in a RING finger-dependent manner, whi

is accomplished by the ubiquitination of target proteins. Recently, the RING finger
TRAF2 and TRAF6 have been shown in vitro to mediate a novel form of
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polyubiquitination (13,18). The well-characterized degradative pathway of ubiquitina

involves polyubiquitination wherein ubiquitin chains are formed with covalent linka

one ubiquitin molecule to the target protein and further molecules of ubiquitin are

covalently linked to K48 of the previous ubiquitin. K48-linked polyubiquitination l

to proteasomal degradation of the targeted protein. The novel form of ubiquitinatio
mediated by TRAF proteins involves the formation of polyubiquitin chains linked

through K63 of ubiquitin. This does not appear to mediate degradation of the target
proteins. However, TRAF6-mediated K63-linked polyubiquitination appears to be

required for the activation of the IKK complex leading to NF-kB activation. In addi

to ubiquitinating downstream signaling molecules, TRAF6 itself is polyubiquitinated
through a K63 linkage. It is thought that TRAF2 undergoes a similar process.

While K63-linked polyubiquitination appears to be required for NF-kB activation, ou

findings in section 3.3 demonstrate that the RING finger is dispensable for the act

of JNK by TRAF2 if raft translocation of TRAF2 is artificially induced. Taken toget

with the findings that K63-linked polyubiquitination leads to the activation of NFwell as JNK (13), our observations that M/P-T2A87 can activate JNK but not NF-kjB
(Fig. 3.3.4) suggest that RING finger-mediated polyubiquitination of TRAF2 may

mediate its translocation into lipid rafts. Although translocation is sufficient fo

activation, the ubiquitination process is likely to be required in addition to tran

for NF-kB activation. A caveat to this hypothesis is that the RING fingers on vario
TRAF proteins may function differently. TRAF3 does not translocate to insoluble

complexes or activate JNK upon overexpression, but replacement of the RING finger o
TRAF3 with the RING finger of TRAF5 has been shown to induce its translocation and
its ability to activate JNK (19). However, endogenous TRAF3 has been shown to be
strongly recruited to lipid rafts upon CD40 engagement or LMP1 expression (20-22),
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which may be mediated by its hetero-oligomerization with TRAF5. The murine splice
variant of TRAF2, TRAF2A, can activate JNK but not NF-kB (23), so it is possible that
TRAF2A possesses an intrinsic property of the RING finger that enables raft
translocation, but is not capable of mediating K63-linked polyubiquitination leading to
NF-kB activation.

While the possibility remains that the RING finger mediates ubiqutination and raft
translocation as completely separate processes, it is simpler and more likely that the
RING finger mediates one process, which results in the other process. Thus, RINGmediated K63-linked polyubiquitination of TRAF proteins may increase the affinity of
TRAFs for lipid rafts either intrinsically or by mediating the interaction of
polyubiquitinated TRAFs with raft-specific proteins. Alternatively, the RING finger of
oligomerized TRAF proteins may mediate translocation into rafts, where proteins
mediating polyubiquitination reside, thus the co-localization of TRAFs and ubiquitinating
enzymes enables their activation. Given that enforced raft localization of M/P-T2A87 can
activate JNK signaling but not NF-kB activation in the absence of the RING finger, it
seems likely that ubiquitination may precede raft translocation, since there is no evidence
that raft translocation is absolutely necessary for NF-kB activation. However,
ubiquitination is required for NF-kB activation. Therefore, an orderly progression of
TRAF signaling may proceed as follows: 1) ligand-mediated receptor trimerization, 2)
TRAF recruitment and trimerization, 3) recruitment of TRAF-interacting signaling
molecules in the soluble fraction, 4) RING finger-mediated polyubiquitination of the IKK
complex and TRAFs (leading to NF-kB activation), and 5) polyubiquitin-mediated TRAF
translocation to lipid rafts leading to JNK activation (Figure 4.2). Clearly, the role of
ubiquitination in RING-dependent raft translocation and kinase activation merits further
investigation.
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Figure 4.2. Proposed
model

of ubiqutin-

mediated signaling by
T R A F proteins. See
text for details.
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4.4 Raft translocation as a m e c h a n i s m of T R A F signaling
T h e role of lipid rafts has been an emerging theme in signal transduction in recent years
(24-26). Because of the differential affinities of various proteins for lipid-ordered
microdomains, these domains m a y serve to concentrate certain proteins in close
proximity to one another while excluding other proteins. Recently, rafts have also been
suggested to be involved in cell polarity, by redistributing relative amounts of
transmembrane and raft-associated proteins on different sides of a cell (27). W e have
observed a crucial role of raft translocation in TRAF2-mediated signaling (section 3.3).
O f particular interest is that, while raft translocation of T R A F 2 is necessary for its ability
to activate certain signals, once it has translocated to lipid rafts, it does not relocalize to
the soluble cytoplasmic fraction in the absence of T R A F l . Furthermore, w h e n T R A F 2 is
trapped in insoluble complexes as a result of an initial receptor engagement, it cannot
activate signals in response to subsequent receptor engagements. Thus, the translocation
of T R A F 2 to rafts appears to simultaneously activate downstream signals and inactivate
T R A F 2 . While T R A F 2 does accumulate in lipid rafts to s o m e extent during steady-state
signaling, it appears that a majority of insoluble T R A F 2 m a y not be raft-associated.
T R A F l , which is not expressed in naive cells, is upregulated by TRAF2-dependent
signals, and its function appears to be to regulate steady-state levels of soluble T R A F 2 . It
also prevents the steady-state association of T R A F 2 with the cytoskeletal protein Filamin.
T R A F 2 must be able to translocate to rafts in order to associate with Filamin. It appears
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that TRAF2 undergoes a cycle of raft translocation, internalization (possibly medi
interactions with caveolin), and sequestration in insoluble cytoskeletal complexes

degradation. While raft translocation is necessary for the positive effects of TRA

(activation of signaling cascades), it appears that raft translocation downregulate

ability of activated TRAF2 to activate further signaling cascades in the absence o
TRAFl. Therefore, raft translocation serves a positive and negative role in TRAF2
signaling.

The temporally regulated positive and negative roles of raft translocation in TRAF

signaling is reminiscent of the temporally regulated positive and negative roles o

proteins in TRAF6-mediated Akt activation (section 3.1). In each case, the associat

components of a TNFR protein signaling complex with a regulatory factor (Cbl in the

case of TRAF6 and c-Src and lipid rafts in the case of TRAF2) is necessary for bot

activation of a signaling pathway and the ultimate quenching of that signal. This t

complex regulation is seen in other examples of Cbl signaling, such as from the EGF

receptor (16), and in Src-family kinase signaling (28), where only activated kinas

susceptible to degradation by ubiquitination or inactivation by phosphatases. It is

that in all of these cases, downregulation of a given component takes place as a di
consequence of the component's activation.

Since TRAF2's solubility is regulated by TRAFl, how is TRAF6 regulated? While we

have found that TRAF2 becomes insoluble in the steady state in the absence of TRAFl
we have not found the same to be true for TRAF6. Furthermore, while TRAF2 can

induce steady-state raft translocation of CD40, TRAF6 appears to inhibit steady-sta
translocation of CD40 (Figure 3.3.2). TRAFl or TRAF3 alone do not localize to
insoluble complexes upon overexpression, while TRAF2 and TRAF5 do localize to
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insoluble complexes (data not shown). This appears to directly correlate to the abi
overexpressed TRAF2 and TRAF5 to activate NF-kB and JNK, while overexpressed
TRAFl and TRAF3 cannot. Although it can activate NF-kB and JNK, TRAF6 does not
accumulate in insoluble complexes upon overexpression, and it been suggested that
TRAF6 does not translocate to lipid rafts upon CD40 stimulation (10). However, the

methods used to identify raft-associated TRAFs are based on relative detergent solu

It is possible that TRAF6 is in fact raft associated upon ligand stimulation, but n
strongly as TRAF2 and it was therefore not detected in defined "raft fractions."

In the case of LMP1 expression, it was found that TRAF2 and TRAF3 could be either

detected or not detected in defined "raft fractions," depending on the lysis condit

(22). TRAF6 can interact with and is a potent activator of c-Src, a dually acylated

associated kinase. Given these observations, it appears likely that TRAF6 may be ab
translocate to lipid rafts in order to activate kinase cascades in the same manner

TRAF2, but it is able to easily dissociate from rafts, whereupon it can activate su
signals. TRAF2, on the other hand, becomes stuck in rafts and/or other insoluble

fractions, and its solubility is regulated by an additional factor, TRAFl. In order

thoroughly examine these possibilities, real-time fluorescence imaging of TRAF2 and

TRAF6 in live cells may be necessary. Additionally, the regulation of TRAF6 after i
activation should be closely examined. TRAF2 can interact with caveolin (29) and

Filamin (30), thus it is possible that TRAF2 is internalized and sequestered in the

cytoskeleton after raft translocation. It has been suggested that Filamin plays a r

TRAF6 signaling (30), but a direct interaction has not been demonstrated. A mode of

activation-induced TRAF6 downregulation through degradative ubiquitination has been
shown, and this pathway may be unique to TRAF6, while sequestration in insoluble
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complexes (and possible subsequent degradation) may be unique to the downregulatio
ofTRAF2.

4.5 Physiological regulation of TRAF signaling

Ultimately, the answers to many remaining questions about TRAF signaling lie in th

observation of different cell types in the context of the whole organism. While TR
can activate a variety of signaling pathways in DCs and OCs, the functional roles
signaling pathways are divergent. We have previously shown that the TRANCE-

R/TRAF6/c-Src/PI3-K pathway leading to the activation of Akt is an important survi

signal for OCs (11). Others have implicated this pathway in TRANCE-mediated surviv

of ductal epithelial cells in breast tissue (31). However, this pathway appears to
crucial in TRANCE-mediated DC survival, as Cbl-b-/- DCs are deficient in TRANCE-

mediated Akt activation, but have no survival defects relative to wild-type DCs (s
3.1). Recently, we have found that TRANCE-mediated survival in mature DCs is

specifically dependent upon the NF-kB subunits p50 and cRel in combination (F. Ouaa

J. Arron, Y. Zhang, Y. Choi, and A. Beg, manuscript submitted). While recent evidenc

has suggested that PI3-K activation may regulate NF-kB transcriptional activity (3
cross-talk between these pathways appears to be highly cell type-specific, and in

be specific to the RelA NF-kB subunit. Another level of cell type specificity in T

signaling comes from the transcriptional regulation of TNFR proteins. It has recent

been shown that there are numerous alternatively spliced forms of CD40 in differen
types that may have differential abilities to interact with TRAFs (33). Given the
observations that tyrosine phosphorylation on a particular residue of TRANCE-R

regulates its cell surface expression (section 3.4) and that TRAF6 deficiency comp
abrogates TRANCE-mediated signal activation despite the ability of full-length
TRANCE-R to signal through TRAF2 (34), it is possible that TRANCE-R is similarly
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alternatively spliced. In addition to the specific effects of proximal components o

signaling complex, it is likely that other, TRAF-independent signals that are activ

within the cell may affect signals downstream of TRAFs. For example, IFN-y stimulat
of OC precursors has been shown to induce the degradation of TRAF6 (35). Taken

together, these and many other observations demonstrate that an understanding of TR
signaling must be at a level deeper than simple protein-protein interactions.

4.6 Conclusions

It is clear is that the fine regulation of TRAF signaling in primary cells is depen

multiple factors, including: 1) the relative levels of various TRAFs within a given

the availability of soluble TRAFs for ligand-dependent signaling, 3) the availabili

downstream signaling components that interact with TRAFs, and 4) the recent history

TRAF-dependent signals in a given cell. These all contribute to the differential ac

of various signaling pathways, ultimately leading to different gene expression prof
and cellular effects. While the work presented here has made considerable progress
toward elucidating structural and functional features of the mechanisms of TRAF

signaling, it has raised a number of further questions. What are the individual rol
RING and each Zn finger in TRAF2 and TRAF6? While it is structurally similar to
TRAF2, TRAF3 does not appear to regulate signaling in the same way as TRAF2 - what
does TRAF3 do? What does TRAF4 do? We have identified a biochemical role for
TRAFl, but there do not appear to be a strong phenotype in TRAFl-/- mice. What are
some physiological situations in which TRAFl-mediated TRAF2 regulation might be
important? TRANCE-R, a TNFR family protein, has three TRAF6 binding sites and two

TRAF 1/2/3/5 binding sites. These account for about 10% of its cytoplasmic tail. CD

which binds to the same TRAFs, has a considerably shorter cytoplasmic tail. What do
the rest of TRANCE-R do? What non-TRAF proteins does it interact with, in TRAF
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dependent and independent fashions? Ultimately the observations about the molecular
phenomena that underlie TNF family signaling must be extrapolated into a
comprehensive understanding of and ability to manipulate the wide range of
physiological processes linked to inflammation and immunity.
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